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ABSTRACT 
DEIDRE WASHINGTON: The Effect of Patient Race on Patient-Provider Communication 
with Pediatric Asthma Patients 
(Under the direction of Dr. Susan Blalock) 
 
Asthma is one of the most common chronic pediatric conditions in the United States.  
African-Americans and other racial/ethnic minority groups are disproportionately affected, 
having a higher prevalence and suffering more adverse health outcomes. The National 
Asthma Education and Prevention Program has issued guidelines to assist physicians and 
other healthcare providers with the diagnosis and management of asthma. In addition to 
specific topics of asthma management, such as symptom monitoring and pulmonary function 
tests, the guidelines also emphasize the importance of effective communication when 
discussing topics of asthma management. Effective patient-provider communication is an 
important aspect of quality of care and has been linked with improved health outcomes. The 
objective of this research was to determine whether patient race was associated with 
differences in patient-provider communication about selected asthma management topics. 
This was a cross-sectional secondary analysis of survey and clinic visit audiotape data 
collected in North Carolina from 2006 to 2009 from physicians at pediatric and general 
practice clinics, patients with asthma, and their caregivers (parents). An instrument 
developed specifically for this research was used to code communication information from 
transcripts of the audiotapes. Multivariate analyses were used to examine the association of 
patient race with communication about four selected asthma management topics. 
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Overall, selected topics of asthma management were shown to be discussed to 
varying degrees during the course of these medical visits, not necessarily in accordance with 
the recommended guidelines. The results from multivariate analysis did not show any 
significant association between patient race and communication regarding the selected 
asthma management topics. The interaction between patient race and the reason for the visit 
was also not significantly associated with communication regarding the selected topics. 
Patients visiting the doctor for annual check-ups and other reasons unrelated to asthma were 
generally less likely to discuss asthma management than those visiting the doctor for an 
asthma-related reason.  
The results from this study suggest that patient-provider communication regarding 
asthma management topics is not associated with patient race, and is not contributing to 
disparities in this population. Additional research is needed to understand the source of 
observed health disparities in pediatric asthma patients.
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 CHAPTER ONE: INTRODUCTION 
 
Asthma is a chronic lung disease characterized by the inflammation and narrowing of 
the airways (NHLBI 2008). Approximately 6.7 million children in the United States are 
affected by asthma, making it one of the most common chronic pediatric conditions in the 
country (Akinbami, Moorman et al. 2009). It is a major cause of childhood disability, and 
can place significant burdens on the child and their family, including missed school days, 
limitations in activities, such as sports and play, and increased medical costs (Juniper 1997; 
Newacheck and Halfon 2000; Braman 2006).  
Although there is no cure for asthma, with appropriate management it can be well-
controlled, significantly reducing the burden experienced by the patient and family. The 
National Asthma Education and Prevention Program (NAEPP), an initiative of the National 
Institutes of Health, has issued comprehensive guidelines for physicians and other health care 
providers, which include recommendations for the ongoing management and treatment of 
asthma (NHLBI 2007). These guidelines, which rely on clear and effective communication 
between the patient, their caregiver (parent/legal guardian), and the healthcare provider, can 
help physicians manage asthma effectively in their patients, thereby reducing the burden for 
the patient and their family. 
Asthma, being one of the most prevalent chronic conditions in children, is a serious 
public health concern, and as such, has been studied extensively by the research and medical 
communities. Over the past several years, a convincing body of research has emerged to
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indicate that the burdens of asthma are not experienced equally among all children diagnosed 
with this condition (Akinbami, LaFleur et al. 2002; Canino, Koinis-Mitchell et al. 2006). 
Specifically, racial disparities in asthma prevalence and outcomes have been reported for 
several years, and continue to persist today (Targonski, Persky et al. 1994; Evans, Sadowski 
et al. 2009). African-American children, as well as children of other racial minority groups, 
are more likely to experience adverse outcomes related to asthma, including emergency 
department visits, hospitalizations, and death, compared to white children (Erickson, 
Iribarren et al. 2007). These disparities in adverse outcomes cannot be attributed to racial 
disparities in prevalence alone, suggesting that other contributory factors need to be 
identified (Cabana, Lara et al. 2007).  
Racial disparities are complex, and likely have multiple contributing factors, such as 
environmental and socioeconomic factors (Srinivasan, O'Fallon et al. 2003; Adler and 
Rehkopf 2008). As stated above, the persistence of racial disparities in asthma has been well 
established; however, less is known concerning exactly how they arise. Disparities are not 
specific to asthma; several conditions, including hypertension, diabetes, and certain cancers, 
are associated with racial disparities (Hertz, Unger et al. 2005; Viswanath and Emmons 
2006; Peek, Cargill et al. 2007). Some causes of racial disparities, especially those outside of 
the health care system, may be common across conditions and disease states (e.g., 
socioeconomic conditions may contribute to disparities across many conditions) (Williams 
and Jackson 2005). However, others may be more specific to certain diseases (e.g., a delay in 
mammography screening for African-American women leading to higher breast cancer 
mortality) (Peek and Han 2004).  
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Specific causes of racial disparities in pediatric asthma patients have not been 
conclusively identified. In particular, research has not determined whether recommendations 
outlined in the national guidelines are adhered to equally, independent of the patient’s race. 
Optimal asthma control based on the guidelines is dependent on the ability of the patient, 
their caregiver, and the physician to communicate effectively about the child’s asthma, 
including asthma symptoms, lung function, quality of life, and medication use. If differences 
in communication concerning these topics are associated with patient race, it will contribute 
to the body of knowledge on possible causes of disparities in this population. The observed 
racial disparities in health outcomes (emergency visits, hospitalizations, etc) would suggest 
that optimal asthma control is not being achieved equitably.  
Identifying the causes of health disparities is an important first step in reducing these 
disparities. From this information, effective interventions may be designed and implemented 
to reduce and eventually eliminate disparities in pediatric asthma, as well as other conditions. 
In order to determine whether patient-provider communication contributes to disparities in 
this population, this study was designed to determine whether patient race is associated with 
differences in communication regarding four asthma management topics: 1) symptoms, 2) 
lung function, 3) quality of life, and 4) control medication adherence.  
This study is a secondary analysis of data collected as part of a larger National Heart, 
Lung and Blood Institute funded study examining patient-provider communication and health 
outcomes in pediatric asthma patients. The data were collected from five pediatricians’ 
offices in North Carolina from June 2006 through August 2009. The study involved audio-
recording medical visits between pediatric asthma patients, their parents, and healthcare 
providers. The patient and their caregiver also completed questionnaires immediately 
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following the visit. Patients took a spirometry test if one was not administered during the 
visit. During a home visit approximately one month after the office visit, questionnaires and 
spirometry were re-administered to the patient, and caregiver also completed another 
questionnaire as well. 
This dissertation is organized into six chapters. Chapter Two provides background 
information on pediatric asthma management, and a review of the literature on patient-
provider communication and racial disparities in pediatric asthma. Chapter Three describes 
the conceptual model constructed to guide this study. Chapter Four outlines the research 
methods involved in data collection and analysis. Chapter Five provides the results of the 
analyses. Finally, Chapter 6 reviews the major study findings, and discusses the implications 
of study findings, study limitations, and directions for future research. 
 CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
 
Overview 
 This chapter introduces the problem of pediatric asthma in the US, and outlines 
previous research on both patient-provider communication and racial disparities in pediatric 
asthma. The chapter concludes by reviewing previous research to identify the causes of racial 
disparities, and notes that patient-provider communication and its association with race has 
not been extensively studied in a pediatric asthma population, providing the rationale for this 
study. This chapter is organized into the following five sections: 
• Pediatric Asthma Overview 
• Asthma Management 
• Communication About Asthma and Asthma Management 
• Racial Disparities in Pediatric Asthma 
• Causes/Contributors to Racial Disparities 
 
 The Pediatric Asthma Overview section provides a brief overview of pediatric 
asthma in the United States, including prevalence and outcomes, demonstrating that it is a 
serious public health concern. It also introduces select topics from the national guidelines for 
the treatment of asthma that have been developed by the National Asthma Education and 
Prevention Program (NAEPP). The Asthma Management section discusses the topics of 
asthma management which were the focus of this research: asthma symptom monitoring, 
pulmonary function, asthma-related quality of life, and control medication adherence. The 
   6 
 
age
 
Communication and Asthma Management section outlines the importance of patient-
provider communication in the management of asthma, including relevant recommendations 
included in the NAEPP guidelines, and previous research that has been conducted to 
understand and improve communication with pediatric asthma patients. The Racial 
Disparities in Pediatric Asthma section provides information concerning the racial 
disparities that have been observed in pediatric asthma, focusing on health outcomes. Finally, 
the Causes/Contributors to Racial Disparities section summarizes previous research to 
understand the factors that contribute to health disparities. Patient-provider communication 
emerges as an area that warrants further research as a potential contributor to disparities in 
this population. This section also highlights the need to determine the mechanisms through 
which communication may contribute to disparities, in order to aggressively address the 
problem. 
 
Pediatric Asthma Overview 
Introduction 
 
Asthma is a chronic lung disease characterized by the inflammation and narrowing of 
the airways (NHLBI 2008). It is one of the most common chronic pediatric diseases in the 
U.S. (Galant, Crawford et al. 2004; Camargo Jr, Ramachandran et al. 2007). In 2005, almost 
9% of children in the U.S. (aged 2-17), or 6.5 million children, were reported to have current 
asthma (Akinbami 2006). In 2006, this number increased to 6.8 million (Bloom and Cohen 
2009). Asthma is a major cause of childhood disability and can place a heavy burden on 
children and their families (Newacheck and Halfon 2000; Williams 2006). In the most severe 
cases, asthma may be fatal. For these reasons, the Centers for Disease Control and Prevention 
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asserts that asthma continues to be a significant public health problem and should remain a 
priority for the research and medical communities (Akinbami 2006). 
 
Health Outcomes, Healthcare Utilization, and Costs 
Children who have been diagnosed with asthma are likely to experience associated 
symptoms at some point. The most common symptoms associated with asthma are shortness 
of breath, cough, wheezing, and chest pain or tightness (Akinbami 2006; Bailey, Castro et al. 
2008)  The onset of these symptoms, especially when severe, can lead to adverse outcomes, 
including limitations in functional activities, decreased quality of life, and missed school 
days (Diette, Markson et al. 2000). The onset of severe symptoms may also be associated 
with increased healthcare utilization, including primary care visits, emergency department 
(ED) visits, and hospitalizations; in turn, increased healthcare utilization may lead to 
increased costs for the family.  Since 2000, outpatient care for pediatric asthma has 
increased, even though during this time the overall rates of outpatient care for children did 
not increase (Hing, Cherry et al. 2006). In 2004, children with asthma made approximately 
6.5 million visits to physician offices and 500,000 visits to hospital outpatient departments, 
resulting in a total of seven million outpatient visits.  Although outpatient visits can be time-
consuming and costly, effective outpatient care may prevent additional, even more costly 
healthcare use, such as ED visits and hospitalizations (Lieu and Quesenberry Jr 1997). 
Annually, pediatric asthma is responsible for 658,000 to 754,000 ED visits (Camargo Jr, 
Ramachandran et al. 2007; Coffman, Cabana et al. 2008), and an additional 200,000 
hospitalizations.  
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Together, ED visits and hospitalizations account for almost three-fourths of the direct 
costs of asthma (Lieu and Quesenberry Jr 1997). Based on a review of Medical Expenditure 
Panel Survey data in 1996 (using 2003 dollars), direct medical expenditures from pediatric 
asthma amounted to $1009.8 million ($401 per child with asthma) and included payments for 
prescribed medicine, hospital inpatient stays, hospital outpatient care, emergency room visits, 
and office-based visits (Wang, Zhong et al. 2005).  In addition to direct medical costs, 
several indirect costs, which are more difficult to quantify, may be incurred. For example, 
asthma is the most reported cause of school absenteeism for children, accounting for 10-15 
million missed school days annually (O'Connell 2004; Newcomb 2006; Burkhart, Rayens et 
al. 2007).  In general, children with asthma miss 1.5-2 more days per school year than 
children without asthma (Bonilla, Kehl et al. 2005; Moonie, Sterling et al. 2006).  Finally, 
asthma may affect quality of life for the child and his/her family through missed time from 
work, inability to play and decreased family time.  
 
National Guidelines 
The National Asthma Education and Prevention Program (NAEPP) was initiated 
under the National Heart, Lung, and Blood Institute of the National Institutes of Health to 
address issues relating to asthma management. The NAEPP expert panel has issued 
Guidelines for the Diagnosis and Management of Asthma to provide comprehensive 
guidance to health care providers regarding four specific aspects of asthma care: 1) 
assessment and monitoring, 2) patient education, 3) control of factors contributing to asthma 
severity, and 4) treatment with medication. Only those aspects that directly relate to this 
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research are referenced here, including severity classification, pharmacotherapy 
(medications), and patient-provider communication. 
The first version of the guidelines was published in 1991, with updates released in 
1997 (selected topics updated in 2002) and 2007. The 1997/2002 report was the most current 
when data collection began under the protocol of the parent grant. All references to the 
NAEPP guidelines refer to the 1997/2002 version, unless otherwise noted.  The major 
differences between the 1997 and 2007 guidelines is an increased emphasis on assessing 
asthma control rather than severity in the latest report.  
 
Asthma Severity Classifications 
The 2007 guidelines classify asthma into 4 distinct severity groups based on several 
impairment criteria, including symptoms, nighttime awakenings, rescue medication use, 
activity limitations and lung function. In order of increasing severity, the four groups are: 1) 
intermittent, 2) mild persistent, 3) moderate persistent and 4) severe persistent. A more 
detailed example is presented in Appendix 1.  
 
Medications 
Most asthma can be managed with the proper use of medications. Several classes of 
medications are available and are prescribed to manage/reduce asthma symptoms, improve 
quality of life, reduce the frequency and severity of exacerbations, and reverse airflow 
obstruction (NHLBI 2007). Medications are categorized into two groups: long-term 
preventive (control) medications and quick-relief (rescue) medications. Control medications, 
normally prescribed to use everyday, are indicated to maintain control of persistent asthma, 
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and rescue medications are indicated to treat acute symptoms and exacerbations (NHLBI 
2007). Daily control medication use can reduce exacerbations, as well as over-dependence on 
rescue medications, which has been observed in pediatric asthma patients (Butz, Tsoukleris 
et al. 2006).  Also, according to NAEPP guidelines, patients who have been diagnosed with 
persistent asthma require a medication from both groups. Below, Table 1 lists some common 
classes of medications, along with some commonly recognized brand names. Table 1 was 
constructed from the most recent version of the NAEPP guidelines and the master medication 
list from the parent grant. Many pediatric patients with asthma also have allergies, and 
antihistamines may be prescribed, in addition to asthma medications, to help alleviate certain 
asthma and/or allergy symptoms (Reicin, White et al. 2000; Baki 2002).  
 
Summary 
In summary, pediatric asthma is a common and serious problem. For the millions of 
children in the U.S. who are affected by asthma, consequences of the disease may include 
increased health-care utilization, increased family costs, missed school, and missed work for 
parents/caregivers. The National Heart, Lung, and Blood Institute of the NIH has developed 
and updated comprehensive guidelines that physicians and other health care providers can 
use to diagnose and treat asthma. These guidelines include information on asthma severity 
and appropriate medications for management.  
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Table 1. Common Classes of Asthma Medications (from 2007 NAEPP guidelines and 
parent grant Medication List) 
 
Class Generic Name Common Brand Name 
Rescue (Quick-Relief)   
Short-acting beta agonists Albuterol, Levalbuterol, 
Pirbuterol 
Proventil, Xopenex, 
Maxair® 
Control (Preventive)   
Inhaled Corticosteroids 
(ICS) 
Budesonide Pulmicort®, 
Rhinocort® 
Fluticasone Flovent®, Flonase® 
Mometasone Asmanex®, Nasonex® 
Triamcinolone Azmacort®, Nasocort® 
Systemic Corticosteroids Prednisone Deltasone® 
Long-acting Beta Agonist Salmeterol Serevent® 
Inhaled corticosteroid and 
long-acting beta agonist 
Salmeterol and fluticasone Advair® 
Leukotriene Modifiers Montelukast Singulair® 
Mast-cell Stabilizer Cromolyn sodium, 
Nedocromil 
Intal®, Tilade® 
Immunomodulators/ 
Monoclonal antibodies 
Omalizumab Xolair® 
Methylxanthines Theophylline Slo-bid®, Theo-Dur® 
 
 
Asthma Management 
This section introduces four important aspects of asthma management: 1) asthma 
symptom monitoring, 2) pulmonary function monitoring, 3) asthma-related quality of life and 
4) control medication adherence. The next section describes the importance of patient-
provider communication for asthma management overall, with an emphasis on these four 
topics. 
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Asthma Symptom Monitoring 
An integral part of asthma management involves the ability of the patient and parent 
to identify and control asthma symptoms (coughing, wheezing, chest pain or tightness, and 
shortness of breath). The guidelines recommend that every patient who has asthma should be 
taught by their physician to recognize symptom patterns that indicate inadequate asthma 
control. The guidelines also recommend that symptoms and clinical signs of asthma should 
be assessed at each health care visit through physical examination and appropriate questions, 
preferably over a short (2-4 week) recall period. Many children with asthma experience 
symptoms. In one study of 121 children with asthma, 51% of the children reported one to 
four symptoms days during the last month (Butz, Walker et al. 2007). Nighttime symptoms 
and exercise-induced symptoms are specific indicators of inadequate asthma control (Diette, 
Markson et al. 2000; Fiese, Winter et al. 2007; Henry and Robert 2008). Determining 
symptom frequency is also an important element of asthma management. It is often used to 
make an initial diagnosis of asthma, as well as to determine severity (Magzamen, Patel et al. 
2008; Thorsteinsdottir, Volcheck et al. 2008). 
 
Pulmonary Function Monitoring 
Spirometry  
 
A second important aspect of asthma management includes monitoring pulmonary 
function. One method of measuring pulmonary function is spirometry. Spirometry is a 
physiological test that measures how an individual inhales or exhales volumes of air as a 
function of time (Miller, Hankinson et al. 2005). The administration of a spirometry test 
includes having the subject take a big breath in, inhaling as much air as possible until lungs 
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are as full as possible, followed by having the subject immediately blow all the air out as 
hard and fast as possible until no more air comes out. Finally, the subject inhales again as 
forcibly and fully as possible, completing one test cycle. This procedure should be repeated 
until three acceptable tests are obtained (Sleath, Ayala et al. 2006; Council-Australia 2009). 
Acceptability criteria is extensive, and includes, but is not limited to: no premature 
termination, no cough, and no evidence that the patient took an additional breath during 
expiration (Council-Australia 2009).  Three common measurements from spirometry are the 
forced vital capacity (FVC), the forced expiratory volume in one second (FEV1), and forced 
expiratory flow between 25% and 75% of the FVC (FEF25-75). The forced vital capacity 
(FVC) is the maximal volume of air forcibly exhaled from the point of maximal inhalation. 
The forced expiratory volume in one second (FEV1) is the volume of air forcibly exhaled 
during the first second of the FVC. The forced expiratory flow between 25% and 75% of the 
FVC (FEF25-75) is the mean volume of air exhaled over the middle half of the FVC, and is 
regarded as a sensitive measure of small airway narrowing, and may be more relevant for 
patients with mild asthma (Council-Australia 2009). The subject’s scores are compared 
against expected values to assess possible airway obstruction. Expected spirometry values 
vary, and depend on the patient's height, age, sex, and racial or ethnic background (Margolis, 
Montoya et al. 1997; Petty 2001). For example, when the FEV1/FVC ratio is lower than 
normal (<70%), there may be airflow obstruction. Assessment by spirometry is not 
necessarily indicated at every asthma visit. A spirometry test should be administered every 1-
2 years to assess the maintenance of airway function, according to the NAEPP guidelines 
(NHLBI 2007). However, the test may be administered more often, depending on asthma 
severity and response to management. A spirometry test is administered in a medical office 
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by a nurse, or other trained healthcare professional. Not all primary care clinics have the 
capability to administer spirometry.  
 
Peak Flow Meter Use  
A second method of monitoring pulmonary function is a peak flow assessment with a 
hand-held peak flow meter. A peak flow meter measures peak expiratory flow, which is how 
fast one can exhale air after a maximum inhalation. A peak flow meter measures airway 
constriction and can detect lung airway narrowing hours or days before symptoms occur 
(Burkhart, Rayens et al. 2007). Unlike spirometry, peak flow measurements can be taken at 
home, as well as in a medical office. As with spirometry, normal “expected” values depend 
on patient characteristics such as age, height, etc. The 1997/2002 guidelines recommend that 
daily peak flow monitoring should be considered for patients with moderate or severe 
persistent asthma, as well as for those with mild asthma who do not perceive their symptoms 
until airway constriction is severe. Peak flow meter use is almost always accompanied by an 
asthma action plan. This action plan has instructions about what should be done for the 
patient (e.g use of rescue inhaler or seeking immediate medical treatment), based on where 
the results fall along a continuum. Peak flow monitoring has been associated with improved 
health outcomes in school-aged children (Burkhart, Rayens et al. 2007).  Poor peak flow 
measurements may indicate that the asthma is not being managed very well by the patient in 
between medical visits (e.g., poor adherence to preventive medications).  
As stated above, in earlier editions of the NAEPP guidelines, daily peak flow 
monitoring was recommended for patients with moderate-to-severe asthma (NHLBI 1997).  
The use of peak flow meters was somewhat deemphasized in the 2007 guidelines (NHLBI 
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2007). The 2007 edition of the guidelines states that “although peak flow monitoring to guide 
chronic asthma management has been reported to be valuable….the results are not consistent 
enough for this tool to be recommended uniformly for all asthma patients.  Thus, the relative 
usefulness of peak flow measurements as monitoring tools can be individualized…”  In 
addition the 2007 edition also cites a systematic review of the evidence, conducted in 2002, 
concluding that previous studies did not clearly show that a peak-flow monitoring-based 
action plan was better than a symptom monitoring-based plan in improving asthma 
outcomes. Therefore, the 2007 edition is different from the 1997/2002 editions in that the 
recommendation for daily peak flow monitoring was deleted.  
 
Asthma-Related Quality of Life 
In addition to symptoms, children with asthma may also be bothered by the physical, 
social, educational and emotional impairments that they experience as a result of having 
asthma (Usherwood, Scrimgeour et al. 1990; Nocon 1991; Townsend, Feeny et al. 1991; 
Christie, French et al. 1993). Asthma-related quality of life measures can indicate how much 
the patient’s disease interferes with daily life, and how well the patient is adapting to living 
with asthma. As such, physicians may use quality of life (QoL) in their decisions about 
treatment planning and medication use (Everhart and Fiese 2009). Decreases in quality of 
life, particularly activity limitations, are associated with poor asthma control (Mudd, 
Bollinger et al. 2006). Children with asthma often report lower quality of life compared to 
children without asthma, meaning children with asthma are more likely to report activity 
limitations due to asthma, report negative emotions, and miss more school (Marsac, Funk et 
al. 2007; Van Gent, Van Essen et al. 2007). As stated earlier, asthma is also associated with 
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missing time from work (for parents/caregivers), and exemplifies how asthma may impact 
the quality of life for the patients’ family.  
There are validated instruments available that can assess quality of life, including 
asthma-related quality of life specifically for pediatric asthma patients, such as the Pediatric 
Asthma Quality of Life Questionnaire (Juniper, Guyatt et al. 1996).  However, these 
instruments may be long and time-consuming too complete.  These validated instruments are 
normally used for research purposes rather than in everyday visits, during which physicians 
may verbally ask similar questions to assess the patient’s quality of life.   
 
Medication Adherence 
Control Medication Adherence 
Adherence to control medications is an important component of asthma control. 
Adherence requires the patient taking the medication according to the instructions of the 
physician. Under ideal circumstances, a physician will always prescribe a control medication 
to a patient for whom it is indicated, communicate to the patient the importance of taking it 
daily, and demonstrate proper technique; afterwards, the patient will hopefully take the 
medication accordingly. A breakdown of any of these steps can lead to adverse health 
outcomes for the patient. These adverse outcomes can include increased symptoms, 
exacerbations, physician visits, increased rescue medication use, emergency room visits, and 
hospitalizations (Wennergren, Kristjansson et al. 1996; Blias, Ernest et al. 1998; Adams, 
Fuhlbrigge et al. 2001; Smith, Rascati et al. 2004; Smith, Mildenhall et al. 2005; Stern, 
Berman et al. 2006). 
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Non-Adherence 
Non-adherence with prescribed asthma treatment causes compromised treatment 
effectiveness, including greater morbidity, mortality, and health care utilization costs 
(O'Connor, Bender et al. 2004). Non-adherence to a medication may take various forms, 
including not filling/refilling prescriptions, patient taking an incorrect dosage, improper 
dosing intervals, and premature discontinuation. In addition, incorrect inhaler technique is an 
important example of non-adherence, usually leading to sub-optimal dosing (Milgrom 1997; 
Kelly 2001). Poor medication adherence has been documented extensively, including in 
pediatric asthma patients (DeMore, Adams et al. 2005; Camargo Jr, Ramachandran et al. 
2007; Burgess, Sly et al. 2008). In a study of a group of children aged 8-12 years old taking 
both beta agonists and inhaled corticosteroids, adherence (defined in this study as taking 
doses within the correct time window) was 48% and 32%, respectively (Milgrom, Bender et 
al. 1996). Another study of 171 children with persistent asthma found that adherence rates 
over a mean observation period of 203 days was 59% (95% CI: 48-65%) with montelukast 
and 44% (90% CI: 35-50%) with fluticasone, both control medications; adherence in this 
study was calculated from pharmacy refill data (Sherman 2001).  
 
Contributors to Non-Adherence 
Both patient and physician behaviors may contribute to non-adherence. Additionally, 
in this population, factors that impact adult adherence may also affect children’s adherence, 
because adults (caregivers) often have responsibility for their children’s medication, 
especially at younger ages. Lemanek identified several issues that have been associated with 
non-adherence in the pediatric asthma population, including the complexity of the medical 
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regimen, medication side effects, the presentation of symptoms, and satisfaction with care 
(Lemanek 1990).  In one study, the two most common reasons parents cited for their child’s 
non-adherence were ‘simply forgetting,’ or their child’s reaction to being given medication 
(Burgess, Sly et al. 2008).  Beliefs that parents have about asthma medications can also 
impact their child’s adherence. Studies have shown that parents of children with asthma may 
believe that control medications are to be used only when symptoms appear, that their child 
may become too dependent, or that their child may experience side effects; all of these 
beliefs are associated with poor adherence (Farber, Capra et al. 2003; Bender and Bender 
2005).  
 
Communication About Asthma and Asthma Management 
Patient-Provider Communication 
Effective patient-provider communication has long been recognized as an integral 
component of high quality care, and as such, has been studied extensively. Communication 
during medical visits serves multiple purposes, including creating an effective inter-personal 
relationship, exchanging information, and making treatment-related decisions (Ong, de Haes 
et al. 1995). More recently, researchers have been using increasingly sophisticated techniques 
to study and analyze communication between physicians and their patients, including 
audiotapes, videotapes, and advanced coding systems (Wissow 1998; Tates and Meeuwesen 
2000; Tates, Elbers et al. 2002; Wissow and Kimel 2002; Roter 2003). Wissow, an expert in 
pediatric communication, especially advocates methods of direct observation (recording) of 
provider-patient communication as opposed to recall. Direct observation is, in principle, less 
subject to bias; can be assessed by multiple observers to insure inter-rater reliability, and 
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preserves the maximum amount of raw data for re-analysis as new hypotheses are developed 
(Wissow and Kimel 2002).   
 
Importance of Communication for Asthma Self-Management and Improving Outcomes 
Communication about asthma is a vital component of disease management; the 
NAEPP guidelines stress the importance of effective communication between physicians and 
patients in order to achieve optimal asthma control (NHLBI 1997). Patients and/or parents 
must effectively communicate to the physician how well they believe the child’s asthma is 
being controlled; this can be conveyed by reporting the frequency of symptoms, results of at-
home lung function monitoring, or any impact on the patient or family’s quality-of-life (i.e 
negative feelings, activity limitations, missed school days). In addition, effective 
communication between the patient (child), the parent and the physician is necessary to 
ensure the proper use of and adherence to control medications; it is primarily the 
responsibility of the physician to emphasize the role and importance of these asthma 
medications (Rachelefsky 2007). Patients/families and physicians need to have a common 
understanding of the nature of asthma, treatment goals, the role of medications and self-
management practices (Peterson-Sweeney, McMullen et al. 2003).  
Overall, effective communication with health care providers may lead to better health 
outcomes. Studies have shown an association between physician communication and adverse 
asthma-related outcomes (Cabana, Slish et al. 2006). For example, in a randomized trial in 
which physicians participated in an education program that included reviewing asthma 
guidelines, specific communication techniques, and key asthma educational messages, 
children of physicians in the intervention group reported a significant decrease in days where 
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activity was limited by asthma, and fewer visits to the emergency room because of asthma in 
the year follow-up period, compared to children of control group physicians (Cabana, Slish et 
al. 2006).  Clark, who has extensively studied methods to improve patient-provider 
communication, recently reported results from a 2-year follow-up of parents of pediatric 
asthma patients whose physicians underwent training to improve their asthma-related clinical 
and counseling skills in a randomized trial (Clark, Cabana et al. 2008). Compared to parents 
whose physicians did not undergo the training, parents from the intervention group were 
more likely to report that their children were less likely to have sleep disruption due to 
asthma symptoms (OR: 0.25, p=0.033). Children in the intervention group also had, on 
average, fewer ED visits in the two years after baseline (p=0.04) (Clark, Cabana et al. 2008). 
In another study, a 30-minute individualized session where a nurse explained asthma and its 
implications to the patient improved adherence, and was associated with improved clinical 
outcomes, including medication adherence, self-reported control, and quality of life (Janson, 
Fahy et al. 2003). Results from these studies suggest that improving physicians’ 
communication skills can be associated with improved outcomes for pediatric asthma 
patients.  
The remainder of this section will briefly outline the importance of communication on 
the aforementioned aspects of asthma management: 1) symptom assessment, 2) pulmonary 
function, 3) quality-of-life, and 4) medication adherence.   
 
Communication – Symptoms 
As stated in the guidelines, communication about symptoms is an important aspect of 
asthma management. In the previously mentioned Butz study of 121 asthma patients, the 
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majority of whom were experiencing symptoms, the authors noted that the majority of these 
parents and children only communicated symptom experience to the doctor after prompting 
(by the doctor). Additionally, parents of children with moderate-to-severe asthma symptoms 
may underestimate the seriousness of their child’s symptom experience. If such 
underestimations are communicated to the physician, it could adversely influence treatment 
decisions (Halterman, Yoos et al. 2006). Symptom reporting has also been shown to be 
influenced by the way that questions are asked (Cabana, Slish et al. 2005). In a study by 
Cabana and colleagues, they report that when parents of children with asthma were asked a 
global assessment question (e.g., How well controlled is your child’s asthma at the 
moment?), the answers given regarding symptoms were indicative of ‘good’ asthma control. 
This was a multiple choice question, with 4 responses: 1) very well controlled, 2) somewhat 
well controlled, 3) not very well controlled, and 4) not controlled at all. Responses were 
dichotomized, with the first two responses categorized as ‘good’ control, and the latter two 
categorized as ‘poor’ control. However, when the same parents were asked more specific 
symptoms questions (e.g., In the past 2 months, how often did symptoms such as coughing, 
wheezing, chest tightness or shortness of breaths interfere with sleep?), their responses 
indicated that their child had ‘poor’ asthma control. These different issues highlight the need 
for effective, accurate, and comprehensive communication of symptom experience between 
the physician and the parent and/or patient. Table 2 gives several recommendations for the 
ways that physicians should assess asthma symptoms and adherence to medicines; this table 
was adapted from the 1997 NAEPP guidelines (NHLBI 1997). 
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Table 2.  Examples of Questions Physicians May Ask to Assess Symptoms    
Experienced by the Patient (adapted from NAEPP guidelines) 
(Global Assessment)  Has your asthma been better or worse since your last visit?   
(Recent Assessment)  In the past 2 weeks, how many days have you:   
Had problems with coughing, wheezing, shortness of breath, or chest tightness        
during the day? 
Awakened at night from sleep because of coughing or other asthma symptoms?  
Had symptoms while exercising or playing?         
 
 
Communication – Pulmonary Function (Spirometry & Peak Flow) 
No studies were identified that examined communication about spirometry test 
results. However, if a spirometry test is performed, it is the responsibility of the physician to 
communicate the results, in lay terms, to the parent and/or patient, including what the results 
indicate about overall asthma control. A poor spirometry test may indicate that the asthma is 
not being managed very well in between medical visits. 
Similarly, no studies were identified that specifically examined communication about 
peak flow meter technique or results. However, if the doctor has recommended that the 
patient monitor their asthma with a peak flow meter, it is critical for the patient and/or parent 
to be able to use the peak flow meter appropriately, understand the results of any tests 
performed at home, respond appropriately in accordance with the asthma action plan, and 
communicate all of this to the physician at the next visit. Table 3 gives examples of questions 
that physicians may pose to assess peak flow results and correct peak flow monitoring 
technique; this table was adapted from the 1997 NAEPP guidelines (NHLBI 1997). 
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Table 3.  Examples of Questions Physicians May Ask to Assess Peak Flow Results     
and Peak Flow Technique (adapted from NAEPP guidelines) 
What is the highest and lowest your peak flow has been since your last visit? 
  
Has your peak flow dropped below ____ L/min (80% of personal best) since your last visit? 
What did you do when this occurred?     
 
Please show me how you measure your peak flow?    
 
When do you usually measure your peak flow?         
  
 
 
Communication – Quality of Life 
Physicians should also assess asthma-related quality of life for their pediatric asthma 
patients. In a study of children with asthma, almost 63% of the children reported some 
activity restriction due to asthma; however, only 30% of parents reported that their child’s 
asthma was out of control from some to all of the time (Butz, Walker et al. 2007).  
Assessment of different aspects of asthma-related quality of life, such as activity limitations 
or negative emotions, is another way for the physician to ascertain whether a child’s asthma 
is being well-controlled. Table 4 provides sample questions for monitoring quality of life; 
this table was adapted from the 1997 NAEPP guidelines (NHLBI 1997). 
 
Table 4.  Examples of Questions Physicians May Ask to Monitor Asthma-Related 
Quality of Life (adapted from NAEPP guidelines) 
Since your last visit, how many days has your asthma caused you to: 
    
Miss work or school?     
  
Reduce your activities?     
  
(For caregivers) Change your activity because of your child's asthma? 
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Communication – Control Medication Adherence 
 
The NAEPP guidelines recommend that a patient’s adherence to his or her asthma 
medication regimen be regularly monitored (NHLBI 1997). This is especially essential if the 
physician determines that the asthma is not being managed very well through prior 
assessment of symptoms, quality of life, and pulmonary function. It is important for health 
care providers to recognize factors associated with adherence and non-adherence, as well as 
barriers to adherence (Rachelefsky 2007; Burgess, Sly et al. 2008; Howell 2008). 
Communication has been suggested as a key for improving asthma medication adherence 
(Broers, Smets et al. 2005; Rachelefsky 2007). One of the most critical aspects of 
communication involves the physician educating the patient and parent on pharmacotherapy, 
especially how the use of and adherence to a control medication translates into symptom 
reduction and better overall asthma management (NHLBI 1997). The guidelines recommend 
that asthma self-management education, including the role of medications, should begin at 
the time of diagnosis and continue through follow-up care through repetition and 
reinforcement. Reviewing the success of the treatment plan with the patient and parent at 
each visit and making adjustments as needed should also encourage medication adherence. 
Table 5 provides sample questions for monitoring adherence to control medications; this 
table was adapted from the 1997 NAEPP guidelines (NHLBI 1997).  
Table 5 – Examples of Questions Physicians May Ask to Monitor Adherence to Control 
Medications (adapted from NAEPP guidelines) 
How often do you take each medication?         
How much do you take each time?     
Have you missed or stopped taking any regular doses of your medications for any 
reason? 
Have you had trouble filling your prescriptions (e.g., for financial reasons)?   
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Summary 
 In summary, effective communication is an important component of optimal asthma 
care. Poor asthma control may manifest in several different ways, and it is vital that any 
indicators of poor control are communicated clearly between the physician and the patient 
and/or parent. Interventions to improve physicians’ communication skills have been linked 
with improved outcomes for the patient, underscoring the role communication plays in the 
health of pediatric asthma patients. Communication may be the key to improving health 
outcomes for patients most likely to experience adverse health outcomes. 
 
Racial Disparities in Pediatric Asthma 
Several adverse health outcomes associated with pediatric asthma occur more 
frequently within certain racial groups compared to others, exemplifying a racial health 
disparity. Health disparities can be defined as differences in health status among diverse 
groups of people and include the disproportionate burden of disease, disability and/or 
mortality (Bull and Miller 2008).  Disparities occur across populations (pediatric, adult, and 
geriatric) and therapeutic areas (Levy and Sidel 2006). Disparities in pediatric asthma 
prevalence, outcomes, and healthcare utilization have been well documented (Akinbami 
2006; Canino, Koinis-Mitchell et al. 2006; Gupta, Carrión-Carire et al. 2006; Diette and 
Rand 2007; Kruse 2007; Mangan, Wittich et al. 2007; Moorman, Rudd et al. 2007; Brim, 
Rudd et al. 2008; Forester, Ong et al. 2008; Ginde 2008; Rand and Apter 2008; Rosenbaum 
2008; Evans, Sadowski et al. 2009; Flores, Snowden-Bridon et al. 2009). Several leading 
national institutions have acknowledged the existence of racial health disparities in asthma, 
including the National Center on Minority Health and Health Disparities of the National 
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Institutes of Health, the Office of Minority Health and Health Disparities of the CDC, and the 
Agency for Healthcare Research and Quality. They suggest that research to reduce and 
ultimately eliminate disparities become a national priority.  
 
Prevalence Disparities 
The prevalence of pediatric asthma has been documented to be higher in many racial 
and/or ethnic minority groups, especially African-American children, compared with white 
children (Quinn, Shalowitz et al. 2006; Diette and Rand 2007). The prevalence of asthma in 
white children is estimated to be between approximately 7.7% - 8.4% (Brim, Rudd et al. 
2008; Bloom and Cohen 2009). In contrast, the percentage of African-American children 
with asthma is reported to be approximately 13%-15.6% (Akinbami 2006; Quinn, Shalowitz 
et al. 2006; Bloom and Cohen 2009). In children of Hispanic origin, prevalence has been 
reported to be as low as 5.9% or as high as 9.4% (Rosenbaum 2008; Bloom and Cohen 
2009). The wide range is likely due to prevalence differences in children from separate 
subgroups of Hispanic origin (for example, Puerto Ricans vs. Mexican Americans), because 
the distribution of these separate subgroups may have varied across studies (Rosenbaum 
2008). Less information is known about some other racial groups; specifically, Asian 
American and American Indian/Alaska Native children have been historically 
underrepresented in the pediatric asthma literature (Brim, Rudd et al. 2008). Brim and 
colleagues, using 2001-2005 aggregated data from the National Health Interview Survey, 
reported that the current pediatric asthma prevalence rate in American Indians /Alaska 
Natives was 13.0%. Asian Indian and Chinese children have the lowest prevalence rates, 
4.2% and 5.1% (Brim, Rudd et al. 2008).  
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Asthma-Related Outcomes & Healthcare Use 
Many studies have found that minorities, and especially African-Americans, 
experience a disproportionate burden of adverse asthma related health outcomes; minorities 
(African-American and Latinos) have higher asthma morbidity, mortality and health care 
utilization (Riekert, Butz et al. 2003; Akinbami 2006; Gupta, Carrión-Carire et al. 2006; 
Kruse 2007; Ginde 2008). African-Americans are reported to have higher mortality rates 
from asthma, compared with whites (Lang and Polansky 1994; Targonski, Persky et al. 
1994). Researchers in Chicago found that between the years 1968-1991, asthma mortality 
increased by 337% for African-Americans, while remaining stable for non-Hispanic whites 
(Targonski, Persky et al. 1994). A recent government report by the Centers for Disease 
Control and Prevention,  National Surveillance for Asthma-United States, 1980-2004, 
reported that rates of emergency department use for the 3-year period of 2001-2003 are 
higher overall for African-American adults and children compared with white adults/children 
(21.0 per 100 for African-Americans with current asthma per year compared with 7.0 per 
whites with current asthma per year) (Moorman, Rudd et al. 2007). Also, in an older, 
retrospective cohort study using Medicaid claims data from Washington state, African-
American children with asthma were more likely than white children with asthma to make 
emergency department visits or to be hospitalized for asthma; the adjusted odds ratio were 
1.7 [95% CI: 1.34 to 2.15] and 1.42 [95% CI: 1.03 to 1.96], respectively (Lozano, Connell et 
al. 1995).  
Results from these studies suggest that disparities in asthma-related healthcare 
utilization exist independent of the disparities in asthma prevalence. In another study using 
data from the National Hospital Discharge Survey and the US vital statistics system, asthma 
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hospitalizations for white children aged 5-18 years decreased from 11.5 to 8.1 (discharges) 
per year per 10,000 of the population between 1980-1984 and 2000-2002, respectively 
(Gupta, Carrión-Carire et al. 2006) . In contrast, for African-American children, the rate 
increased slightly, from 34.3 to 36.5 discharges per year per 10,000 of the population. This 
finding that the rates of hospitalizations are going in opposite directions for whites and 
African-Americans, along with no evidence that prevalence rates are following a similar 
pattern, suggests that this disparity is also independent of prevalence. 
 
Asthma Care 
 Racial disparities in health related outcomes may be linked with disparities in asthma-
related health care. Asthma care has been shown to be worse for African-Americans 
compared to whites. Fewer African-American adults reported care consistent with 
recommendations for medication use, self-management education, avoiding triggers and 
specialist care compared to white adults (Krishnan, Diette et al. 2001). African-Americans 
are also more likely to have their asthma severity underestimated by the physician than white 
patients (Okelo, Wu et al. 2007).  Underestimation of asthma severity was then associated 
with a lower likelihood of: (1) daily use of an inhaled corticosteroid, (2) being told what to 
do for an asthma flare-up, and (3) being told how to prevent asthma-flare-ups. African-
Americans with underestimated severity were also less likely to rate their overall asthma care 
and communication with their physician as “very good” or “excellent”. 
The following sections review reported racial disparities regarding the four aspects of 
asthma care/management discussed previously (i.e., asthma symptoms, pulmonary function, 
quality of life and control medication adherence). 
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Symptoms 
There is limited information on racial differences in the ways that children report 
their asthma symptoms. However, it has been shown that there are racial differences in the 
way adults with asthma report (experience) asthma symptoms. In one study, African-
American adults with asthma were less likely to report nocturnal awakenings, complain of 
dyspnea (shortness of breath) or experience chest pain than whites with asthma 
(Trochtenberg, BeLue et al. 2008).  It is unclear whether this difference was due to an actual 
difference in symptoms or if it was due to communication styles. It has also been shown that 
different methods of symptom assessment can produce differences in the answers (Yoos, 
Kitzman et al. 2003; Halterman, Yoos et al. 2006). Additionally, Yoos and colleagues found 
that when asked about their child’s symptom experience, minority families appeared to be 
less accurate (‘accuracy’ measured by the correlation between objective and subjective 
measures); however, the association was no longer significant when the model was adjusted 
for asthma severity.  
 
Pulmonary Function 
Racial differences also exist in pulmonary function. For example, a comparison of 
young children in Detroit (not necessarily with asthma, but adjusted for asthma diagnosis) 
showed that African-American children had significantly smaller FVC values than white 
children (Joseph, Ownby et al. 2000). Several additional studies have confirmed the role that 
race plays when considering normal predicted vales of FVC, FEV1, and other measurements 
of lung function (Pool and Greenough 1989; Sylevester, Milligan et al. 2005; Trochtenberg, 
BeLue et al. 2008; Hankinson, Kawat et al. 2010). 
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Quality of Life 
Racial differences have also been observed in asthma-related quality of life. In a 
study of 2,128 adults with asthma, African-Americans were found to report significantly 
worse quality of life, even after adjusting for demographic characteristics and asthma 
severity (Haselkorn, Lee et al. 2008). African-American and Latino children with asthma 
have been shown to have worse emotional health and miss more school days because of 
asthma than white children with asthma (Lieu, Lozano et al. 2002; Meng, Babey et al. 2007). 
 
Medication Adherence 
Some studies have demonstrated disparities in rates of adherence to asthma 
medications, primarily in adults. In a one-month study of 86 adults with asthma, adherence 
was significantly lower among minority patients (29% minority vs. 51% white, p<.001) (Le, 
Bilderback et al. 2008). Adherence was measured by MDILog, an electronic monitoring 
device. In another study of 85 adults, African-Americans were significantly less likely to be 
completely adherent than white patients in bivariate analysis (OR; 0.23, CI: [0.10-0.56]) 
(Apter, Boston et al. 2003). In multivariate analysis, the odds ratios increased to 0.35, yet this 
was still statistically significant.  
 
 Summary 
Racial health disparities are evident in many different aspects of asthma, especially in 
the rates of adverse outcomes. Reducing and eliminating racial health disparities has been 
identified as a priority for the research community by several national organizations. More 
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research is needed to understand the causes of racial disparities in health outcomes observed 
in pediatric asthma populations.  
 
Contributors to Disparities 
Understanding how racial disparities in asthma-related health outcomes occur and 
persist is a critical first step towards the ultimate goal of developing and implementing 
programs and policies to eliminate them. Racial health disparities are extremely complex, 
and are hypothesized to be the result of many different factors, including social conditions 
(e.g., poverty), institutional conditions (e.g., economic system), individual demographics 
(e.g., education, SES), and biologic/genetic pathways (e.g., genetic ancestry) (Adler and 
Rehkopf 2008; Warnecke, Oh et al. 2008). Previous research has explored several different 
sources of the racial disparities that are observed in pediatric asthma outcomes; associated 
factors have been shown to include socioeconomic status, cultural beliefs and fear of 
medications (Cabana, Lara et al. 2007; Diette and Rand 2007; Mangan, Wittich et al. 2007; 
Forester, Ong et al. 2008). Some other potential reasons for the observed disparities observed 
include differences in access to health care, under-use of control medications, environmental 
exposures, and differences in quality of care (Erickson, Iribarren et al. 2007). Patient-
provider communication, a subset of quality of care, warrants additional research in this 
population. 
 
Patient-Provider Communication 
Patient-physician communication has been considered as a possible source of some of 
the health disparities that are seen among racial and ethnic minorities, and also as an 
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important means for addressing these issues (Diette and Rand 2007; Okelo, Wu et al. 2007; 
Smith, Betancourt et al. 2007; Weiss 2007; Bigby and Ashley 2008; Rand and Apter 2008). 
Several studies have reported that differences in race and ethnicity between patients and their 
providers can present important cultural barriers to effective communication (Levy 1985; 
Kagawa-Singer 2003; Diette and Rand 2007). These cultural barriers include beliefs, 
practices and medical expectations (Mull 1993). It has been shown, for example, that 
minority status is associated with more negative medication beliefs (e.g., it is not necessary 
to take as much medicine as the doctor prescribed) (Mull 1993). Cooper, in particular, has 
done extensive work in the field of patient-physician relationships and racial health 
disparities. She and colleagues have shown that communication during medical visits differs 
between African-American and white patients, with physicians being more verbally 
dominant and engaging in less patient-centered communication with African-Americans 
(Johnson, Roter et al. 2004). Cooper stresses the need for more research to understand the 
mechanisms through which race impacts communication. This may lead to the development 
of interventions to reduce disparities (Cooper, Hill et al. 2002; Johnson, Roter et al. 2004; 
Cooper, Beach et al. 2006).     
Different characteristics of the patients, physicians, and the health-care system may 
contribute to poor communication. Some of the patient characteristics that may contribute to 
poor communication are health literacy and health beliefs (Diette and Rand 2007). For 
example, it has been reported that among low-income minority patients, beliefs about the 
effectiveness of their asthma medications, as well as their perception of the quality of their 
communication with their physician, were associated with poor adherence with control 
medication (Apter 1998). Also, physicians may be contributing to health disparities through 
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inadvertent biases and/or stereotyping. An Institute of Medicine report (2003) concluded that 
inadvertent bias, stereotyping and prejudice are likely important contributing factors to health 
disparities. Physician beliefs may be driving these stereotypes. For example, van Ryn and 
Burke interviewed 193 physicians following 618 patient encounters to determine how race 
and socio-economic status affected physicians’ perceptions of patients (van Ryn and Burke 
2000). The results show that physicians tended to perceive African-Americans more 
negatively on a number of dimensions, including beliefs about following medical advice, 
though not medication adherence specifically. Only 42% of African-Americans were rated by 
physicians as having no risk for “non-compliance” with medical advice, compared to 57% of 
whites. 
 
 
Background Summary 
Pediatric asthma is a serious chronic condition, and optimal management involves an 
ongoing partnership between the physician, patient and parent. Clear and effective 
communication is an integral part of that partnership. However, minority patients are less 
likely to achieve optimal management than their white counterparts. Differences in 
communication may be a significant contributor to health disparities in this population. This 
research was developed to explore whether there were differences, by patient race, in patient-
provider communication concerning four specific aspects of asthma management: symptom 
monitoring, pulmonary function, asthma-related quality of life, and control medication 
adherence. 
 
 CHATPER THREE: CONCEPTUAL FRAMEWORK 
 
 In this chapter, I present the conceptual model that was used to guide this research. 
Both of the aims of this research attempt to determine if patient-provider communication 
about the specific asthma-related topics highlighted in the previous chapter (asthma 
symptoms, pulmonary function, quality of life, control medication adherence) vary as a 
function of patient race. No adaptable models were identified that address the effect patient 
race may have on patient-provider communication. Therefore, a conceptual model was 
constructed from a review of the existing literature to identify characteristics that would 
likely be associated with the experience of asthma, and/or communication about these 
experiences. The model proposes that patient race, as well as the interaction of patient race 
with the reason for the visit, will be associated with patient-provider communication about 
asthma symptoms, pulmonary function, asthma-related quality of life, and control medication 
adherence. Figure 1 below presents the conceptual model.  The specific aims of the research, 
as well as the hypotheses for each aim, are presented after Figure 1. 
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Figure 1. Relationship between Patient’s Race, Reason for Visit and Communication about 
Asthma Symptoms, Pulmonary Function, Quality of Life and Medication Adherence 
 
Control Variables
Patient Gender, Age, Asthma 
Severity, Insurance, Asthma 
Meds, Comorbidities, Past Visits 
with Dr., Caregiver Education, 
Dr. Gender, Yrs in Practice, 
Length of Visit
Communication
Discussions of:
Symptoms
Pulmonary Function
Asthma Related Quality of Life
Control Med Adherence
Assessment
Education Provided
Reason for Visit
Patient Race
 
Specific Aim 1 
To examine the relationship between patient race and patient-provider communication, 
including discussions about asthma symptoms, pulmonary function, quality-of -life, and 
control medication adherence 
H1:  A comprehensive discussion of asthma symptoms is less likely to occur if the 
patient is minority than if the patient is white 
H2: Pulmonary function (from peak flow meter or spirometry) is less likely to be 
discussed if the patient is minority than if the patient is white 
H3: A comprehensive discussion of asthma-related quality-of-life is less likely to 
occur if the patient is minority than if the patient is white 
H4:  Adherence to control medication is less likely to be discussed if the patient is 
minority than if the patient is white 
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H5: The physician will be less likely to provide education about the importance of 
adherence if the patient is minority than if the patient is white 
 
Specific Aim 2 
To determine if the relationship between patient race and the asthma communication 
variables specified above (asthma symptoms, pulmonary function, quality-of-life, and 
control medication adherence) varies depending on the primary purpose of the visit 
(whether the primary purpose of the visit is asthma) 
H6:  Racial differences on the communication variables will be greatest when the 
primary purpose of the visit is not related to asthma.  
 
Outcome Variables 
All of the outcome variables in the conceptual model and specific aims are aspects of 
communication regarding asthma management determined to be important based upon 
previous research and the NAEPP guidelines (NHLBI 1997; Apter 1998; Asmussen, Weiss et 
al. 2004; Cabana, Slish et al. 2006). Although it is not mandated that physicians follow these 
guidelines, they provide the most comprehensive collection of evidence-based practices 
recommended to improve asthma outcomes. Therefore, this research was partially framed as 
a study of how closely physicians were adhering to the guidelines when treating pediatric 
asthma patients, and whether there were any differences associated with the race of the 
patient.  
Taken together, communication about the topics of asthma management included in 
the model, asthma symptoms, pulmonary function, asthma-related quality of life, and control 
medication adherence, allows the physician to assess the patient’s overall asthma control. 
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Symptom assessment is an important aspect of assessing disease management, and should 
usually be a part of the communication (NHLBI 1997).  Even if the patient and/or parent do 
not always volunteer this information, it is the responsibility of the physician to inquire 
(NHLBI 1997). Pulmonary function is a second, more clinical method to assess disease 
management, either through a discussion of results from at-home monitoring with a peak 
flow meter, or in-office assessment with spirometry. Asking about quality-of-life is another 
way that physicians can assess overall disease management, as it involves a discussion about 
how asthma may be impacting the child (and family) on a daily basis, whether it is 
preventing them from any activities they would otherwise be able to do, or any negative 
emotions they may be having. Communication on quality of life may indicate a more patient-
centered method of communication by the physician. Finally, according to the NAEPP 
guidelines, patients with persistent asthma should be actively taking at least one control 
medication. Physicians should assess the patient’s adherence to his or her control medication, 
especially if prior assessment of symptom experience or pulmonary function monitoring has 
indicated that the patient does not have optimal disease control. It is also the responsibility of 
the physician to educate the patient and/or parent about the importance of being adherent to 
any prescribed medication, especially if non-adherence is reported.  
 
Patient Race 
 Patient race is the primary independent variable for all hypotheses in Aim 1. Race has 
been shown to be associated with both asthma prevalence and asthma-related health 
outcomes, as described in the previous chapter (Akinbami 2006; Gupta, Carrión-Carire et al. 
2006; Diette and Rand 2007). Often, patients who identify themselves as belonging to a 
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racial minority group have a higher prevalence of asthma and worse health outcomes (Kruse 
2007; Brim, Rudd et al. 2008). These disparities continue to persist, and in spite of the 
previous research that has been conducted, the causes of the disparities are not fully 
understood. This gap in the literature provided the rationale for this research. The model 
proposes that patient race has a direct effect on patient-provider communication regarding the 
aforementioned topics of asthma management.  Patient-provider communication has been 
shown to have an effect on health outcomes (Cabana, Slish et al. 2006). Therefore, if the 
hypotheses are supported, and patient race is shown to be associated with communication 
about asthma management, it will support the argument that patient-provider communication 
may be contributing to disparities in health outcomes in pediatric asthma. 
 
Reason for Visit 
 The interaction between patient race and the reason for the medical visit is the 
primary independent variable for all hypotheses in Aim 2. As presented in the previous 
chapter, the aforementioned aspects of asthma management are highlighted as important 
topics in the NAEPP guidelines (NHLBI 1997). As a chronic condition, pediatric asthma 
should be monitored closely, and the NAEPP guidelines state that “symptoms and clinical 
signs of asthma should be assessed at each health care visit through physical examination and 
appropriate questions.” However, the conceptual model hypothesizes that communication 
about asthma management will be greater for patients being seen for asthma than for a reason 
other than asthma. Moreover, because discussions of asthma management may be less 
structured in visits where the primary reason for the visit is not asthma, these visits may 
provide greater opportunity for biases that affect patient-provider communication about 
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asthma. Therefore, the model also proposes that the effect of patient race on patient-provider 
communication regarding the aforementioned topics of asthma management may be 
moderated by the reason for the visit. Specifically, if there are differences in communication 
between minority and white patients, these differences may be magnified if asthma is not the 
primary reason for the visit. Thus, the model hypothesizes that a minority patient visiting the 
doctor for a non-asthma related reason is less likely to discuss aspects of asthma management 
than: (1) a white patient being seen for asthma, (2) a minority patient being seen for asthma, 
or (3) a white patient being seen for a non-asthma related reason. Aim 2 also addresses an 
important gap in the literature. No studies were identified that examined the interaction 
between patient race and reason for the visit on patient-provider communication. If there is 
an association between patient race and communication, and this association varies as a 
function of the primary nature of the visit, it will provide an important avenue for additional 
research to explore health disparities in pediatric asthma.  
 
Control Variables 
In addition to the primary independent and outcome variables described above, the 
review of the literature indicated that other patient, caregiver, and physician characteristics 
should be considered as well when testing the hypotheses above. These characteristics have 
been shown to be associated with patient-provider communication, or with specific asthma 
outcomes (e.g. symptom experience).  
 
Patient and Caregiver Characteristics 
Basic demographic information, including age and gender, have been shown to 
influence patient-provider communication in patients with asthma. Patient age has been 
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reported to influence participation in the conversation at the prompting of the physician, with 
the physician addressing older children more, in a sample of 4-12 year olds (Tates, 
Meeuwesen et al. 2002). Girls have also been shown to participate less in some specific types 
of talk, and physicians are more likely to give more information to boys (Cox, Smith et al. 
2007). It has also been reported that women with asthma report a lower quality of life than 
men (Skobeloff, Spivey et al. 1992).  
Asthma severity may also impact communication. Studies have found that children’s 
ability and accuracy at reporting asthma symptoms decreases as their asthma severity 
increases (Yoos, Kitzman et al. 2003; Butz, Walker et al. 2007).  
A family’s socioeconomic status (SES) encompasses many different things, and is 
normally measured with family income, parental education level, and parental occupation.  
SES has been associated with communication styles. For example, a review of 12 papers that 
examined the relationship of patient SES with physician’s communication style found that 
lower SES was associated with a less participatory consulting style, characterized by less 
information giving and less partnership building (Willems, De Maesschalck et al. 2005). The 
most economically disadvantaged patients were less likely to report that providers always 
explained things so that they understood, compared to patients not economically 
disadvantaged (DeVoe, Wallace et al. 2009). The caregiver’s education level may also 
impact communication; physicians may provide more information if they perceive the 
caregiver to have a high level of educational attainment (Cabana, Chaffin et al. 2008). If 
physicians believe that certain patients are not likely to follow their advice, they may be less 
likely to counsel and educate these patients (Cabana, Lara et al. 2007). A family’s SES can 
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also influence the type of insurance they have, and having health insurance has been 
associated with better communication (DeVoe, Wallace et al. 2009).   
 
Physician Characteristics 
Physicians have different communication styles, and certain characteristics of the 
physician may be associated with different communication styles. One such characteristic is 
the number of years since they graduated from medical school. For example, one study 
showed that recent graduates considered themselves to have a more empathetic 
communication style, as opposed to a more problem-oriented approach (Barnsley 1999). 
Gender may also influence communication, as female physicians have been reported to be 
more empathic communicators, to engage in more active partnership behaviors and to engage 
in more patient-centered communication (Roter and Hall 2004; Nicolai and Demmel 2007).  
 
Summary 
 This chapter proposes a conceptual model for examining the relationship between 
patient race and patient-provider communication, and describes the hypotheses that were 
tested in this research. Patient race and reason for visit were identified as the primary 
variables of interest. Any effect of patient race on patient-provider communication regarding 
the aforementioned topics of asthma management, and any moderating effect that reason for 
visit has on the relationship between patient race and communication will provide important 
information about possible contributors to health disparities in this pediatric asthma 
population. 
 CHAPTER FOUR: METHODS 
 
In this chapter, I outline the methods and procedures used in the conduct of this study. 
The chapter begins with an overview of the study and a description of the study setting. 
Information concerning participant eligibility and data collection procedures is provided 
next. The following section describes the sources of data for the study, including 
transcription and coding information. The next section provides information on participation 
rates, and final patient enrollment. Then, all of the study variables are described in detail. 
Finally, the data analysis plan is described, including data management, preliminary 
analyses, and primary analyses for each specific aim of the study. 
 
Overview 
The study hypotheses were tested by conducting secondary analyses of data collected 
pursuant to a larger study funded by the National Heart, Lung and Blood Institute of the 
National Institutes of Health. The primary study is examining the relationship between 
patient-provider communication and health outcomes in pediatric asthma patients. Patient 
enrollment and data collection for the primary study began in June 2006; enrollment closed 
in September 2009. Six clinics in North Carolina participated in the study. Data were 
collected in conjunction with a regular clinic visit. Patients were not asked to schedule a 
doctor’s visit specifically for the study. The encounter between the patient, the patient’s 
parent (or caregiver, used interchangeably), and the physician within the examination room 
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was audio-recorded by a recorder set-up by the research assistant. Data were also collected 
from patients and parents via questionnaires. The patient also demonstrated asthma devices 
techniques and completed a spirometry test, if one was not administered as part of the 
medical visit. A standard operating procedure for administering the spirometry test was part 
of the study protocol. 
A research assistant conducted a follow-up visit in the patient’s home approximately 
one month after the office visit, during which the patient and parent completed questionnaires 
similar to those completed in the office. Spirometry was also administered at home. 
However, data from the home visit questionnaires were not used in this analysis and 
therefore they are not described further.  
This secondary analysis was submitted to the Biomedical Institutional Review Board 
(IRB) of the University of North Carolina at Chapel Hill. It was determined that this research 
did not constitute human subjects research as defined under federal regulations, and did not 
require IRB approval (study was exempted from IRB approval).   
 
Study Setting 
Physicians were recruited from five pediatric clinics and one general practice clinic 
located in rural and suburban areas of North Carolina. Physicians were asked to participate 
based on whether they regularly saw pediatric asthma patients. In total, forty-four providers 
from the six clinics agreed to participate in the study. Written consent was obtained from 
each participating physician. All of the medical clinics accepted Medicaid in addition to 
private insurance. This is advantageous, because clinics that accept Medicaid are more likely 
to serve a racially diverse patient population (Dubay, Kenney et al. 2002). Therefore, the 
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patient base from these clinics was likely to support this research, for which a racially diverse 
sample was necessary.  
 
Enrollment Period 
Patient enrollment for the study began in June 2006. The first patients from clinics 1, 
2, 3 and 5 were enrolled by September 2006; the first patient from clinic 4 was enrolled in 
April 2007, and the first patient from clinic 6 was enrolled in December 2007. Patient 
enrollment officially closed in September 2009, although enrollment had already been 
stopped at some clinics. Enrollment at clinic 2 ended in October 2007, enrollment at clinic 3 
ended in April 2008, and enrollment in clinic 6 ended in October 2008. 
 
Patient Eligibility 
Children (between 8-16 years old) with a prior diagnosis of asthma and scheduled for 
an upcoming office visit during the enrollment window were identified by clinic staff as 
potential study participants. The upcoming visit did not necessarily have to be asthma-
related. When clinic staff called parents prior to the day of their visit to remind them of the 
visit, they were asked to also briefly mention the primary study, to gauge possible interest.  
On the day of the visit, after the parent checked-in with clinic staff, a member of the staff 
asked the parent if they would be interested in participating in the study. If the parent was 
interested, the staff member connected the parent and patient with a research assistant to 
explain the study in more detail in the waiting room. After explaining the primary study, the 
research assistant administered an eligibility screener to determine if the patient and parent 
met all eligibility criteria.  
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Patients were eligible to participate in the study if they met the following criteria: (a) 
were between the ages 8 and 16 years old, (b) were able to speak and read English, (c) were 
able to read the assent form, (d) had been seen at the clinic at least once before, (e) were 
present at the visit with an adult caregiver (parent or legal guardian) who was at least 18 
years old, and (f) had been previously diagnosed with asthma. The parents’ eligibility was 
determined based upon parent/legal guardian status, age, and ability to read and speak 
English. If the patient and parent were eligible and agreed to participate, the research 
assistant obtained written informed consent from the parent and written assent from the child.  
Each patient/parent dyad was assigned a unique identification number. This number 
was based on the clinic the patient attended and the physician the patient saw on the day of 
enrollment. (For example, patient 020405 was enrolled at clinic 02, saw the physician 
designated as 04, and was the fifth patient enrolled for that physician).  
 
Data Sources 
Data came from the following sources: (1) a patient eligibility screener, (2) the office 
visit audiotapes (3) the questionnaire administered to patients immediately following the 
office visit, (4) the questionnaire administered to caregivers immediately following the office 
visit, (5) patient medical records, and (6) physician questionnaires. Each of these sources is 
described in more detail below. 
 
Data Collection Procedures 
 The research assistant administered an eligibility screener to the patient and their 
caregiver to determine their eligibility for the study. The eligibility screener included 
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questions about the patient’s age, the caregiver’s age, the patient’s ability to read and speak 
English, the caregiver’s ability to read and speak English, any prior visits at the clinic, and 
the caregiver’s relationship with the patient. Questions were also asked about the patient’s 
asthma medications and frequency of asthma symptoms. Answers to questions about 
medication and symptoms were used to classify the patient’s asthma severity. A copy of the 
eligibility screener is included as Appendix 2. 
If a patient and parent were deemed to be eligible and agreed to participate in the 
study, the research assistant accompanied them from the waiting room into the examination 
room. Prior to the physician entering the exam room, the research assistant set up a digital 
tape recorder and microphone, began recording, and exited the room. Recording may have 
been stopped and re-started by the physician or research assistant during the visit for certain 
reasons, such as a prolonged discussion with the patient’s sibling, leaving the room for an 
extended period (e.g., to perform a spirometry test), or discussions of a very personal nature. 
At the conclusion of the visit, as the physician was leaving, the research assistant re-entered 
the exam room and stopped the tape recorder.  
In addition to the audiotape, data were also collected from patient and parent 
questionnaires. After the patient exam, the research assistant accompanied the patient and 
parent to a separate space within the office, usually an empty office or exam room. The 
parent completed a brief self-administered questionnaire regarding their child’s asthma, 
including medications, their relationship with the physician, and at-home management. The 
research assistant administered a questionnaire to the patient. If space permitted, the parent 
and patient were physically separated as far apart as possible, to reduce the amount of 
parental assistance with the questionnaire. As part of this questionnaire, the research assistant 
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asked the patient to demonstrate using his or her normal asthma devices. For example, the 
research assistant asked the patient to demonstrate using an inhaler (with or without a 
spacer), a diskus, and a turbuhaler, as applicable. All patients were asked to demonstrate 
using a peak flow meter, regardless of whether they used one on a regular basis. A 
spirometry test was also administered by the research assistant to assess pulmonary function, 
if one had not been completed by clinic staff as part of the medical visit. 
  Additional information about the patient was obtained from a review of the patient’s 
medical record. After the visit, the research assistant reviewed the patient’s chart in order to 
record information on initial asthma diagnosis, previous visits, asthma-related emergency 
room visits and hospitalizations, and any comorbidities. The timing of the medical record 
review varied, from the day of enrollment up to six months afterwards. 
 Finally, data on physicians came from a self-administered physician questionnaire. 
Shortly after each physician agreed to participate in the study, he or she completed a brief 
questionnaire, which included demographic questions, as well as questions about their views 
on asthma management.  
 
Coding of Audiotape Visits 
Transcript Generation 
  All office visit audiotapes were transcribed under the protocol of the primary study; 
transcription occurred under the supervision of the principal investigator.  Having 
transcriptions of the medical visits makes the coding of the audiotapes more reliable (Mishler 
1984; Waitzkin 1990).  The transcribing rules used in this study have been used by the 
principal investigator before and were adapted from transcribing rules used by previous 
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researchers in the area of physician-patient communication (Mishler 1984; Waitzkin 1990).  
All identifying information was removed when the audiotapes were transcribed, such as 
names and schools. The transcriptionists were blinded to the study hypotheses. All 
audiotapes will be destroyed at the conclusion of the primary study. 
 
Coding 
All communication variables come from the transcripts of the audiotapes; two 
separate coding instruments were used. The Primary Coding Instrument (PCI) was developed 
under the protocol of the primary study. The Supplemental Coding Instrument (SCI) was 
developed specifically for this secondary analysis.  
 
Primary Coding Instrument (PCI) 
 The Primary Coding Instrument (PCI) was developed during the pilot study of the 
primary study. The PCI was designed to code characteristics of communication and other 
aspects of the visit. The principal investigator trained research assistants on how to code the 
transcripts using the PCI. Coders were trained using 12 transcripts from the pilot study. 
During training, 0.80 was used as a floor for coder inter-rater reliability.  Practice and 
training continued until this minimum level of reliability was achieved. After coders 
achieved this minimal level of reliability, they began coding the actual transcripts. All coders 
coded 20 of the same transcripts. Spot checks of coder performance were conducted by the 
principal investigator throughout the coding process to assure that reliability levels were 
being maintained.  If a problem in a coder’s performance was detected, the coder was 
immediately pulled from coding the transcripts and went back to practice. The coder resumed 
    49
age
 
coding when the minimum level of 0.80 was achieved. The coders were blinded to the 
hypotheses of both the primary study and this secondary study, as well as patient 
characteristics (e.g., patient race).   
 
 
Supplemental Coding Instrument (SCI) 
 
 The Supplemental Coding Instrument (SCI) was developed specifically for this 
secondary analysis. The SCI was developed to code for communication variables not 
captured by the PCI. I developed the SCI, in conjunction with my advisors, which included 
the principal investigator of the primary study. I trained one other coder on the SCI according 
to the methods outlined above for the PCI, using an identical 0.80 minimum inter-rater 
reliability. The coder and I practiced until we achieved an inter-rater reliability of 0.80, and 
periodically checked to ensure this level was being maintained. Reliability was calculated on 
approximately 10% of the total sample, and an inter-rater reliability of 0.80 was maintained 
on all items.  I performed all of the coding with the SCI, and was therefore not blinded to the 
study hypotheses. However, both the reliability coder and I were blinded to the patient’s race 
when coding. The SCI and the coding rules for the SCI are included as Appendices 3 and 4, 
respectively. 
 
Participation Rates/Refusals 
A total of 385 eligible asthma patients were approached about participating in the 
study by a research assistant. Of these, 52 parents/patients declined to participate in the 
study. Common reasons given for not wanting to participate included: either the patient or 
parent was not interested in participating, the parent did not have the time to participate, or 
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the parent did not want the home visit.  Based upon the final enrollment of 333 patients, the 
participation rate for the study was 86%. This is in line with the 80% participation rate 
anticipated by the principal investigator of the main grant, based upon prior research (Sleath 
et al. 2003; Sleath et al. 2002). This participation rate does not include potential participants 
who were approached by the research assistant and determined to be ineligible.  
 
Final Sample Size 
A total of 333 patients were enrolled in the study, as shown in Figure 2. The 
audiotapes for 27 patients were unusable, either because the tape was blank and contained no 
audio, or because there was too much static/interference to accurately hear and transcribe 
what was on the tape. Blank tapes were often the result of technical problems by the research 
assistants, such as using dead batteries in the recorder or forgetting to turn on the 
microphone. Of the 306 tapes with usable audio content, there were 46 instances where the 
tape cut-off prematurely, before the end of the visit, per the primary coder of the PCI. In 
these 46 cases, the primary investigator and I independently reviewed the transcripts, and 
determined whether there was enough content to warrant inclusion in the final sample for 
analysis. We came to the same determination in each case, deciding to retain 44 of these 46 
patients in the analysis, leaving a sample of 304 patients. Additionally, patient enrollment 
was particularly slow at one of the six participating clinics. This clinic was the only one that 
was a general family practice, and did not see pediatric patients exclusively (Clinic 6). Only 
four patients were enrolled at this clinic. After a year, the decision was made to cease 
enrollment at this clinic, and to exclude any of the patients enrolled at this clinic from the  
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Figure 2. Determination of Final Sample Size 
333 Patients 
Enrolled
Exclude 27 patients 
with no audio
N = 306
Exclude 3 patients 
from Clinic 6
N=301
Exclude 2 ineligible 
patientsN = 299
Exclude 3 patients 
with a lot of missing 
data
N = 304
N = 301
Exclude 2 patients 
for cut-off audio
Exclude 3 patients 
from Clinic 6
Exclude 2 ineligible 
patients
Exclude 3 patients 
with a lot of missing 
dataFinal N = 296
 
 
analyses. One of these four patients would have already been excluded due to an unusable 
audiotape. The other three were excluded, leaving 301 patients.   
A review of the symptom and medication use information on the eligibility screener 
by the research team pharmacist and physician determined that three patients were ineligible 
for the study, and should not have been enrolled. Two of these patients were already 
excluded from the analysis due to audio problems; the third patient was excluded from the 
analysis. The eligibility screener was missing for another patient. For this patient, a review of 
information regarding medication use and symptom frequency ascertained via other research 
documents (parent and patient office questionnaires) did not support the case for the patient’s 
eligibility. Therefore, this patient was also excluded from the analysis, leaving 299 patients.  
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The patient files for an additional three patients either could not be located, or had a 
large amount of missing data, and nearly all of the independent variables would have had to 
have been imputed for analysis. Therefore, these three patients were not included in the 
analyses. Thus, a total of 296 patients were included in the analysis.  
 
Variables and Measures 
This section describes all of the variables that were used in the primary and 
preliminary analyses. Table 6 outlines all key variables that will be included in the analyses, 
including sources and range. A more detailed description of the variables follows the table. 
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Table 6.  All Variables: Variable Name, Source, Range 
 
VARIABLE SOURCE RANGE 
Communication – Asthma Symptoms 
Asthma Symptoms Discussed 
Supplemental Coding 
Instrument (SCI) 
1 = Yes                 
0 = No 
Initiator of Asthma Symptom Discussion 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
Symptoms Experienced 
1 = Yes                 
0 = No 
9 = n/a 
Symptoms Reported By 
1 = Caregiver (parent) 
0 = Patient 
9 = n/a 
Nighttime Symptoms Discussed 
1 = Yes                 
0 = No 
Initiator of Nighttime Symptom Discussion 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
Exercise-Induced Symptoms Discussed 
1 = Yes                 
0 = No 
Initiator of Exercise-Induced Symptom 
Discussion 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
Daytime Symptoms Discussed 
1 = Yes                 
0 = No 
Initiator of Daytime Symptoms Discussion 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
Symptom Frequency Discussed 
1 = Yes                 
0 = No 
Initiator of Symptom Frequency Discussion 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
Physician Makes Suggestions to Alleviate 
Asthma Symptoms 
1 = Yes                 
0 = No 
9 = n/a 
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VARIABLE SOURCE RANGE 
Communication – Spirometry 
Spirometry Discussed SCI 
1 = Yes                 
0 = No 
Initiator of Spirometry Discussion 
 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
Spirometry Test Performed at Visit PCI 
1 = Yes 
0 = No 
Results of Day’s Spirometry Test Discussed 
 
SCI 
1 = Yes 
0 = No 
9 = n/a 
Spirometry Interpretation by Physician 
2 = Good  
1 = Ambiguous  
0 = Poor  
9 = n/a 
Physician Makes Suggestions to Improve 
Spirometry Results/Asthma Control 
1 = Yes 
0 = No 
9 = n/a 
Communication – Peak Flow 
Peak Flow Meter Discussed PCI 
1 = Yes 
0 = No 
Initiator of Peak Flow Discussion 
SCI 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
Peak Flow Meter Results Discussed 
1 = Yes 
0 = No 
Peak Flow Interpretation by Physician 
2 = Good  
1 = Ambiguous  
0 = Poor  
9 = n/a 
Physician Makes Suggestions to Improve 
Peak Flow Readings/Asthma Control 
1 = Yes 
0 = No 
9 = n/a 
Communication – Quality of Life 
Activity Limitation (AL) Discussed 
SCI 
1 = Yes 
0 = No 
Initiator of AL Discussion 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
AL Reported 
1 = Yes 
0 = No 
9 = n/a 
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VARIABLE SOURCE RANGE 
Communication – Quality of Life (continued) 
AL Reported By 
SCI 
1 = Caregiver (parent) 
0 = Patient 
9 = n/a 
Negative Emotions (NE) Discussed  
1 = Yes 
0 = No 
Initiator of NE Discussion 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
NE Reported 
1 = Yes 
0 = No 
9 = n/a 
NE Reported By 
1 = Caregiver (parent) 
0 = Patient 
9 = n/a 
Missed School Discussed 
1 = Yes 
0 = No 
Initiator of Missed School Discussion 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
Physician Makes Recommendations to 
Improve Patient’s Quality of Life (QoL) 
1 = Yes 
0 = No 
9 = n/a 
Family QoL Discussed 
1 = Yes 
0 = No 
Initiator of Family QoL Discussion 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
Communication – Control Medication Adherence 
Medication Adherence Discussed PCI 
1 = Yes 
0 = No 
Initiator of Adherence Discussion 
SCI 
1 = Doctor          
2 = Caregiver (parent)           
3 = Patient 
9 = n/a 
Non-Adherence Reported 
1 = Yes 
0 = No 
9 = n/a 
Non-Adherence Reported By 
1 = Caregiver (parent) 
0 = Patient 
Education on Adherence Provided PCI 
1 = Yes 
0 = No 
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VARIABLE SOURCE RANGE 
Primary Independent Variables 
Patient Race Child Survey (CS) 
1 = Minority        
0 = White 
Reason for Visit Parent Survey (PS) 
1 = Asthma 
0 = Non-asthma 
Control Variables - Patient Characteristics 
Ethnicity 
 
 
CS 
 
1 = Hispanic                   
0 = Non-Hispanic 
Gender 
1 = Male               
0 = Female 
Age, in years 8 – 16 
Asthma Severity Eligibility Screener 
1 = Moderate/Severe       
0 = Mild  
Private Insurance Coverage PS 
1 – Private 
0 –  Other 
Number of Asthma Medications 0 – 5 
Number of Co-Morbid Conditions Medical Record 
Abstraction 
0 – 11 
Number of Past Visits With Physician 0 – 70 
Control Variables - Caregiver Characteristics 
Education, in years PS 2 – 20 
Control Variables - Physician Characteristics 
Gender Physician 
Questionnaire 
1 = Male                
0 = Female 
Years Since Medical Degree Received 1 – 43 
Other Control Variables 
Length of Visit, in minutes Primary Coding 
Instrument (PCI) 
2.32 – 45.72 
Tape Cuts-Off Prematurely 
1 = Yes                 
0 = No 
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Outcome Variables 
The following sections describe the communication variables, as well as other 
outcomes variables. Data were collected on four separate areas of asthma management: 
asthma symptoms, pulmonary function, asthma-related quality of life, and control medication 
adherence. Most of the communication variables are dichotomous, indicating whether any 
discussion of the topic occurred, rather than the content of the discussion.  
 
Communication – Asthma Symptoms 
Asthma Symptoms Discussed: This variable indicates whether any discussion of asthma 
symptoms occurred (including nighttime, exercise-induced, or daytime). It was coded as 
‘yes’ if during the visit either the patient or parent mentioned any coughing, wheezing, chest 
pains, or shortness of breath that the patient had been experiencing recently. These are 
collectively referred to as ‘asthma symptoms.’ In addition, if the patient or parent mentioned 
any other symptoms that are not usually considered asthma symptoms, but that the patient or 
parent clearly attributed to asthma (i.e. headaches, dizziness, etc), the variable was coded as 
‘yes.’ Finally, this variable was also coded as ‘yes’ if the physician asked about any asthma 
problems that the patient may have been experiencing, or a general question about asthma 
(i.e. How is your asthma doing?), even if the patient did not report that he or she was 
experiencing any symptoms. Discussion of possible medication side effects was not included 
in this variable.  
 
Initiator of Symptom Discussion: In cases where Asthma Symptoms Discussed 
was coded as ‘yes’, this variable indicates the person who initiated the conversation. 
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If the discussion was prompted by the physician asking about asthma symptoms, the 
physician was coded as the initiator. If asthma had previously been mentioned in the 
conversation, and the physician asked about any problems or troubles, the physician 
was coded as the initiator. Otherwise, the initiator was coded as either the patient or 
the parent, depending on who first mentioned the topic.  
 
Symptoms Experienced: In cases where Asthma Symptoms Discussed was coded 
as ‘yes’, this variable indicates whether the patient was experiencing asthma 
symptoms (or symptoms that the patient or parent attributed to asthma.). It was coded 
as ‘yes’ if the patient or parent stated that the patient was experiencing any asthma 
symptoms. If the patient or parent stated specifically that the patient was not 
experiencing any asthma symptoms, it was coded as ‘no.’ 
 
Symptoms Reported By: In cases where Symptoms Experienced was coded as 
‘yes’, this variable indicates who first said that the patient was experiencing 
symptoms, i.e., the patient or the parent/caregiver. 
 
Table 7 below outlines the Coding Rules that were applied to transcripts when coding the 
above Symptoms communication variables; these Coding Rules were developed to 
accompany the Supplemental Coding Instrument (SCI). The first four columns give all 
combinations of situations that may surround the discussion. The last three columns outline 
how each Symptom variable was coded in the corresponding situation. 
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Table 7.  Coding Rules for Symptom Communication Variables 
 
SITUATION CODED VARIABLES 
Asthma 
has been 
mentioned 
Physician 
asks about 
problems  
(asthma 
specific) 
Physician 
asks about 
problems 
(not asthma 
specific) 
Patient or 
Parent 
Mentions 
Asthma 
Symptoms 
Asthma 
Symptoms 
Discussed 
Initiator Symptoms 
Experienced 
No No No No No N/A N/A 
No Yes No No Yes Physician No 
No No No Yes Yes Patient or 
Parent 
Yes/No 
No Yes No Yes Yes Physician Yes/No 
No No Yes  No No N/A N/A 
No Yes Yes No Yes Physician No 
No No Yes Yes Yes Patient or 
Parent 
Yes/No 
No Yes Yes Yes Yes Physician Yes/No 
Yes Yes No No Yes Physician No 
Yes No No No No N/A N/A 
Yes Yes No Yes Yes Physician Yes/No 
Yes No No Yes Yes Patient or 
Parent 
Yes/No 
Yes Yes Yes  No Yes Physician No 
Yes No Yes No Yes Physician No 
Yes Yes Yes Yes Yes Physician Yes/No 
Yes No Yes Yes Yes Physician Yes/No 
 
Nighttime Symptoms Discussed: This variable indicates whether asthma nighttime 
symptoms were specifically discussed. This may include trouble falling asleep at night, or 
waking up anytime in the middle of the night, due to asthma symptoms. 
 
Initiator of Nighttime Symptoms Discussion: In cases where Nighttime Symptoms 
Discussed is coded as ‘yes’, this variable indicates the person who initiated the 
discussion. If the discussion was prompted by the physician asking about nighttime 
asthma symptoms, the physician was coded as the initiator. Otherwise, the initiator 
was coded as either the patient or the parent, depending on who first mentioned the 
topic. 
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Exercise-Induced Symptoms Discussed: This variable indicates whether asthma symptoms 
specifically experienced during exercise or other comparable physical activity (playing, 
recess, PE class, sports, etc.) were discussed.  
  
Initiator of Exercise Symptom Discussion:  In cases where Exercise-Induced 
Asthma Symptoms Discussed is coded as ‘yes’, this variable indicates the person 
who initiated the discussion. If the discussion was prompted by the physician asking 
about exercise-induced asthma symptoms, the physician was coded as the initiator. 
Otherwise, the initiator was coded as either the patient or the parent, depending on 
who first mentioned the topic. 
 
Daytime Symptoms Discussed: This variable indicates whether asthma symptoms 
experienced specifically during the daytime (but not during exercise) were discussed.  
 
Initiator of Daytime Symptoms Discussion: In cases where Daytime Symptoms 
Discussed is coded as ‘yes’, this variable indicates the person who initiated the 
discussion. If the discussion was prompted by the physician asking about daytime 
symptoms, the physician was coded as the initiator. Otherwise, the initiator was 
coded as either the patient or the parent, depending on who first mentioned the topic. 
 
Symptom Frequency Discussed: This variable indicates whether the frequency with which 
the patient may or may not have been experiencing symptoms was discussed. The frequency 
may have been in relation to any specified period of time, such as a day, a night, a week, or a 
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month. It may also include a discussion of how often the patient had to use his or her rescue 
inhaler (e.g., albuterol) during any specified period of time, since rescue inhaler use almost 
always indicates the patient is experiencing acute symptoms.  
 
Initiator of Symptom Frequency Discussion: In cases where Symptom Frequency 
Discussed is coded as ‘yes,’ this variable indicates the person who initiated the 
discussion. If the discussion was prompted by the physician asking about symptom 
frequency, the physician was coded as the initiator. Otherwise, the initiator was coded 
as either the patient or the parent, depending on who first mentioned the topic. 
 
Physician Makes Suggestions to Alleviate Asthma Symptoms: In cases where the patient 
or parent reported that the patient was experiencing any kind of symptoms (i.e., Symptoms 
Experienced coded as ‘yes’), this variable indicates whether the physician subsequently 
made a recommendation to help the patient alleviate the symptoms. A recommendation may 
have included a change in medication regimen, suggestions about avoiding asthma triggers, 
or adjustments in physical activity.  
 
Communication - Spirometry 
Spirometry Discussed:  This variable indicates whether any discussion of spirometry 
occured. It was coded as ‘yes’ if any reference to spirometry was made, even if a spirometry 
test was not performed on that day. For instance, the physician may have stated that a 
spirometry test was not needed since one was just performed three months ago. In addition, 
    62
age
 
this variable was coded as ‘yes’ if there was any reference to a “breathing test” or “lung test.” 
These terms are often used interchangeably with spirometry.  
 
Initiator of Spirometry Discussion: In cases where Spirometry Discussed was 
coded as ‘yes,’ this variable indicates the person who initiated the discussion. If the 
discussion was prompted by the physician mentioning spirometry in any context, the 
physician was coded as the initiator. If the patient or parent/caregiver inquired about a 
spirometry test, either he or she was coded as the initiator.  
 
Spirometry Test Performed at Visit: This variable indicates whether a spirometry test was 
performed that day as part of the medical visit by clinic staff. It includes spirometry tests 
administered by the study research assistant only if the physician specifically referred to the 
test in the course of the visit. 
 
Spirometry Test Results Discussed: This variable indicates whether the physician discussed 
the results of a spirometry test, performed on that day, with the patient and/or 
parent/caregiver.  
 
Spirometry Interpretation by Physician: In cases where Spirometry Test Results 
Discussed was coded as ‘yes,’ this variable indicates how the physician interpreted 
the results of the spirometry test and its relation to overall asthma control for the 
patient. This variable was coded as either: 1) good results/good control, 2) 
ambiguous, or 3) not good results/poor control. If the physician indicated that the test 
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results were good (normal), with no qualifications, this variable was coded as ‘good.’ 
If the physician indicated that the results were not adequate,  this variable was coded 
as ‘poor.’ However, in cases where the physician described the results as good, but 
with some qualifications, or where it was difficult to definitively determine how the 
results were being interpreted, the variable was coded as ambiguous. (Example: 
“..This looks ok, but not great”) 
 
Physician Makes Suggestions to Improve Spirometry Results: In cases where the 
Spirometry Interpretation variable was coded as either ‘poor’ or ‘ambiguous,’ this variable 
indicates whether the physician subsequently made a recommendation to help the patient 
achieve better control. 
 
Communication – Peak Flow Meter 
Peak Flow Meter Discussed: This variable indicates whether any discussion of peak flow 
meter use occurred, regardless of whether the patient regularly used one at home.  This 
variable came from the Primary Coding Instrument (PCI). On the PCI, peak flow discussion 
is broken down into five separate categories. If any of these categories were coded ‘yes’ on 
the PCI, the Peak Flow Meter Discussed variable was coded as ‘yes’ for the present study.  
The box below was adopted from the coding rules of the PCI and briefly describes each of 
the peak flow categories. 
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Excerpt from the Coding Rules from the Primary Coding Instrument:  
1) Provider asks about peak flow use: 
Includes whether the child is using a peak flow meter currently or whether the provider is 
suggesting use of a peak flow meter. 
 
2) How often to use: 
Includes discussion of when a peak flow meter should be used, or discussion of how often to 
use it if needed on a regular basis. 
 
3) Explains zones: 
Includes discussion of zones based on result of using peak flow meter.  These zones are often 
referred to by color: red, yellow, green.  Can include if the doctor reviews the zones that have 
already been set.   
 
4) What to do if in zone: 
Includes what medications the patient should take if in different zones.  Also, includes if 
peak flow should be repeated more often during certain periods or after administration of 
medication.  Includes the doctor informing the patient of who to call and what medications to 
take based on the zone they are in. 
 
5) Provider suggests keeping a journal: 
Includes if the provider suggests keeping a record of peak flow measurements, or whether he 
inquires about continued record keeping.  This can also include if the patient is keeping a 
journal of asthma symptoms. 
 
 
Initiator of Peak Flow Discussion: In cases where Peak Flow Meter Discussed was 
coded as ‘yes,’ this variable indicates the person who initiated the discussion. It will 
be applied in the same manner as the variables listed above. 
 
Peak Flow Meter Results Discussed: This variable indicates whether there was any 
discussion of peak flow meter results, either from home or from a test administered at 
the visit by the physician.  
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Peak Flow Results Interpretation by Physician:  In cases where Peak Flow Meter 
Results Discussed was coded as ‘yes,’ this variable indicates how the physician 
interpreted the results of the peak flow use and its relation to overall asthma control 
for the patient. The categories (good, ambiguous, poor) are identical to those for the 
spirometry variable described above. 
 
Physician Makes Suggestions to Improve Peak Flow: In cases where the interpretation of 
the peak flow results was poor or ambiguous, this variable indicates whether the physician 
subsequently made a recommendation to help the patient achieve better control. 
 
Communication – Asthma-Related Quality of Life 
Coding rules for the quality-of-life variables were adapted from two sources: 1) the Pediatric 
Asthma Quality of Life Questionnaire (PAQLQ), a validated instrument used to measure 
quality of life in pediatric asthma patients (Juniper, Guyatt et al. 1996; Okelo, Wu et al. 
2004) and the NAEPP guidelines. The PAQLQ asks 23 questions in three domains: 
symptoms, activities, and emotions. Discussions of Asthma Symptoms were not included 
here, because they were coded as a separate category. The PAQLQ asks about the previous 
week; however, for the purposes of these variables, reference to any time period was 
acceptable. The four domains comprising the quality of life variables include: activity 
limitation, negative emotions, missed school, and family’s quality of life. Each domain is 
described in greater detail below. 
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Activity Limitation (AL) Discussed: This dichotomous variable indicates whether any 
discussion of activity limitation due to asthma occurred. For example, there may have been 
discussion of whether the patient was able to keep up with others during recess, had to take 
more breaks than normal, or wasn’t able to participate in any pleasurable activity (e.g., band).  
 
Initiator of AL Discussion: In cases where AL Discussed was coded as ‘yes,’ this 
variable indicates the person who initiated the discussion. It was applied in the same 
manner as the variables listed above. 
 
AL Reported: In cases where AL Discussed was coded as ‘yes,’ this variable 
indicates whether the patient or parent reported that the patient had been experiencing 
activity limitations. 
 
AL Reported By: In cases where AL Reported was coded as ‘yes’, this variable 
indicates whether the patient or parent first mentioned that the patient was 
experiencing activity limitations.  
 
Negative Emotions (NE) Discussed: This dichotomous variable indicates whether any 
discussion of negative emotions experienced by the patient due to asthma occurred during the 
office visit. Trigger words, including those adapted from the PAQLQ, include: frustrated, 
worried, concerned, troubled, angry, irritable, different, left-out, uncomfortable, frightened 
by an attack, sad, angry, embarrassed, or upset. 
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Initiator of NE Discussion: In cases where NE Discussed was coded as ‘yes,’ this 
variable indicates the person who initiated the discussion. It was applied in the same 
manner as the variables listed above. 
 
NE Reported: In cases where NE Discussed was coded as ‘yes,’ this variable 
indicates whether the patient or parent reported that the patient had been experiencing 
negative emotions. 
 
NE Reported By: In cases where NE Reported was coded as ‘yes’, this variable 
indicates whether the patient or the parent first mentioned that the patient was 
experiencing negative emotions.  
 
Physician Makes Suggestions to Improve Patient’s Quality of Life (QoL): In cases where 
the patient’s quality of life had been affected (AL Reported or NE Reported coded as 
‘yes,’), this variable indicates whether the physician subsequently made a suggestion to help 
the patient improve his or her quality of life. 
 
Missed School Discussed: This dichotomous variable indicates whether any discussion of 
the patient missing school due to asthma occurred. 
 
Initiator of Missed School Discussion: In cases where Missed School Discussed 
was coded as ‘yes,’ this variable indicates the person who initiated the discussion. It 
was applied in the same manner as the variables listed above. 
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Family’s QoL Discussed: This dichotomous variable indicates whether any discussion of the 
family’s quality of life due to the patient’s asthma occurred. For example, it may include 
discussion of a parent missing work, or not being able to devote as much time as desired to 
another child. 
 
Initiator of Family QoL Discussion: In cases where Family QoL Discussed was 
coded as ‘yes,’ this variable indicates the person who initiated the discussion. It was 
applied in the same manner as the variables listed above. 
 
Communication – Control Medication Adherence 
Control Medication Adherence Discussed: This variable indicates whether there was any 
discussion of adherence to a control medication. Discussion of adherence to control 
medications was coded as ‘yes’ if during the visit either the patient, parent or physician 
discussed whether the patient was taking his or her control medication as instructed by the 
physician. In some instances, the patient was taking more than one control medication. If 
adherence to any asthma control medication was discussed, this variable was coded as ‘yes.’ 
This variable is from the Primary Coding Instrument. The excerpt below from the Coding 
Rules for the Primary Coding Instrument outlines how this variable was coded. 
Excerpt from Coding Rules from Primary Coding Instrument: 
Adherence:  For controller meds adherence refers to info or questions about taking meds 
when you’re suppose to and how you’re suppose to.     
Example:  “Are you taking your medicine everyday like I told you to?”   
                                     “So he is doing his Advair twice a day, he’s not missing that?”  
                                      “Every night? 
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Initiator of Adherence Discussion: In cases where Control Medication Adherence 
Discussed was coded as ‘yes’, this variable indicates the person who initiated the 
discussion. It was applied in the same manner as the variables listed above. 
 
Non-Adherent: In cases where Control Medication Adherence Discussed was 
coded as ‘yes’, this variable indicates whether the patient was non-adherent. It was 
coded as ‘yes’ if the patient or parent reported that the patient was not taking the 
control medication in accordance with the physician’s instructions. For example, if 
the patient or parent reported ‘forgetting’ or ‘skipping doses’, this variable was coded 
as ‘yes’. If the patient or parent did not mention any of these things, the variable was 
coded as ‘no’. 
 
Non-Adherence Reported By: In cases where Non-Adherent was coded as ‘yes’, 
this variable indicates whether the patient or the parent initially said that the patient 
was non-adherent.  
 
Adherence Education Provided: This variable indicates whether the physician provided 
education on the importance of patient adherence to control medication.  It was coded as 
‘yes’ if during the visit the physician explained to the patient or parent the importance of 
taking a control medication everyday, the purpose of a control medication (vs. a rescue 
medication), or explained how taking the control medication may reduce asthma symptoms 
and over-dependence on a rescue medication (e.g., albuterol). This variable is from the 
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Primary Coding Instrument. The excerpt below from the Coding Rules for the Primary 
Coding Instrument outlines how this variable was coded. 
 
Excerpt from Coding Rules from Primary Coding Instrument: 
 
Purpose: If they discuss what a medication is used for.   This would also include the reasons 
that a patient needs the medicine, or why they are using or want to use the medicine.   
 
Example for education on purpose of controller med: “…the main objective is to try to 
prevent the symptoms, not deal with the symptoms as they come up. Like you said,…once 
he’s having a bad attack….he can’t suck the medicine out of the Pulmicort turbuhaler right? 
Okay. So…He needs to be on a medicine every single day…to prevent his symptoms.” 
 
 
Example for education on purpose for controller med: “Singulair is an allergy medicine and I 
chose it because it also helps with asthma.” 
 
In addition to the adherence education variable described above, a separate variable from the 
PCI reads: The provider explains that the child needs to take his controller every day. If this 
variable was coded as ‘yes’ on the PCI, the Adherence Education Provided variable was 
coded as ‘yes’ in this study. 
 
Primary Independent Variables 
Patient Race: Patients (children) were asked to select the category that best described their 
race. Patients were given six categories from which to choose. In addition, patients were 
allowed to indicate more than one category. For analysis, race was dichotomized into two 
categories: minority and white. Patients who selected any minority category (any other than 
White), even in conjunction with selecting ‘White,’ were categorized as minority for the 
purposes of this analysis 
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Race question as it appears on the child questionnaire: 
 
Which of the following best describes your race? (You may select more than one 
category.) 
 
 a American Indian or Alaskan Native 
 b Asian 
 c Black or African American 
 d Native Hawaiian or other Pacific Islander 
 e White 
          f       Other: 
                           g. specify    
 
Reason for Visit: This dichotomous variable indicates whether or not the primary reason for 
the visit was asthma, as reported by the parent.  
 
Control Variables: Patient Characteristics 
Ethnicity: Ethnicity is a dichotomous variable indicating whether patients are of Hispanic 
ancestry. 
Ethnicity question as it appears on the child questionnaire: 
Are you Hispanic or Latino? [Were you or your parents born in Mexico, Central 
America, South America, Cuba, or Puerto Rico?] 
 
  1 Yes 
  0 No 
 
Gender: Gender is a dichotomous variable indicating whether the patient is male or female.  
 
Age: This variable indicates the patient’s age at enrollment. Patient age ranged from 8-16 
years. 
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Private Insurance Coverage: Private insurance coverage is a dichotomous variable 
indicating whether the patient was covered by a private insurance company on the day of 
enrollment. Parents were given a choice of five different options to indicate their child’s 
insurance coverage. The insurance options on the parent questionnaire included: none, 
private, Medicaid, NC Health Choice, and Other. NC Health Choice is a state program that 
provides free or reduced price coverage for children whose families make too much money to 
qualify for Medicaid yet cannot afford private insurance.  All responses other than private 
were collapsed into a separate Other category. 
 
Asthma Severity: Asthma severity is a dichotomous variable indicating whether the research 
assistant classified the patient as having: 1) mild persistent asthma or 2) moderate-to-severe 
persistent asthma. The research assistant made this classification based upon the responses 
given to questions asked during eligibility screening regarding symptom frequency and 
medication use. A doctor or pharmacist later verified the classification made by the research 
assistant. The eligibility screener has been validated against physician diagnosis (Joseph 
1996; Clark, Brown et al. 2002; Lewis, Robins et al. 2004).  
 
The research assistant classified the patient as having moderate-to-severe asthma if the 
patient:  
o reported experiencing daytime symptoms everyday, or 
o reported experiencing nighttime symptoms five or more times a month, or  
o reported taking two or more asthma control medications.  
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The research assistant classified the patient has having mild asthma if the patient:  
o did not meet the criteria for moderate-to-severe asthma, and  
o reported experiencing daytime symptoms more than two times a week, or 
o reported experiencing nighttime symptoms two-four times a month, or  
o reported taking one asthma control medication. 
 
The symptom frequency questions were based on the NAEPP guidelines. The medication 
questions were based on previous research validating medication use as a way to classify 
asthma severity (Lewis, Robins et al. 2004). 
 
Number of Asthma Medications: This variable indicates the number of different asthma 
medications the child used in the past week, according to the parent. In addition, if the parent 
indicated that the child was taking an antihistamine for asthma, it was counted as an asthma 
medication. 
 
Number of Co-Morbid Conditions: This variable indicates the number of co-morbid 
chronic conditions the patient had been diagnosed with. This information was obtained by the 
research assistant from the review of the patient’s medical records. 
 
Number of Past Visits with Physician:  This variable indicates the number of prior visits 
the patient has had with the physician over their lifetime. These visits may have been for any 
purpose (not just asthma-related).   
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Control Variables: Caregiver Characteristics 
Education: This variable indicates the number of years of education completed by the 
parent/caregiver accompanying the patient to the visit. 
 
Control Variables: Physician Characteristics 
Gender: Gender is a dichotomous variable indicating whether the physician is male or 
female.  
 
Years Since Medical Degree Received: This variable indicates the number of years since 
the physician received his or her medical degree at the time he or she agreed to participate in 
the primary study.  
 
Other Control Variables 
Length of Visit: This variable indicates the amount of time, in minutes, that the patient spent 
with the physician during the visit. It was often less than the length of the actual tape. Often, the 
research assistant began the tape recorder before the physician entered the examination room. 
Also, the physician may have exited the room after beginning for various reasons (e.g. to 
retrieve medication samples). And, as noted above, recording may have been stopped and re-
started for different reasons. In most cases, notes on the transcript indicated when the physician 
first entered the room, and whether he or she left and returned. In cases where this information 
could not be gleaned from the transcript, the actual audiotape was reviewed.   
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Tape Cut Off Prematurely: This dichotomous variable indicates whether the tape recorder 
cut off before the verbal communication between the patient, parent, and physician in the 
exam room was complete.  
 
Creation of Composite Variables 
 In addition to the variables described above, several variables were created by 
combining information from multiple sources. The creation of these variables is described 
below. 
 
Racial Concordance 
A new variable, Racial Concordance, was created to indicate whether the patient and 
caregiver each reported their respective race in the same way (1 = Racially Concordant, 0 = 
Not Racially Concordant). This variable was created because of the importance of the race 
variable for this analysis, and it would be informative to know whether the race of the patient 
was the same as the race of the parent. For example, a patient whose parents are of different 
races may have reported his or her race as both African-American and white, while the 
child’s mother reported her race as white only. This situation would be coded as ‘Not 
Racially Concordant.’  Results from preliminary analyses will determine whether this 
variable will be included in the primary analyses. If a large percentage (>25%) of the sample 
has racial discordance, this variable will be included in the primary analyses. Otherwise, it 
will be used for descriptive purposes only. 
 
. 
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Comprehensiveness of Symptom Discussion 
 A new variable, Comprehensiveness of Symptom Discussion, was created to 
indicate the comprehensiveness of the discussion concerning asthma symptoms. This 
variable was created from the following four symptom variables: 
• Nighttime Symptoms Discussed 
• Exercise-Induced Symptoms Discussed 
• Daytime Symptoms Discussed 
• Symptom Frequency Discussed 
The Comprehensiveness of Symptom Discussion variable ranged from 0-4. For 
visits where asthma symptoms were not discussed at all, the variable had a value of zero. 
Each ‘yes’ response increased the value for the Comprehensiveness variable by one point.   
In instances where asthma symptoms were discussed, yet none of the four areas listed above 
was included in the discussion, one point was given. 
 
Comprehensiveness of the Quality of Life Discussion 
A new variable, Comprehensiveness of the Quality-of-Life Discussion, was 
similarly created to indicate the comprehensiveness of the discussion concerning the patient 
and family’s asthma-related quality of life. This variable was created from the following four 
quality-of-life variables: 
• Activity Limitations Discussed 
• Negative Emotions Discussed 
• Missed School Days Discussed 
• Family’s Quality of Life Discussed 
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The Comprehensiveness of the Quality of Life Discussion variable ranged from 0-
4. For visits where none of these aspects of quality-of-life were discussed, the variable had a 
value of zero. Each ‘yes’ response increased the value for the Comprehensiveness variable 
by one point.  
 
Quality of Life Problem Reported 
 A new dichotomous variable, Quality of Life Problem Reported, was created to 
indicate whether the patient reported a quality of life problem, either by expressing that 
he/she was experiencing any Activity Limitation or Negative Emotion.   
 
Pulmonary Function Discussed 
 A discussion of pulmonary function may have included a discussion of spirometry or 
peak flow meter use. From these two separate variables, a new dichotomous variable, 
Pulmonary Function Discussed, was created, indicating whether either of these two topics 
was discussed.  
 
Poor Pulmonary Function 
 A new dichotomous variable, Poor Pulmonary Function, was created to indicate 
whether the physician interpreted either the patient’s spirometry test results or current peak 
flow meter readings as ‘poor’ or ‘ambiguous.’ 
 
 
 
    78
age
 
Sample Size and Statistical Power  
Power analyses were performed using SAS 9.1.3 (Cary, NC) after data collection was 
completed. Actual sample sizes for the two independent groups and frequency of the 
outcome for the reference group (white patients) were used to calculate the effect size (odds 
ratio) that the study would be powered to detect. Power analyses were performed on three 
dichotomous outcome variables. For the variable Pulmonary Function Discussed, the 
frequency of ‘yes’ responses in the reference group was 53%. Given a sample of 296 
patients, a power of 0.80, and an alpha of 0.05, the study was powered to detect an odds ratio 
of 0.50. For the variable Adherence Discussed, the frequency of ‘yes’ responses in the 
reference group was 49%. Given a sample of 251 patients (patients on a control medication), 
a power of 0.80 and an alpha of 0.05, the study was powered to detect an odds ratio of 0.46.  
For Adherence Education Provided, the frequency of ‘yes’ responses in the reference group 
was 24%. Given a sample of 251 patients, a power of 0.80, and an alpha of 0.05, the study 
was powered to detect an odds ratio of 0.35.  
 
Data Analysis 
Data Management 
 Data from the Supplemental Coding Instrument were entered into a SPSS 14.0 
dataset. All other study data obtained as part of the primary study had previously been 
entered into separate SPSS datasets. After all datasets were complete, one master SPSS 
dataset for this research was created by merging datasets by patient’s unique ID number, and 
retaining only the variables included in this analysis. This master dataset was converted into 
SAS datasets for all analyses to be completed using SAS 9.1.3 (Cary, N.C.). 
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Data Cleaning 
 Several steps were taken to ensure both the accuracy and completeness of the dataset. 
The entire dataset was analyzed to determine if any values were outside of the appropriate 
range for each variable. In all instances that values outside the expected range were found, 
the original patient file was reviewed and the value corrected. 
 The dataset was also reviewed for missing data. In each instance where a missing 
value was found, the first step was to review the hard copy source (questionnaire, coding 
instrument, etc) to determine whether it was simply data entry error or omission. Table 8 
reports all the instances where data were missing from the original patient file. The variable 
that had the most missing values was the number of past visits with the physician. There 
were 36 instances where this variable was missing. There were three missing values for the 
number of co-morbidities, four missing values for years of education for the caregiver, and 
two missing values for the type of insurance for the child. 
 
Table 8.  Variables with Missing Values, and Number of Missing Values 
Variable Number of Missing Values 
Number of Past Visits with Physician  36 
Caregiver Education, in Years  4 
Number of Co-morbidities  3 
Private Insurance   2 
 
 
 For instances where the data were truly missing due to patient non-response, analyses 
were performed to detect any pattern of missingness, which in turn determined the method 
for addressing the problem. The strongest assumption is that the data are missing completely 
at random (Allison 2009). Two methods were used to detect any patterns of missingness. 
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First, patients were divided into two groups: those with missing responses and those without. 
T-tests and chi-square statistics were calculated to detect mean differences on key 
independent variables, continuous and categorical, respectively, between the two groups.  
The two groups did not differ significantly on any of the variables, with the exception of 
years of education for the caregiver, which itself had missing data. Second, a dummy 
variable was created to indicate whether a patient had any missing values. A logistic 
regression of this variable was run on independent variables where no observations were 
missing. None of the coefficients were significant, indicating that the assumption of the 
variables being missing completely at random (MCAR) was not violated (Allison 2009). 
However, since the first test did indicate that patients with missing data did differ 
significantly from patients with no missing data, on caregiver education, a more conservative 
assumption was made that the data were missing at random (MAR). This assumption can not 
be tested directly, because it requires knowledge of the missing values (Faris, Ghali et al. 
2002; Allison 2009).   
 Multiple imputation is a preferable method for addressing missing data that are 
assumed to be missing at random (Allison 2009). Multiple imputation was performed in SAS 
9.1.3. The Markov Chain Monte Carlo (MCMC) algorithm method was used for multiple 
imputation. An advantage of this method over a multivariate normal expectation-
maximization (EM) algorithm is that, in MCMC, after generating predicted values, random 
draws are made from the simulated error distribution for each regression equation and added 
to the predicted values for each individual to produce the imputed values, thereby 
compensating for the downward bias in variance estimates that usually results from other 
methods (Allison 2009).  Five imputed datasets were generated, and the appropriate model 
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was run on each imputed dataset. The results from these five datasets were combined to 
produce valid parameter estimates and standard errors for each model.   
 
Preliminary Analyses 
 This section describes several different analyses that were conducted to characterize 
the sample of patients and inform decisions about primary analyses. Descriptive statistics 
were calculated for all independent and dependent variables. Frequencies and percents were 
calculated for the categorical and dichotomous variables. Similarly, means and standard 
deviations were calculated for all continuous and count variables. Descriptive statistics were 
calculated for the complete sample, and by patient race. T-tests and chi-squared tests were 
used to test for significant differences between minority patients on continuous and 
categorical values, respectively. Descriptive statistics for the primary independent and 
dependent variables were also calculated by clinic, and ANOVA methods were used to assess 
differences among clinics.  If there were significant differences in any of the key independent 
variables by clinic, a ‘dummy’ variable for clinic was included in the primary analyses. For 
all continuous and count variables, the data were plotted to examine the structure and 
deviations from normality. Decisions on variable transformation based on skewness were 
made on an individual basis. The variation of the independent and control variables were 
examined. Independent variables with very small variation were not included in the primary 
analyses. 
 Other information was provided to describe additional characteristics of the sample, 
including the specific reason for the visit for patients where the reason is coded as ‘Other.’ 
Information will also be provided on the identity of the caregiver (e.g. mother, father, 
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grandparent) and other people present in the room during the patient’s medical visit. In order 
to retain maximal power in the primary analyses, this information will only be provided 
descriptively, and will not be included in the models for the primary analyses.  
 Descriptive statistics were calculated for the physicians included in the primary 
analyses. Bivariate relationships between the primary communication variables and patient 
characteristics were assessed using t-tests and chi-square statistics. These relationships were 
examined to understand the distribution of the independent variables to the dependent 
variables. A correlation matrix was also constructed to examine the relationships between the 
independent variables.  Finally, the patients excluded from the analysis due to problems with 
the audio were compared to the 296 included in the analysis; this was done for descriptive 
purposes. 
 
Primary Analysis   
Analysis - Aim 1 
 To examine the relationship between patient race and communication, including 
discussions about asthma symptoms, pulmonary function, quality-of -life, and control 
medication adherence. 
H1:  A comprehensive discussion of asthma symptoms is less likely to occur if the 
patient is minority than if the patient is white 
H2: Pulmonary function (from peak flow meter or spirometry) is less likely to be 
discussed if the patient is minority than if the patient is white 
H3: A discussion of asthma-related quality-of-life is less likely to occur if the patient 
is minority than if the patient is white 
H4:  Adherence to control medication is less likely to be discussed if the patient is 
minority than if the patient is white 
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H5: The physician will be less likely to provide education about the importance of 
adherence if the patient is minority than if the patient is white 
 
Hypotheses 1-5 were tested by running models utilizing generalized estimating 
equations. The patients were clustered by physician, to account for intra-physician 
correlation.  The alpha level for all analyses was 0.05. 
For each hypothesis above, the primary independent variable was Patient Race. The 
corresponding communication variable was included in each separate model as the dependent 
variable. Other explanatory variables included in each of the above models were: Reason for 
Visit, Age, Patient Gender, Insurance Coverage, Asthma Severity, Number of Asthma 
Medications, Number of Comorbidities, Past Number of Visits, Years Since M.D. Received, 
Caregiver Education, Physician Gender, Length of Visit, and Tape Cuts Off. 
Models to test Hypotheses 4 and 5 were only run on the subset of the sample that 
reported control medication use on the Eligibility Screener. The additional explanatory 
variables of Symptoms Experienced, Poor Pulmonary Function, and Quality of Life 
Problem Reported were also included in the model for Hypothesis 4, because if the 
physician appreciated that the patient was experiencing any negative effects of asthma, it was 
hypothesized that this should be associated with an increased likelihood of discussing control 
medication adherence. The additional explanatory variable of Non-Adherent was included 
in the model for Hypothesis 5, because it was hypothesized that a patient report of non-
adherence should be associated with an increased likelihood of the physician providing 
education on the importance of medication adherence.  
For each model, the ratio of the deviance to the degrees of freedom (DF) was 
reviewed, to assess goodness of fit. Because each model was run five times (five imputed 
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datasets), the mean ratio for model was reported. Deviance is defined as two times the 
difference of the log likelihood for the mean (“expected”) model and the log likelihood under 
the fitted model. It has an approximate chi-square distribution with n-p degrees of freedom, 
where n is the number of observations, and p is the number of predictor variables. If the 
model fits the data well, the ratio of the deviance to the degrees of freedom should be about 
one (Boyle, Flowerdew et al. 1997).  Large ratio values may indicate model misspecification 
or an over-dispersed response variable; ratios less than one may also indicate model 
misspecification or an under-dispersed response variable. As a consequence of these 
dispersion issues, the standard errors are incorrectly estimated. However, assuming the model 
is correctly specified, the regression estimates remain unbiased in the presence of ill-
dispersion. 
 
Analysis – Aim 2 
To determine if the relationship between race and the communication variables 
specified above varies as a function of the primary purpose of the visit (i.e., whether the 
primary purpose of the visit is related to asthma). 
H6:  Racial differences on the communication variables will be greatest when the 
primary purpose of the visit is not related to asthma.   
 
An interaction term between Race (Minority =1, White = 0) and Reason for Visit 
(Asthma = 1, Non-Asthma = 0) was created for this Aim. First, the values for Reason for 
Visit were reverse coded, so that Asthma = 0 and Non-Asthma =1. Therefore, a patient who 
was both a minority AND had a non-asthma-related visit had a value of 1. All other patients 
had a value of 0.   
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 Similar to Aim 1, separate logistic models using generalized estimating equations 
were run for each of the communication outcome variables, as appropriate.  For each model, 
the primary independent variable was the Race/Reason for Visit interaction variable. The 
same group of explanatory variables listed above in Aim 1 was also included in these models, 
and the models with Adherence Discussed and Education on Adherence as the dependent 
variables also included the same additional explanatory variables. Goodness of fit for each 
model will be reported as described above for Aim 1.  
 
Additional Analyses 
As described above, all minority patients were combined into one category 
(Minority) to maintain maximum power in the models. However, a separate sensitivity 
analysis was run to examine whether this significantly altered the results from having an 
African-American/Black category.  Models were also run using complete case analysis to 
account for missing data as opposed to multiple imputation. The analyses were re-run: (1) 
stratifying by reason for the visit, and (2) re-coding the reason for the visit so that other 
asthma-related conditions were included in the asthma category.   
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER FIVE – RESULTS 
 
Sample Characteristics 
Characteristics of the 296 patients included in the analyses are presented in the first 
column of Table 9. For the total sample, the majority of the visits, 56%, were asthma-related. 
The average patient age was 11 years (SD=2.4). The majority of the patients, 54%, were 
male. Most patients were classified as having moderate-to-severe asthma (72%) and were not 
covered by private insurance (71%). These patients either had no insurance (1%), or were 
covered by Medicaid (52%) or NC Health Choice (18%). NC Health Choice is a state 
program that provides free or reduced price coverage for children whose families make too 
much money to qualify for Medicaid yet cannot afford private insurance.  The average 
number of asthma-related medications that patients used in the previous week was 2.2 
(SD=0.9) and ranged between 0 and 5.  The average number of chronic co-morbid conditions 
that patients had in addition to asthma was 2.4 (SD=1.9). The number of co-morbid 
conditions ranged from 0 to 11. On average, patients had seen their doctor 11 times before 
(SD=11.5). The responses to this question varied widely, with number of prior visits ranging 
from 0 to 70. The average number of years of education for the caregiver was 12.8 (SD=2.5), 
and ranged from 2 to 20. The average visit lasted 15.2 minutes (SD=8.5). Visit length ranged 
from 2.3 minutes to 45.7 minutes. 
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Table 9 - Characteristics of Total Sample and Stratified by Patient Race  
      
 Total Sample  Minority White  
Sample Characteristics (N=296)   (N=131) (N=165) 
 
Reason for Visit, (%)    .   
Asthma Related  55.8   64.9 48.5*  
Non-Asthma Related 44.2   35.1 51.5*  
Age, mean (sd) 11.1 (2.4)   11.2 (2.4) 11.0 (2.4)  
Male, (%) 53.7   62.6 46.7*  
Asthma Severity, (%)       
Mild 28.0   27.5 28.5  
Moderate-to-Severe 72.0   72.5 71.5  
Insurance Coverage, (%) (a)       
Private 28.7   15.4 39.6*  
Other 70.6   84.6 60.4*  
Number of Asthma Medications, mean (sd) 2.2 (0.9)   2.2 (1.1) 2.1 (0.8)  
Number of Co-morbid Conditions, mean (sd) (b) 2.4 (1.9)   2.0 (1.8) 2.7 (1.9)*  
Number of Past Visits with Physician, mean (sd) (c) 11.1 (11.5)   11.0 (10.7) 11.2 (12.1)  
Caregiver Education (in years), mean (sd) (d) 12.8 (2.5)   12.4 (2.5) 13.1 (2.5)*  
Length of Visit (in minutes), mean (sd) 15.2 (8.5)   14.7 (7.4) 15.6 (9.2)  
*p<0.05      
(a) Variable contains 2 missing values      
(b) Variable contains 3 missing values      
(c) Variable contains 36 missing values       
(d) Variable contains 4 missing values      
 
The majority of visits by minority patients, 65%, were asthma-related, compared to 49% for 
white patients (χ2 =7.96, p=0.01). Approximately 63% of the minority patients were male, 
compared to 47% of white patients (χ2 =7.45, p=0.01). The insurance coverage distribution 
also differed significantly between the two groups. Approximately 15% of the minority 
patients were covered by private insurance, compared to almost 40% of the white patients (χ2 
=20.75, p<0.01). Minority patients had an average of 2.0 (SD=1.8) co-morbid conditions, 
compared to 2.7 (SD=1.8) for white patients (p<0.01). The caregivers of minority patients 
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reported completing an average of 12.4 (SD=2.5) years of education compared to 13.1 
(SD=2.5) years for the caregivers of white patients (p=0.03).  
The two groups did not differ significantly from each other on average age, asthma 
severity, average number of asthma medications, average number of past visits with the 
physician, or the average length of the visit. 
 
Sample Characteristics, by Clinic 
This section further describes characteristics of the sample, stratified by clinic. 
Sample characteristics stratified by clinic are presented in Table 10. In part due to differences 
in enrollment duration, patient enrollment was not evenly distributed among the five clinics. 
Clinic 1 enrolled the most patients, 115, which was almost twice as many as the next highest 
enrollment clinic, clinic 5, which enrolled 68 patients. Clinic 2 enrolled the fewest patients 
(n=20). 
There were several differences in patient characteristics by the clinic in which they 
were enrolled. The distribution of minority and white patients varied among the five clinics 
(F=11.78, p<0.001). Minority enrollment ranged from 29% at clinic 5 to 80% at clinic 2. The 
reason for the visit also varied across clinics (F=13.73, p<0.01). “Asthma” as the reason for 
the visit ranged from 37% at clinic 5 to 100% at clinic 2.  Other variables that varied across 
clinic were: average number of asthma medications reported (F=7.99, p<0.01), the average 
number of co-morbidities recorded (F=27.45, p<0.01), and the average length of visit 
(F=3.38, p=0.01).  The average number of asthma medications ranged from 1.9 (SD=0.9) at 
clinic 5 to 2.9 (SD=1.0) at clinic 3. The average number of co-morbid conditions ranged from  
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Table 10 - Sample Characteristics and Primary Discussion Variables, Stratified by Clinic 
      
 
Clinic 1 Clinic 2 Clinic 3 Clinic 4 Clinic 5 
Sample Characteristics (N=115) (N=20) (N=36 ) (N=57 ) (N=68) 
Race of Patient, (%) *      
Minority 32.2 80.0 77.8 52.6 29.4 
White 67.8 20.0 22.2 47.4 70.6 
Reason for Visit, (%)*      
Asthma Related  48.7 100.0 91.7 54.4 36.8 
Other Reason 51.3 0.0 8.3 45.6 63.2 
Age, mean (sd) 11.3 (2.5) 10.6 (1.9) 11.4 (2.3) 11.1 (2.5) 10.9 (2.4) 
Male, (%) 55.7 65.0 52.8 63.2 39.7 
Asthma Severity, (%)      
Mild 27.8 50.0 19.4 28.1 26.5 
Moderate-to-Severe 72.2 50.0 80.6 71.9 73.5 
Insurance Coverage, (%) (a)      
Private 27.0 21.0 19.4 40.4 29.9 
Other 73.0 79.0 80.6 59.6 70.1 
Number of Asthma Medications,  
mean (sd)* 2.0 (0.9) 2.4 (1.0) 2.9 (1.0) 2.1 (0.8) 1.9 (0.9) 
Number of Co-morbid Conditions,  
mean (sd) (b)* 3.1 (1.7) 1.5 (2.4) 1.9 (1.6) 0.7 (0.8) 3.2 (1.6) 
Number of Past Visits with  
Physician, mean (sd) (c) 11.4 (11.7) 12.2 (13.5) 10.3 (11.9) 13.2 (12.5) 8.6 (9.0) 
Caregiver Education (in years),  
mean (sd) (d) 12.8 (2.4) 12.3 (2.3) 12.4 (2.4) 13.6 (2.8) 12.4 (2.5) 
Length of Visit (minutes), mean 
(sd)* 13.5 (8.3) 14.1 (9.2) 17.1 (7.9) 18.1 (8.2) 15.2 (8.5) 
Primary Discussion Variables 
          
Comprehensiveness of Symptom 
Discussion Score, mean (sd)* 2.1 (1.2) 3.0 (1.0) 2.2 (1.1) 2.6 (0.7) 2.3 (1.1) 
Pulmonary Function Discussed, 
(%)* 40.0 80.0 69.4 61.4 63.2 
Asthma-Related QoL Discussed, 
(%) 23.5 40.0 44.4 38.6 32.4 
Patient on a Control 
Medication, (N) (N=96) (N=17) (N=33) (N=54) (N=51) 
Control Medication Adherence 
Discussed 47.9 82.4 63.6 57.4 49.0 
Education on Adherence Provided 27.1 58.8 36.4 29.6 23.5 
* Significant difference between at least 2 clinics at p<0.05     
(a) Variable contains 2 missing values      
(b) Variable contains 3 missing values      
(c) Variable contains 36 missing values       
(d) Variable contains 4 missing values      
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0.7 (SD=0.8) at clinic 4 to 3.2 (SD=1.6) at clinic 5.  The average length of visit for clinic 1 
was 13.5 min (SD=8.3 min), compared to 18.1 min (SD=8.1 min) for clinic 4.  
Differences on the primary communication variables were also examined. Differences 
were observed in the average comprehensiveness of symptom discussion (CSD) score 
(F=5.15, p=0.01), and the frequency of any discussion of pulmonary function (F=5.66, 
p<0.01).  The average CSD score ranged from 2.1 at clinic 1 to 3.0 at clinic 2. Pulmonary 
function was discussed in 40% of the visits at clinic 1, compared to 80% of the visits at clinic 
2. 
Originally, Clinic was not intended to be included as a control variable in the primary 
analyses. However, due to the observed differences in sample characteristics by clinic, the 
decision was made to control for clinic in all primary analyses. A sensitivity analysis was 
performed without including the clinic identifiers.  
 
Physician/Provider Characteristics 
Forty-four providers originally agreed to participate in the study. Three were from the 
clinic that was dropped from the study. Additionally, there were five for whom no patients 
enrolled in the study, and one whose only patient was excluded from the analysis. Therefore, 
there were 35 physicians/providers for whom patients were included in this analysis. Of these 
35, four were physician assistants, nurse practitioners, or nurses. Seventeen of the study 
providers were male (48%). The average number of years since the provider had graduated 
from medical school was 17.7 (SD=10.0). The number of years ranged from 1 to 43. The 
number of patients enrolled per provider ranged from 1 patient (2 providers) to 29 patients (1 
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provider). The average number of patients per provider was 8.5 (SD=6.5). The modal 
enrollment was 7 patients (5 providers).   
 
Characteristics of the Office Visit 
 This section describes the characteristics of the office visit, specifically the 
communication variables and associated variables that came from the coding of the audiotape 
transcripts. Each of the following topics is described separately: symptoms, pulmonary 
function, asthma-related quality of life, and control medication adherence. Information on the 
communication variables and associated variables are presented in Table 11, both for the 
entire sample (first column) and stratified by patient race (second and third columns). 
 
Discussion of Asthma Symptoms  
 Overall, asthma symptoms were discussed in 277 of the 296 visits, approximately 
94% of the visits. The average score for the comprehensiveness of the symptom discussion 
was 2.3 (SD=1.1). The two dimensions of symptom experience that were discussed most 
often were nighttime symptoms and exercised-induced symptoms, which were discussed in 
71% and 74% of the visits, respectively. The least frequently discussed dimension was 
daytime symptoms, which was discussed in 13% of the visits. In the 277 visits where 
symptoms were discussed, 204 patients (74%) reported that they were experiencing 
symptoms. In the 204 visits where the patient was experiencing symptoms, the physician 
provided a suggestion to the patient and/or parent in 181 (89%) visits to help improve the 
symptoms. There were no statistical differences on any of the symptom discussion variables 
between minority patients and white patients.   
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Table 11 Communication and Associated Variables, Total Sample and Stratified by Patient 
Race 
 Total Sample Minority White 
 (N=296) (N=131) (N=165) 
Communication and Associated Variables       
Symptoms     
Asthma Symptoms Discussed, % (n) 93.6 (277) 93.9 (123) 93.3 (154) 
Comprehensiveness of Symptom Discussion, 
mean (sd) 2.3 (1.1) 2.3 (1.1) 2.3 (1.1) 
Nighttime Symptoms Discussed, % (n) 70.6 (209) 69.5 (91) 71.5 (118) 
Exercise-Induced Symptoms Discussed 74.3 (220) 73.3 (96) 75.2 (124) 
Daytime Symptoms Discussed 13.2 (39) 15.3 (20) 11.5 (19) 
Symptom Frequency Discussed 63.2 (187) 61.8 (81) 64.2  (106) 
Symptoms Experienced (where symptoms 
discussed)(a) 73.6 (204) 72.4 (89) 74.7 (115) 
Suggestions Given to Help Manage Symptoms 
(where symptoms experienced) (b) 88.7 (181) 93.3 (83) 85.2 (98) 
Pulmonary Function, % (n)   
    
Pulmonary Function Discussed 55.7 (165) 59.5 (78) 52.7 (87) 
Poor or Ambiguous Pulmonary Function Scores 
(where pulmonary function discussed) (c) 40.6 (67) 42.3 (33) 39.1 (34) 
Spirometry       
Spirometry Discussed 46 (136) 42.8 (56) 48.5 (80) 
Spirometry Performed at Visit 38.2 (113) 36.6 (48) 39.4 (65) 
Spirometry Results Discussed (where spirometry 
performed) (d) 77.9 (88) 81.2 (39) 75.4 (49) 
Poor or Ambiguous Spirometry Results (where 
results discussed) (e) 58.0 (51) 66.7 (26) 51 (25) 
Suggestions Given to Improve Pulmonary 
Function (where results were ambiguous or 
poor) (f) 86.3 (44) 84.6 (22) 88.0 (22) 
Peak Flow Meter       
Peak Flow Meter Discussed 21.3 (63) 23.7 (31) 19.4 (32) 
Current Peak Flow Meter Results Discussed 
(where peak flow meter discussed) (g) 44.4 (28) 45.2 (14) 43.8 (14) 
Poor or Ambiguous Peak Flow Results (where 
current results discussed) (h) 57.1 (16) 50.0 (7) 64.3 (9) 
Suggestions Given to Improve Peak Flow 
Results (where results are ambiguous or poor) (i) 75.0 (12) 85.7 (6) 66.7 (6) 
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Communication and Associated Variables Total Sample Minority White 
Asthma-Related Quality of Life, % (n)   
    
Any QoL Discussed 32.1 (95) 32.1 (42) 32.1 (53) 
Activity Limitation (AL) Discussed 27.4 (81) 26.7 (35) 27.9 (46) 
Negative Emotions (NE) Discussed  3 (9) 3.1 (4) 3 (5) 
Missed School Discussed 6.4 (19) 6.9 (9) 6.1 (10) 
Family QoL Discussed 2.4 (7) 4.6 (6) 0.6 (1) * 
Patient Experiencing QoL Problems (where QoL 
Discussed) (j) 45.3 (43) 42.9 (18) 47.2 (25) 
Suggestion Give to Help ImproveQoL (where 
patient reported experiencing QoL problems) (k) 60.5 (26) 72.2 (13) 52.0 (13) 
Control Medication Adherence, % (n) (n=251) (n=107) (n=144) 
Medication Adherence Discussed 54.6 (137) 62.6 (67) 48.6 (70)* 
Education on Adherence Provided 30.3 (76) 38.3 (41) 24.3 (35)* 
Non-Adherence Reported (where adherence 
discussed) (l) 31.4 (43) 31.3 (21) 31.4 (22) 
*p<0.05    
(a) N-Total (NT)=277; N-Minority (NM)=123; N-White (NW)=154   
(b) NT=204; NM=89; NW=115    
(c ) NT=165; NM=78; NW=87    
(d) NT=113; NM=48; NW=65    
(e) NT=88; NM=39; NW=49    
(f) NT=51; NM=26; NW=25    
(g) NT=63; NM=31; NW=32    
(h) NT=28; NM=14; NW=14    
(i) NT=16; NM=7; NW=9    
(j) NT=95; NM=42; NW=53    
(k) NT=43; NM=18; NW=25    
(l) NT=137; NM=67; NW=70    
 
 
Discussion of Pulmonary Function 
 Pulmonary function (either spirometry or peak flow meters, or both) was discussed in 
165 of the 296 visits, or 56% of the visits. The sections below describe communication about 
the two methods for measuring pulmonary function, spirometry and peak flow meters, 
separately. 
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Discussion of Spirometry 
Spirometry was discussed during 46% (n=136) of the visits. A spirometry test was 
actually administered during 38% (n=113) of the visits. In the 113 visits where a spirometry 
test was administered, the test results were discussed during 78% (n=88) of the visits. In the 
88 visits where the results of the spirometry test were discussed, the interpretation of the 
results (pulmonary function at the time) was determined to be poor or ambiguous during 58% 
(n=51) of the visits. The following excerpts from two transcripts provide examples of 
physicians’ interpretations that were coded as poor and ambiguous, respectively. 
• Physician: “alright buddy look,  let me tell you, these numbers don’t look too good 
really and we need to put him on, get him back on his medicines here for some of this 
breathing problem” 
 
• Physician: “Um, I mean this is… let me show you ah, she’s not bad.  She’s not 
perfect but she’s pretty close to doing good…” 
 
In the 51 visits where the results were determined to be ambiguous or poor, the physician 
made a suggestion to the patient and/or parent to help improve pulmonary function during 
86% (n=44) of the visits. The following excerpt provides an example of a suggestion made 
by a physician to help improve pulmonary function based on spirometry results. 
• Physician: “…his numbers on the spirometry, that’s what I am looking at, um, they 
look ok, they could be better…let me put him on 5 days of prednisone and you 
continue to use this albuterol for five days.” 
 
Caregiver: “Okay” 
 
Physician: “Take one pill once a day and he is going to do this albuterol before 
school, after school, dinner time and bedtime, 4 puffs with the spacer.” 
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Caregiver: “Okay.” 
 
Physician: “…then I want him to stay on his Singulair, he should be on a 10 mg 
tablet, one pill once a day everyday and that’s to prevent and control his asthma and 
then I what I want to do is see ya’ll back in two weeks” 
 
Caregiver: “Okay” 
 
Physician: “And I want to repeat his spirometry in two weeks after this course of 
steroids and after the five days of albuterol and I want to see if his numbers look 
better” 
 
Caregiver: “Okay” 
 
Physician: “Now if his numbers look better then fine, we’ll leave him on Singulair, if 
his numbers don’t look better then we are going to step up to something a little bit 
stronger than Singulair”  
 
There was no statistical difference for any of the spirometry variables between minority 
patients and white patients.  
 
Discussion of Peak Flow 
 Overall, peak flow meter use was discussed during 21% (n=63) of the visits. 
Of these 63 visits, current peak flow readings were discussed during 44% (n=28) of the 
visits. In the 28 visits where current peak flow readings were discussed, the interpretation of 
the results was poor or ambiguous in 57% (n=16) of these visits. The following excerpt 
provides an example of a physician’s interpretation that was coded as poor.  
 
    96
age
 
• (peak flow meter results being discussed) 
Physician: “Now I’m looking at a big difference between what you should be doing and 
what you blew.”   
 
In the 16 visits where the results were interpreted as poor or ambiguous, the physician 
made a suggestion to help improve pulmonary function in 75% (n=12) of these visits. The 
following excerpt provides an example of a suggestion made by a physician to help improve 
pulmonary function based on peak flow meter results.  
• (peak flow meter use is being discussed.) 
Patient: “I’m in my yellow zone right now.” 
 
Physician: “Then, then as you progress you can get wheezing, tightness of chest, 
shortness of breath, inability to sleep because you cough so much, ok.” 
 
Patient: “I’ve had that.” 
 
Physician: “All that is yellow zone stuff and then it tells you here what to do, you 
know. Here you will do your first step, is use your quick, ah, quick relief medication, 
that’s the Albuterol.” 
 
Caregiver: “Okay.” 
 
Physician: “And within the first hour you do three treatments.” 
 
Caregiver: “Okay.” 
 
Physician: “So that’s to open the airway. So you do treatment twenty minutes later, 
treatment, twenty minutes later, treatment, twenty minutes later, treatment.” 
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There was no statistical difference for any of the peak flow meter discussion variables 
between minority patients and white patients.  
 
Discussion of Asthma-Related Quality of Life 
 Asthma-related quality of life (at least one of the four dimensions) was discussed 
during 32% (n=95) of the visits. The most common component of asthma-related quality of 
life (QoL) that was discussed was activity limitation, which was discussed during 27% 
(n=81) of the visits. Negative emotions about asthma were discussed during 3% (n=9) of the 
visits. Missed school due to asthma was discussed during 6% (n=19) of the visits. The 
family’s quality of life due to the patient’s asthma was discussed during 2% (n=7) of the 
visits. 
In the 95 visits where asthma-related QoL was discussed, the patient reported 
experiencing QoL problems (either activity limitations or negative emotions) during 15% 
(n=43) of the visits. In these 43 visits where the patient reported have any QoL problems, the 
physician made a suggestion to the patient and/or parent to help improve the QoL during 
61% (n=26) of the visits. The following excerpts provide examples of suggestions made by a 
physician to help improve quality of life for a patient who reported experiencing activity 
limitations. 
• Physician: “What about PE….Do you have problems every time you have PE?” 
 
Patient: “…Yeah, I walk around the thing five times and then I stop and get some 
water…” 
 
Physician: “Why do you have to stop?” 
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Patient: “Because after I walk a certain amount of time my asthma will start kicking 
in.” 
 
Physician: “What exactly will happen?” 
 
Patient: “I start wheezing (unclear) and sometimes I feel like I get slow walking and I 
feel like I need to rest.” 
 
Physician: “Yes, ok, all of what you described is very consistent with asthma that is 
not well controlled, these are all good things for us to take care of with an asthma 
action plan and have you use some control medicine that you use everyday.”  
 
• (…earlier discussion established a problem when playing sports…) 
 
Physician: “….the sports, you want the coach to pull him out because he is getting 
more winded, that is telling me things are not as good as they could be because there 
are Olympic athletes and pro football players and pro baseball players who can do all 
the sports they want to do with their asthma so there is not any reason he should not 
be able to play as hard as the next kid, be as good as an Olympic athlete. Ok, so I 
would increase his Advair dose from 100 to 250, follow me?” 
 
Caregiver: “Um hum” 
 
Physician: “You do it once a day?” 
 
Caregiver “Um hum” 
  
Physician: “I would do it twice a day.” 
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Family-related quality of life was more likely to be discussed with minority patients 
compared to white patients. This discussion occurred during six visits with a minority patient 
compared to one visit with a white patient, for frequencies of 4.6% and 0.6%, respectively (χ2 
= 5.00, p=0.03). The following excerpts provide examples of discussion of family-related 
quality of life. 
• (discussing child’s night time cough) 
Caregiver: “..It’s just like, it sounds like an eighty year old woman or man 
Physician: “Right, right” 
Caregiver: “I mean, it just tears me up” 
 
• Physician: “ You watch his football games and basketball games?” 
Caregiver: “Um hum” 
Physician: Do you worry about him when he is playing?” 
Caregiver: “Yeah” (unclear) 
There were no statistical differences with any of the other quality of life discussion variables 
between minority and white patients.  
 
Discussion of Control Medication Adherence and Education 
Approximately 85% of the patients (n=251) reported using a control medication for 
asthma prior to enrollment in the study. All analyses regarding control medication adherence 
(preliminary and primary) refer only to this subset of 251 patients. Approximately 82% of the 
minority patients (n=107) were on a control medication. In comparison, approximately 87% 
of the white patients (n=144) were on a control medication. 
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Overall, adherence to control medication was discussed during 55% (n=137) of these 
251 visits. The physician educated the patient and/or parent on the importance of adherence 
to asthma control medications during 30% (n=76) of these visits. In the 137 visits where 
adherence was discussed, either the patient or parent reported non-adherence during 32% 
(n=44) of the visits.  
Adherence to control medications was discussed during 63% (n=67) of the visits with 
minority patients compared to 49% (n=70) of the visits with white patients (χ2=4.86, p=0.03).  
Education on the importance of adherence was discussed during 38% (n=41) of the visits for 
minority patients compared to 24% (n=35) of the visits with white patients (χ2=5.71, p=0.02). 
There was no difference in non-adherence between minority and white patients. 
 
Additional Descriptive Characteristics of Visit 
 Information on whether the physician, caregiver, or patient initiated discussion of 
specific aspects of asthma symptoms, pulmonary function, quality of life, and control 
medication adherence is presented in Table 12. In the 277 visits where symptoms were 
discussed, the physician initiated the discussion during 84% (n=233) of the visits. In the 204 
visits where it was reported that the patient was experiencing symptoms, the parent initially 
reported symptoms in 63% (n=129) of the visits compared to the patient initially reporting 
the symptoms in 37% (n=75) of the visits. A discussion of pulmonary function was almost 
always initiated by the physician. Of the 136 visits where spirometry was discussed, the 
discussion was initiated by the physician in 97% (n=132) of the visits. Of the 63 visits where 
peak flow meters were discussed, the discussion was initiated by the physician in 89% 
(n=56) of the visits.  Asthma-related quality of life was the topic where patients were more  
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Table 12- Discussion Initiators About Asthma Management Topics 
 
   
Communication Variables 
Physician 
Initiates, % 
(n) 
Caregiver 
Initiates, % 
(n) 
Patient 
Initiates, % 
(n) 
Symptoms    
Symptoms Discussion 84.1 (233) 13.7 (38) 2.2 (6) 
Patient Is Experiencing Symptoms  -  63.2 (129) 36.8 (75) 
Nighttime Symptoms Discussion 83.3 (174) 12.9 (27) 3.8 (8) 
Exercise-Induced Symptoms Discussion 67.7 (149) 21.8 (48) 10.5 (23) 
Daytime Symptoms Discussion 69.2 (27) 25.6 (10) 5.1 (2) 
Symptom Frequency Discussion 82.9 (155) 12.3 (23) 4.8 (9) 
Pulmonary Function   
    
Spirometry Discussion 97.1 (132) 2.9 (4) 0.0 (0) 
Peak Flow Meter Discussion 88.9 (56) 11.1 (7) 0.0 (0) 
Asthma-Related Quality of Life   
    
Activity Limitation Discussion 59.3 (48) 25.9 (21) 14.8 (12) 
Patient Is Experiencing Activity Limitation  -  51.2 (21) 48.8 (20) 
Negative Emotions Discussion 11.1 (1) 44.4 (4) 44.4 (4) 
Patient Is Experiencing Negative Emotions  -  57.1 (4) 42.9 (3) 
Missed School Discussion 68.4 (13) 26.3 (5)  5.3 (1) 
Family Quality of Life Discussion 42.9 (3) 57.1 (4) 0.0 (0) 
Control Medication Adherence       
Medication Adherence Discussion 84.7 (116) 12.4 (17) 2.9 (4) 
Patient Is Non-adherent  -  65.1 (28) 34.9 (15) 
 
 
likely to initiate discussion. For example, in the 41 visits where the patient was experiencing 
quality of life limitations, the patient reported this information during 49% (n=20) of the 
visits, almost as often as the caregiver, who reported the information during 51% (n=21) of 
the visits. In the 128 visits where control medication adherence is discussed, the discussion 
was initiated by the physician during 78% (n=107) of the visits. Patient non-adherence to 
control medication was more often reported by the caregiver (66%, n=29) than the patient 
(34%, n=15).   
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Of the 131 visits where the reason for the visit was coded as ‘other,’ the parent wrote-
in ‘asthma’ as a part of the reason for the visit on 6% (n=8) of the questionnaires. An 
example is ‘asthma and flu’. A review of the actual questionnaires confirmed that the parent 
chose ‘other’ as the reason for the visit; thus, the variable was analyzed accordingly. Of the 
same 131 visits, the reason given was closely related to asthma or other 
respiratory/pulmonary conditions on 6% (n=8) of the questionnaires. Examples include: 
allergies, bronchitis, or pneumonia. After the primary analyses were completed, a sensitivity 
analyses was run in which these 16 patients were transferred from the ‘other’ group to the 
‘asthma’ group.   
The following information is provided for descriptive purposes only, and was not 
considered in the primary analyses. Of the 296 visits, the patient’s mother was the only 
primary caregiver present in the exam room during 83% (n=245) of the visits. The patient’s 
father was the only primary caregiver present in the exam room during 6% (n=18) of the 
visits. During 7% (n=22) of the visits, at least two caregivers (usually a mother and father) 
were present in the exam room. For these visits, the person who signed the consent form and 
completed the office questionnaire was identified as the primary caregiver. In the final 3% of 
visits, someone else, either a grandparent or an aunt, was the primary caregiver present in the 
room. For two patients, it appears that the caregiver did not accompany the patient into the 
exam room and/or did not speak at all in the exam room.  For 65% of the visits, there was no 
one else in the room to participate in the conversation except the patient, the caregiver(s), and 
the physician. This does not include a nurse who may have briefly entered to converse with 
the doctor or take the patient to another room. In the other 35% of the visits, there were other 
people in the room who may have participated in the communication, or have otherwise 
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drawn the attention of the patient, caregiver, or physician. In most of these visits, the other 
people in the room were siblings of the patient. 
 
Preliminary Analyses 
 This section describes the results of the preliminary analyses that were conducted on 
all variables to characterize the sample, and also to inform decisions about whether to include 
these variables in the primary analyses. This section also includes: (1) the results of the 
bivariate analyses, and (2) the results of the comparison between the patients included in the 
analyses and those excluded for audio problems. 
 
Initial Variable Review 
 For two patients, the parent did not give a reason for their child’s visit to the doctor 
on their office visit questionnaire. Patients were asked an identical question about the reason 
for their visit on their questionnaire. An analysis of the other questionnaires showed that 
parent and patient answers to this question were in agreement more than 80% of the time. 
Based upon the high percentage of agreement between the patient and the parent, the 
decision was made to substitute the patient’s response for this variable, instead of excluding 
the patient from the analysis or imputation.   
Initial examination of the variable indicating the comprehensiveness of the quality of 
life discussion (score 0-4) revealed very little variation. Of the 296 patients, 201 (68%) had 
no quality of life discussion at all. Of the remaining 95 patients, 82% discussed only one 
dimension of quality of life. There were only 17 visits where two or three dimensions were 
discussed, and none where all four were discussed. Therefore, a dichotomous variable, 
    104
age
 
Quality of Life Discussed, was created. This variable indexed whether any of the four 
dimensions of QoL were discussed (0= No QoL Discussion; 1= QoL Discussion). This 
variable was used as the primary outcome variable for the QoL discussion. 
Examination of the variable indicating the number of prior visits by the patient 
revealed a very large range of 0-70. Because this was not a primary independent or outcome 
variable, and a relatively high percentage (12%) of observations were missing, requiring 
imputation, the decision was made not to transform this variable for the primary analyses.  
The ethnicity variable did not have enough variation to have predictive power in any 
of the models. Approximately 4% of the final sample (12 patients) identified themselves as 
Hispanic or Latino. Therefore, ethnicity was not included in any of the primary analyses.  
 An examination of the variable indicating whether there was racial concordance 
between the parent and the patient revealed that there was 90% racial concordance. 
Therefore, this variable was not included in the primary analyses.  
In 4% (n=11) of the 296 visits, a nurse or physician assistant was present either in 
addition to or instead of a physician, and participated substantially in the communication (as 
opposed to coming into the room only to escort the patient to a separate room for spirometry, 
for example). The type of provider was noted in the study documents; however, due to very 
small numbers, the type of provider was not distinguished in the primary analyses.  
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Bivariate Analysis 
 Tables 13-17 present patient and length of visit by each of the primary discussion 
dependent variables: Comprehensiveness of Symptom Discussion (Table 13); Pulmonary 
Function Discussed (Table 14); Quality of Life Discussed (Table 15); Control Medication 
Adherence Discussed (Table 16); and Adherence Education Provided (Table 17).  
 Table 13 shows the patient and discussion characteristics, stratified by the 
comprehensiveness of symptom discussion (CSD) variables. Of the 296 visits, 275 (93%) 
included a discussion of asthma symptoms. Most of the visits that included a discussion of 
asthma symptoms received a score of 3, indicating that three different components of asthma 
symptoms were discussed. For both white and minority patients, most of the patients 
received an index score of 3. The average CSD score also was significantly associated with 
the reason for the visit. Patients with a CSD score of 0 were less likely to be visiting the 
doctor for asthma compared to patients with a score of 2, 3, or 4 (F=4.32, p<0.01). Also, the 
CSD score increased with the length of visit. Visits with a score of 1 averaged 12.5 (SD=7.3) 
minutes, and visits with a score of 4 averaged 20.6 (9.6) minutes. (F=6.94, p<0.001). 
 Table 14 shows that pulmonary function was discussed in 165 of the visits. 
Pulmonary function was significantly more likely to be discussed if the reason for the visit 
was asthma-related, as opposed to a non-asthma related visit (χ2 = 26.92, p<0.001).  A 
discussion of pulmonary function was more likely to occur with a male patient than with a  
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Table 13 - Sample Characteristics by Comprehensiveness of Symptom Discussion Variable 
(n=296) 
 
Comprehensiveness of Symptom Discussion Score 
      
 
0 1 2 3 4 
Sample Characteristics (n=19) (n=57) (n=64) (n=128) (n=28) 
Race, (%)      
Minority 6.1 23.7 16.8 41.2 12.2 
White 7.9 14.6 25.5 44.9 7.3 
Reason for Visit, (%)*           
Asthma Related 2.4 17.6 21.2 46.1 12.7 
Other Reason 13.0 19.8 22.1 39.7 5.3 
Age, mean (sd) 11.1 (2.4) 11.1 (2.6) 11.0 (2.5) 11.1 (2.3) 11.4 (2.5) 
Gender, (%)           
Male 3.8 18.2 20.8 49.1 8.2 
Female 10.9 19.0 22.6 36.5 10.9 
Asthma Severity, (%)           
Mild 10.8 14.5 28.9 37.3 8.4 
Moderate-to-Severe 5.6 20.2 18.8 45.5 9.9 
Insurance Coverage, (%)           
Private 7.1 14.1 29.4 40.0 9.4 
Other 7.2 20.6 18.2 44.5 9.6 
Number of Asthma Medications, 
mean (sd) 2.2 (1.0) 2.2 (1.0) 2.0 (0.9) 2.2 (0.9) 2.3 (1.0) 
Number of Co-morbid Conditions, 
mean (sd) 3.2 (1.7) 2.6 (1.5) 2.2 (1.8) 2.2 (2.0) 3.1 (1.9) 
Number of Past Visits with 
Physician, mean (sd) 10.6 (13.9) 11.1 (10.0) 13.1 (12.6) 11.1 (11.9) 6.6 (6.6) 
Caregiver Education (in years) 
mean (sd) 12.8 (4.1) 12.9 (2.6) 12.7 (2.0) 12.7 (2.6) 12.8 (1.8) 
Length of Visit, (in minutes), mean 
(sd)* 11.7 (7.1) 12.5 (7.3) 13.8 (8.6) 16.5 (8.1) 20.6 (9.6) 
*p<0.05          
 
female patient (χ2=4.83, p=0.028). A discussion of pulmonary function was also associated 
with a longer visit. On average, a visit that included a discussion of pulmonary function  
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Table 14 - Sample Characteristics by Pulmonary Function Discussion Variable (n=296) 
   
 
Pulmonary Function 
Discussed 
 
Yes No 
Sample Characteristics (n=165) (n=131) 
Race, (%)   
Minority 59.5 40.5 
White 52.7 47.3 
Reason for Visit, (%)*    
Asthma Related 69.1 30.9 
Other Reason 38.9 61.1 
Age, mean (sd) 10.9 (2.3) 11.4 (2.5) 
Gender, (%)*    
Male 61.6 38.4 
Female 48.9 51.1 
Asthma Severity, (%)    
Mild 55.4 44.6 
Moderate-to-Severe 55.9 44.1 
Insurance Coverage, (%)    
Private 60.0 40.0 
Other 54.1 45.9 
Number of Asthma Medications, mean (sd) 2.2 (0.9) 2.1 (1.0) 
Number of Co-morbid Conditions, mean (sd) 2.4 (1.9) 2.5 (1.8) 
Number of Past Visits with Physician, mean (sd) 11.5 (11.5) 10.6 (11.5) 
Caregiver Education (in years) mean (sd) 12.8 (2.5) 12.7 (2.6) 
Length of Visit, (in minutes), mean (sd)* 17.4 (8.7) 12.6 (7.3) 
*p<0.05   
 
lasted 17.4 (SD=8.7) minutes, compared to 12.6 (SD=7.3) minutes for a visit that did not 
include a discussion of pulmonary function (p<0.001). 
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 Table 15 shows that asthma-related quality of life was discussed in 95 of the visits. 
QoL was significantly more likely to be discussed if the reason for the visit was asthma-
related, as opposed to a non-asthma related visit (χ2 =5.14, p=0.023). On average, a visit that 
included a discussion of QoL lasted 16.8 (SD=8.1) minutes, compared to 14.5 (SD=8.6) 
minutes for a visit that did not include a discussion of QoL (p<0.001). 
   Table 16 shows that, of the 251 patients who were on an asthma control medication 
prior to enrollment in the study, adherence was discussed in 165 of the visits. Adherence was 
significantly more likely to be discussed if the patient was minority, as opposed to if the 
patient was white (χ2 = 4.86, p=0.028).  Adherence was also significantly more likely to be 
discussed if the reason for the visit was asthma-related, as opposed to a non-asthma related 
visit (χ2 = 15.44, p<0.001). Adherence was discussed in 59% of the visits of patients with 
moderate-to-severe asthma, compared to 43% of the visits of patients with mild asthma (χ2 
=4.68, p=0.031). Adherence was more likely to be discussed if the patient had poor or 
ambiguous pulmonary function results (72%) than if the patient did not have poor or 
ambiguous results (49.5%) (χ2 =8.95, p=0.003). 
Table 17 shows that education on the importance of adherence to control medication 
was provided in 76 of the 251 visits where the patient was on a control medication. 
Education on the importance of adherence was more likely to be provided if the patient was 
minority than if the patient was white (χ2 = 5.71, p=0.017). This type of discussion occurred 
in 39% of the visits when the primary reason for the visit was asthma-related, compared to 
18% of the visits when the reason for the visit was something other than asthma (χ2 =12.69, 
p<0.001). Education was provided in 71% of the visits when the patient reported non- 
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Table 15 - Sample Characteristics by Quality of Life Discussion Variable (n=296) 
   
 
Quality of Life Discussed 
 
Yes No 
Sample Characteristics (n=95) (n=201) 
Race, (%)   
Minority 32.1 67.9 
White 32.1 67.9 
Reason for Visit, (%)*    
Asthma Related 37.6 62.4 
Other Reason 25.2 74.8 
Age, mean (sd) 11.4 (2.4) 11.0 (2.4) 
Gender, (%)    
Male 32.7 67.3 
Female 31.4 68.6 
Asthma Severity, (%)    
Mild 28.9 71.1 
Moderate-to-Severe 33.3 66.7 
Insurance Coverage, (%)    
Private 34.1 65.9 
Other 31.6 68.4 
Number of Asthma Medications, mean (sd) 2.3 (1.0) 2.1 (0.9) 
Number of Co-morbid Conditions, mean (sd) 2.3 (1.9) 2.5 (1.8) 
Number of Past Visits with Physician, mean (sd) 10.2 (10.2) 11.5 (12.1) 
Caregiver Education (in years) mean (sd) 12.7 (2.5) 12.8 (2.6) 
Length of Visit, (in minutes), mean (sd)* 16.8 (8.1) 14.5 (8.6) 
*p<0.05   
 
adherence, compared to 22% of the visits where the patient did not report non-adherence (χ2 
= 40.79, p<0.001). 
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Table 16 - Sample Characteristics by Control Medication Adherence Discussion Variable 
(n=251) 
 Adherence Discussed 
 Yes No 
Sample Characteristics (n=137) (n=114) 
Race, (%)*   
Minority 62.6 37.4 
White 48.6 51.4 
Reason for Visit, (%)*    
Asthma Related 65.1 34.9 
Other Reason 40.0 60.0 
Age, mean (SD) 11.1 (2.5) 10.9 (2.3) 
Male, (%) 60.1 39.9 
Female, % 47.8 52.2 
Asthma Severity, (%)*    
Mild 43.1 56.9 
Moderate-to-Severe 58.6 41.4 
Insurance Coverage, (%)    
Private 52.1 47.9 
Other 55.1 44.9 
Number of Asthma Medications, mean (sd) 2.4 (0.9) 2.3 (0.8) 
Number of Co-morbid Conditions, mean (sd) 2.2 (1.9) 2.6 (1.8) 
Number of Past Visits with Physician, mean (sd) 11.8 (12.2) 10.8 (10.7) 
Caregiver Education (in years), mean (sd) 13.0 (2.3) 12.8 (2.6) 
Length of Visit, (in minutes), mean (sd)* 15.9 (8.4) 14.3 (8.0) 
Patient Experiencing Symptoms, (%)    
Yes 58.7 41.3 
No  45.6 54.4 
Patient Has Poor Pulmonary Function, (%)*    
Yes 71.9 28.1 
No  49.5 50.5 
Patient Reports Quality of Life Problems, (%)   
Yes 63.2 38.8 
No  53.1 46.9 
*p<0.05   
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Table 17 - Sample Characteristics by Education Provided on Adherence Variable (n=251) 
   
 
Education on Adherence 
Provided 
 Yes No 
Sample Characteristics (n=76) (n=175) 
Race, (%)*   
Minority 38.3 61.7 
White 24.3 75.7 
Reason for Visit, (%)*    
Asthma Related 39.0 61.0 
Othe Reason 18.1 81.9 
Age, mean (sd) 10.8 (2.5) 11.1 (2.4) 
Male, (%) 34.8 65.2 
Female, % 24.8 75.2 
Asthma Severity, (%)    
Mild 26.2 73.8 
Moderate-to-Severe 31.7 68.3 
Insurance Coverage, (%)    
Private 31.5 68.5 
Other 29.5 70.5 
Number of Asthma Medications, mean (sd) 2.5 (1.0) 2.3 (0.8) 
Number of Co-morbid Conditions, mean (sd) 2.2 (2.1) 2.5 (1.8) 
Number of Past Visits with Physician, mean (sd) 12.0 (12.4) 11.1 (11.2) 
Caregiver Education (in years) mean (sd) 12.9 (2.3) 12.9 (2.5) 
Length of Visit, (in minutes), mean (sd)* 16.3 (9.2) 14.6 (7.8) 
Patient Reports Non-Adherence, (%)*    
Yes 70.5 29.5 
No  21.7 78.3 
*p<0.05   
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Correlations 
 Pearson correlation coefficients for continuous variables and phi correlation 
coefficients for categorical variables were generated to test for multicollinearity among the 
independent and control variables. A correlation matrix showing the Pearson correlation 
coefficients for the independent variables is presented in Table 18. None of the correlations 
approached the predetermined level (r=0.70) to indicate that multicollinearity would be a 
problem in the primary analyses (Slinker and Glantz 1985). However, some variables were 
found to be significantly correlated with other variables at a level of p<0.05. The 
relationships between patient race and other independent variables have been presented in 
previous sections. The correlations confirm results presented earlier. Compared to white 
patients, minority patients were more likely to be visiting for an asthma-related reason 
(r=0.16, p=0.005) and be male (r=0.15, p=0.006), and were less likely to have private 
insurance (r=-0.27, p<0.001) than white patients. Minority patients also had fewer co-morbid 
chronic conditions (r=-0.18, p=0.002) than white patients, and their caregivers did not have 
as many years of education (r=-0.13, p=0.029) as the caregivers of white patients.   
 A positive correlation was observed between the number of years of caregiver’s 
education and type of insurance, with caregivers with more years of education being more 
likely to report that their child was covered by private insurance (r=0.29, p<0.001).  In 
addition, patients with moderate-to-severe asthma were on more asthma medications 
compared to children with mild asthma (r=0.26, p<0.001). None of the other bivariate 
correlations exceeded 0.20. Visiting the doctor for an asthma-related reason was positively 
correlated with being male (r=0.11, p<0.05) and using more asthma medications (r=0.16, 
p=0.007), and negatively associated with having more co-morbid chronic conditions 
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Table 18  - Correlations Among Independent Variables     
            
  Minority 
Asthma 
Visit Age Male 
Moderate-
to Severe 
Asthma 
Private 
Insurance 
# 
Asthma 
Meds 
# 
Comorbid- 
ities 
# Past 
Visits 
Yrs. 
Caregiver 
Education 
Length 
of Visit 
Minority 1.00                     
Asthma Visit 0.16* 1.00                   
Age 0.04 -0.08 1.00                 
Male 0.16* 0.11* -0.06 1.00               
Moderate-to-
Severe 
Asthma 0.01 0.08 0.09 -0.02 1.00             
Private 
Insurance -0.27* -0.01 -0.04 0.05 -0.07 1.00           
# Asthma 
Meds 0.09 0.16* -0.12* 0.04 0.26* -0.11 1.00         
# 
Comorbidities -0.18* -0.15* 0.04 -0.10 0.05 -0.05 -0.03 1.00       
# Past Visits -0.01 -0.05 -0.14* 0.05 0.02 0.01 <0.01 -0.01 1.00     
Yrs. 
Caregiver 
Education -0.13* -0.08 0.06 -0.04 -0.03 0.29* 0.04 -0.15* -0.04 1.00   
Length of 
Visit -0.05 <0.01 0.02 0.01 0.07 0.09 0.02 -0.05 -0.04 0.16* 1.00 
*p<0.05           
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(r=-0.15, p=0.013). Patient age was negatively correlated with using more asthma 
medications (r=-0.12, p=0.042) and the number of prior visits (r=-0.13, p=0.030). There was 
a significant negative correlation between having more co-morbidities and years of education 
for the caregiver (r=-0.15, p=0.012). Years of caregiver education was positively correlated 
with the length of the visit (r=0.16, p=0.006). 
    
Comparison of Patients Included in Analyses with Patients Excluded Due to Audio Problems 
The 296 patients retained for analysis were compared with the 26 patients who were 
excluded for not having a usable audiotape. The group of 26 does not include patients who 
would not have been included in the analysis because of ineligibility, enrollment in the 
excluded clinic, or large amounts of missing data. Comparisons were made on eleven sample 
characteristics: patient race, reason for visit, age, gender, asthma severity, insurance 
coverage, number of asthma medications, number of chronic co-morbid conditions, number 
of prior visits with the physician, years of caregiver education, and use of a control 
medication.  The two groups did not differ statistically from each other on any of these 
variables, with the following exceptions: reason for visit, gender and number of prior visits 
with physician. Of the 26 excluded patients, 77% were visiting the doctor for an asthma-
related reason compared to 56% for included patients (χ2 =4.39, p=0.036).  Of the 26 
excluded patients, 77% were male compared to 54% of the included patients (χ2 = 5.21, 
p=0.022). The excluded patients averaged 7.1 (SD=4.8) prior visits with the physician 
compared to 11.1 (SD=10.6) prior visits for the included patients (p=0.01). 
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Primary Analyses – Specific Aim 1 
To examine the relationship between patient race and patient-provider communication, 
including discussions about asthma symptoms, pulmonary function, quality-of -life, and 
control medication adherence 
 This section describes the results of analyses to examine the relationship between 
patient race and patient-provider communication. Generalized estimating equations (GEE), 
clustering patients by physician, were used to test the five primary hypotheses for Aim 1.  
H1:  A comprehensive discussion of asthma symptoms is less likely to occur if the 
patient is minority than if the patient is white 
H2: Pulmonary function (from peak flow meter or spirometry) is less likely to be 
discussed if the patient is minority than if the patient is white 
H3: A comprehensive discussion of asthma-related quality-of-life is less likely to 
occur if the patient is minority than if the patient is white 
H4:  Adherence to control medication is less likely to be discussed if the patient is 
minority than if the patient is white 
 
Five separate models were evaluated for this Aim, corresponding to the five topics of asthma 
discussion. The results for the models from Aim 1 are presented in Tables 19-23. 
  
Comprehensiveness of Symptom Discussion 
 Table 19 shows the results from the regression with the Comprehensiveness of 
Symptom Discussion (CSD) as the dependent variable. Patient race was not associated with a 
decrease in the CSD Score (p=0.66). Patients visiting the physician for asthma scored 1.22 
more points on the CSD variable than patients visiting the doctor for some other reason 
(p<0.01). Each one minute increase in the length of visit was associated with a 1.01 increase 
in the CSD score (p<0.01).  
    116
age
 
Table 19  - Regression of the Comprehensiveness of the Symptom Discussion on Patient, 
Caregiver, and Physician Characteristics, and Clinic Identifiers (n=296) 
     
  Estimate Robust SE 95% CI p value 
Minority 0.97 1.07 0.85-1.11 0.66 
Asthma-Related Visit  1.22* 1.06 1.08-1.38 <0.01 
Male 1.10 1.07 0.97-1.25 0.15 
Age (years) 1.01 1.01 0.99-1.04 0.32 
Moderate-to-Severe Asthma 1.05 1.04 0.97-1.14 0.23 
Number of Asthma Medications 1.01 1.02 0.96-1.06 0.72 
Number of Co-morbid Conditions 1.01 1.14 0.99-1.48 0.33 
Length of Visit (minutes) 1.01* 1.00 1.01-1.02 <0.001 
Caregiver Education (years) 0.99 1.01 0.97-1.009 0.25 
Tape Cut-Off 1.08 1.09 0.92-1.26 0.38 
Private Insurance Coverage 1.02 1.07 0.89-1.16 0.80 
Number of Past Visits with Physician 0.998 1.00 0.99-1.003 0.37 
Number of Yrs Since Physician 
Completed Medical School 0.99 1.01 0.98-1.004 0.21 
Male Physician 0.91 1.09 0.77-1.08 0.28 
Clinic 2 1.33* 1.13 1.05-1.68 0.02 
Clinic 3 0.90 1.12 0.72-1.14 0.38 
Clinic 4 1.20 1.10 0.99-1.45 0.06 
Clinic 5 0.94 1.15 0.72-1.22 0.63 
p<0.05     
  
Clinic 1 was the reference clinic in all models. Patients at clinic 2 scored 1.33 more points on 
the CSD variable than patients at clinic 1 (p=0.02). The mean ratio of the deviance to degrees 
of freedom (DF) of this model was 0.62. This indicates that this model may be mis-specified, 
with slightly incorrect standard errors. However, the estimates remain unbiased, and it is 
unlikely that the significance of the patient race or reason for the visit is affected, since 
neither p-value is close to the threshold of 0.05. 
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Discussion of Pulmonary Function 
 Table 20 shows the results from the model with Pulmonary Function Discussed as the 
dependent variable. Minority patients were no less likely than white patients to have a 
discussion of pulmonary function with their physician (OR 1.25, 95% CI 0.67-2.34). Patients 
visiting the physician for asthma were more likely to have a discussion of pulmonary 
function than those who were visiting the physician for another reason (OR 3.89, 95% CI 
2.51-6.02). A one minute increase in the length of visit was associated with an increased 
likelihood of discussing pulmonary function (OR 1.07, 95% CI 1.04-1.11). Patients at clinics 
2 (OR 3.14, 95% CI 1.08-9.14) and 4 (OR 2.70, 95% CI 1.05-6.94) were more likely to 
discuss pulmonary function than patients at clinic 1. The mean ratio of deviance to DF for 
this model was 1.18, indicating an adequate model fit. 
  
Discussion of Asthma-Related Quality of Life 
 Table 21 shows the results from the model with Quality of Life Discussed as the 
dependent variable. Minority patients were no less likely than white patients to have a 
discussion of asthma-related quality of life with their physician (OR 0.72, 95% CI 0.41-1.26). 
A one year increase in age was associated with an increased likelihood of discussing QoL 
(OR 1.09, 95% CI 1.01-1.09). The mean ratio of deviance to DF for this model was 1.26, 
indicating an adequate model fit. 
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Table 20  - Regression of Pulmonary Function Discussion on Patient, Caregiver, and Physician 
Characteristics, and Clinic Identifiers (n=296) 
     
  Odds Ratio 
Robust 
SE 95% CI p value 
Minority 1.25 1.37 0.67-2.34 0.48 
Asthma-Related Visit  3.89* 1.25 2.51-6.02 <0.0001 
Male 1.62 1.40 0.84-3.12 0.15 
Age (years) 0.96 1.06 0.85-1.08 0.49 
Moderate-to-Severe Asthma 0.86 1.35 0.48-1.56 0.63 
Number of Asthma Medications 0.96 1.16 0.72-1.30 0.81 
Number of Co-morbid Conditions 1.03 1.09 0.86-1.23 0.73 
Length of Visit (minutes) 1.07* 1.02 1.04-1.11 <0.0001 
Caregiver Education (years) 1.03 1.06 0.91-1.16 0.62 
Tape Cut-Off 1.66 1.40 0.86-3.21 0.13 
Private Insurance Coverage 1.15 1.48 0.53-2.50 0.72 
Number of Past Visits with Physician 1.01 1.01 0.99-1.03 0.50 
Number of Yrs Since Physician Completed 
Medical School 0.99 1.02 0.95-1.03 0.58 
Male Physician 0.75 1.43 0.37-1.51 0.42 
Clinic 2 3.14* 1.73 1.08-9.14 0.04 
Clinic 3 1.87 1.75 0.63-5.61 0.26 
Clinic 4 2.70* 1.62 1.05-6.94 0.04 
Clinic 5 2.30 1.92 0.64-8.21 0.20 
p<0.05     
 
Discussion of Control Medication Adherence 
 Table 22 shows the results from the model with Control Medication Adherence 
Discussed as the dependent variable. Minority patients were no less likely than white patients 
to discuss control medication adherence (OR 1.42, 95% CI 0.79-2.58). Patients who were 
visiting the doctor for asthma were more likely to discuss medication adherence than patients 
who were visiting the doctor for a reason other than asthma (OR 2.04, 95% CI 1.14-3.63).  
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Table 21 - Regression of Quality of Life Discussion on Patient, Caregiver, and Physician 
Characteristics, and Clinic Identifiers (n=296) 
     
  Odds Ratio Robust SE 95% CI p value 
Minority 0.72 1.33 0.41-1.26 0.25 
Asthma-Related Visit  1.56 1.32 0.90-2.70 0.11 
Male 1.002 1.29 0.61-1.66 0.99 
Age (years) 1.09* 1.04 1.01-1.19 0.03 
Moderate-to-Severe Asthma 0.92 1.34 0.51-1.64 0.77 
Number of Asthma Medications 1.21 1.18 0.88-1.66 0.24 
Number of Co-morbid Conditions 1.03 1.08 0.89-1.19 0.68 
Length of Visit (minutes) 1.03 1.01 0.99-1.06 0.08 
Caregiver Education (years) 0.95 1.05 0.87-1.04 0.30 
Tape Cut-Off 1.05 1.47 0.49-2.23 0.91 
Private Insurance Coverage 1.22 1.36 0.67-2.22 0.51 
Number of Past Visits with Physician 0.998 1.01 0.97-1.03 0.86 
Number of Yrs Since Physician 
Completed Medical School 1.01 1.02 0.98-1.04 0.72 
Male Physician 0.72 1.53 0.31-1.65 0.44 
Clinic 2 2.21 2.26 0.45-10.92 0.33 
Clinic 3 1.98 1.70 0.70-5.62 0.20 
Clinic 4 1.70 1.64 0.65-4.47 0.28 
Clinic 5 1.31 1.70 0.46-3.73 0.61 
p<0.05     
 
Asthma severity was also a significant predictor of discussing adherence, with patients 
classified as having moderate-to-severe asthma being more likely to discuss adherence than 
patients classified as having mild asthma (OR 2.31, 95% CI 1.14-4.66).  The mean ratio of 
deviance to DF for this model was 1.34, indicating adequate model fit.   
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Table 22  - Regression of Control Medication Adherence Discussion on Patient, Caregiver, 
and Physician Characteristics, and Clinic Identifiers (n=251) 
     
  Odds Ratio Robust SE 95% CI p value 
Minority 1.42 1.35 0.79-2.58 0.24 
Asthma-Related Visit  2.04* 1.34 1.14-3.63 0.02 
Male 1.40 1.40 0.72-2.71 0.32 
Age (years) 1.02 1.05 0.93-1.13 0.65 
Moderate-to-Severe Asthma 2.31* 1.43 1.14-4.66 0.02 
Number of Asthma Medications 0.80 1.14 0.62-1.03 0.08 
Number of Co-morbid Conditions 0.90 1.10 0.75-1.08 0.25 
Length of Visit (minutes) 1.01 1.02 0.97-1.05 0.64 
Caregiver Education (years) 1.11 1.07 0.96-1.27 0.16 
Tape Cut-Off 0.79 1.67 0.29-2.16 0.64 
Private Insurance Coverage 0.81 1.36 0.44-1.47 0.49 
Number of Past Visits with Physician 1.003 1.01 0.98-1.03 0.77 
Number of Yrs Since Physician 
Completed Medical School 0.99 1.02 0.96-1.03 0.61 
Male Physician 1.47 1.58 0.59-3.59 0.40 
Patient Experiencing Symptoms 1.47 1.32 0.86-2.53 0.16 
Patient Has Poor Pulmonary Function 1.73 1.54 0.74-4.04 0.20 
Patient Reports QoL Problems 1.34 1.47 0.63-2.86 0.45 
Clinic 2 2.70 2.12 0.62-11.75 0.19 
Clinic 3 1.15 1.99 0.30-4.41 0.84 
Clinic 4 0.84 1.75 0.28-2.51 0.75 
Clinic 5 1.24 1.82 0.38-4.00 0.72 
p<0.05     
 
Education on Importance of Control Medication Adherence 
 Table 23 shows the results from the model with Education on Adherence Provided as 
the dependent variable. In the original model, the variable Tape Cut-Off was significantly 
associated with whether education on adherence was provided.  Since this make obvious  
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Table 23  - Regression of the Education on Adherence Discussion on Patient, Caregiver, and 
Physician Characteristics, and Clinic Identifiers (n=212) 
     
  Odds Ratio Robust SE 95% CI p value 
Minority 1.20 1.49 0.55-2.64 0.64 
Asthma-Related Visit  2.12 1.62 0.83-5.46 0.12 
Male 1.23 1.48 0.57-2.64 0.59 
Age (years) 0.96 1.07 0.84-1.10 0.55 
Moderate-to-Severe Asthma 0.92 1.38 0.49-1.73 0.80 
Number of Asthma Medications 1.05 1.25 0.68-1.63 0.83 
Number of Co-morbid Conditions 0.98 1.11 0.80-1.21 0.86 
Length of Visit (minutes) 1.02 1.03 0.96-1.08 0.53 
Caregiver Education (years) 1.06 1.07 0.93-1.20 0.39 
Private Insurance Coverage 0.89 1.50 0.40-1.97 0.77 
Number of Past Visits with Physician 1.01 1.02 0.98-1.04 0.60 
 
Number of Yrs Since Physician 
Completed Medical School 1.02 1.02 0.97-1.06 0.43 
Male Physician 1.37 1.99 0.36-5.26 0.65 
Patient Reports Non-Adherence 8.45* 1.60 3.35-21.30 <0.0001 
Clinic 2 4.08 3.04 0.46-36.09 0.21 
Clinic 3 1.56 2.16 0.34-7.11 0.56 
Clinic 4 0.86 1.56 0.36-2.06 0.74 
Clinic 5 1.51 1.95 0.41-5.61 0.53 
p<0.05     
 
    
 
sense, especially sense physicians may be more likely to offer advice  toward the end of the 
visit, the model was re-run, excluding the cases where the tape was cut-off (n=39). The 
results of this model are presented. Physicians were no less likely to provide education on the 
importance of adherence to asthma medication to minority patients than white patients (OR 
1.46, 95% CI 0.72-2.96). Education on the importance of adherence was more likely to be 
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provided to patients reporting non-adherence than those who did not report non-adherence 
(OR 8.45, 95% CI 3.35-21.30). The mean ratio of deviance to DF for this model was 1.07, 
indicating adequate model fit. 
 
Primary Analyses – Specific Aim 2 
To determine if the relationship between patient race and the asthma communication 
variables specified above (asthma symptoms, pulmonary function, quality-of-life, and control 
medication adherence) varies depending on the primary purpose of the visit (whether the 
primary purpose of the visit is asthma) 
 This section describes the results of analyses to examine whether the relationship 
between patient race and patient-provider communication varies depending on the primary 
purpose of the visit. GEE, clustering patients by physician, was again used to test the primary 
hypothesis for Aim 2.  
H6:  Racial differences on the communication variables will be greatest when the 
primary purpose of the visit is not related to asthma.  
 
Five separate models were evaluated for this Aim, corresponding to the five topics of asthma 
discussion. The results for the models from Aim 2 are presented in Tables 24-29. 
 
Comprehensiveness of Symptom Discussion 
 Table 24 shows the results from the regression with the Comprehensiveness of 
Symptom Discussion (CSD) as the dependent variable. The interaction of patient race and 
reason for the visit was not associated with an increase in the CSD Score (p=0.68). The mean 
ratio of deviance to DF for this model was 0.62, again indicating that the model may be mis- 
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Table 24  - Regression of the Comprehensiveness of the Symptom Discussion on Patient, 
Caregiver, and Physician Characteristics, and Clinic Identifiers, with a Patient Race/Reason 
for Visit Interaction (n=296) 
     
  
Estimate Robust SE 95% CI p value 
Minority 0.95 1.08 0.81-1.11 0.53 
Asthma-Related Visit  1.24* 1.08 1.07-1.44 <0.01 
Race/Reason for Visit Interaction 1.05 1.12 0.84-1.31 0.68 
Male 1.10 1.07 0.97-1.26 0.15 
Age (years) 1.01 1.01 0.99-1.04 0.31 
Moderate-to-Severe Asthma 1.05 1.04 0.97-1.14 0.23 
Number of Asthma Medications 1.01 1.02 0.96-1.06 0.67 
Number of Co-morbid Conditions 1.01 1.01 0.99-1.04 0.32 
Length of Visit (minutes) 1.01* 1.004 1.01-1.22 <0.01 
Caregiver Education (years) 0.99 1.01 0.97-1.01 0.26 
Tape Cut-Off 1.07 1.09 0.91-1.26 0.39 
Private Insurance Coverage 1.01 1.07 0.90-1.15 0.82 
Number of Past Visits with Physician 0.998 1.002 0.99-1.003 0.38 
Number of Yrs Since Physician Completed 
Medical School 0.99 1.01 0.98-1.004 0.21 
Male Physician 0.91 1.09 0.77-1.08 0.28 
Clinic 2 1.34* 1.14 1.04-1.73 0.02 
Clinic 3 0.91 1.13 0.71-1.16 0.45 
Clinic 4 1.20 1.11 0.99-1.47 0.07 
Clinic 5 0.94 1.15 0.72-1.23 0.64 
p<0.05     
 
specified. However, the p-value of the interaction term did not approach of the threshold of 
0.05, and it is unlikely that any misspecification affected the significance of this estimate. 
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Discussion of Pulmonary Function 
 Table 25 shows the results from the model with Pulmonary Function Discussed as the 
dependent variable. The interaction of patient race and reason for the visit was not associated 
with a decreased likelihood of discussing pulmonary function (OR 1.12, 95% CI 0.38-3.33). 
The mean ratio of deviance to DF for this model was 1.17, indicating adequate model fit.  
 
Table 25 - Regression of Pulmonary Function Discussion on Patient, Caregiver, and Physician 
Characteristics, and Clinic Identifiers with a Patient Race/Reason for Visit Interaction  (n=296) 
     
  Odds Ratio Robust SE 95% CI p value 
Minority 1.19 1.53 0.52-2.73 0.69 
Asthma-Related Visit  4.07* 1.39 2.14-7.72 <0.001 
Race/Reason for Visit Interaction Term 1.12 1.75 0.38-3.33 0.84 
Male 1.62 1.40 0.84-3.12 0.15 
Age (years) 0.96 1.06 0.85-1.08 0.48 
Moderate-to-Severe Asthma 0.87 1.35 0.48-1.56 0.64 
Number of Asthma Medications 0.97 1.17 0.72-1.30 0.83 
Number of Co-morbid Conditions 1.03 1.09 0.86-1.23 0.73 
Length of Visit (minutes) 1.07* 1.02 1.03-1.11 <0.01 
Caregiver Education (years) 1.03 1.06 0.91-1.17 0.63 
Tape Cut-Off 1.66 1.40 0.86-3.21 0.13 
Private Insurance Coverage 1.15 1.50 0.52-2.55 0.74 
Number of Past Visits with Physician 1.01 1.01 0.99-1.03 0.49 
Number of Yrs Since Physician Completed 
Medical School 0.99 1.02 0.96-1.03 0.58 
Male Physician 0.75 1.42 0.38-1.51 0.43 
Clinic 2 3.19* 1.75 1.07-9.57 0.04 
Clinic 3 1.91 1.74 0.64-5.66 0.25 
Clinic 4 2.73* 1.63 1.05-7.10 0.04 
Clinic 5 2.31 1.92 0.65-8.26 0.20 
p<0.05     
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Discussion of Asthma-Related Quality of Life 
 Table 26 shows the results from the model with QoL discussed as the dependent 
variable. The interaction of patient race and reason for the visit was not associated with a 
decreased likelihood of discussing QoL (OR 1.06, 95% CI 0.39-2.91). The mean ratio of 
deviance to DF for this model was 1.27, indicating adequate model fit. 
 
Table 26  - Regression of Quality of Life Discussion on Patient, Caregiver, and Physician 
Characteristics, and Clinic Identifiers with a Patient Race/Reason for Visit Interaction  (n=296) 
     
  Odds Ratio Robust SE 95% CI p value 
Minority 0.70 1.34 0.39-1.26 0.23 
Asthma-Related Visit  1.59 1.42 0.80-3.16 0.19 
Race/Reason for Visit Interaction 1.06 1.67 0.39-2.91 0.90 
Male 1.002 1.29 0.60-1.66 0.99 
Age (years) 1.09 1.04 1.01-1.18 0.03 
Moderate-to-Severe Asthma 0.92 1.34 0.52-1.63 0.77 
Number of Asthma Medications 1.21 1.17 0.89-1.66 0.23 
Number of Co-morbid Conditions 1.03 1.08 0.89-1.19 0.68 
Length of Visit (minutes) 1.03 1.01 0.997-1.06 0.08 
Caregiver Education (years) 0.95 1.05 0.87-1.04 0.31 
Tape Cut-Off 1.04 1.47 0.49-2.22 0.91 
Private Insurance Coverage 1.22 1.35 0.68-2.20 0.51 
Number of Past Visits with Physician 0.998 1.01 0.97-1.03 0.87 
Number of Yrs Since Physician Completed  
Medical School 1.01 1.02 0.98-1.04 0.72 
Male Physician 0.72 1.53 0.31-1.66 0.44 
Clinic 2 2.24 2.26 0.45-11.06 0.32 
Clinic 3 2.00 1.71 0.70-5.73 0.20 
Clinic 4 1.71 1.67 0.63-4.67 0.29 
Clinic 5 1.31 1.71 0.46-3.75 0.61 
p<0.05     
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Discussion of Control Medication Adherence 
 Table 27 shows the results from the model with Control Medication Adherence 
Discussed as the dependent variable. The interaction of patient race and reason for visit was 
Table 27 -Regression of Education on Control Medication Adherence Discussion on Patient, 
Caregiver, and Physician Characteristics, and Clinic Identifiers, Including a Patient 
Race/Reason for Visit Interaction (n=251) 
     
  
Odds 
Ratio 
Robust 
SE 95% CI p value 
Minority 1.82 1.44 0.89-3.74 0.10 
Asthma-Related Visit  1.71 1.50 0.78-3.79 0.18 
Race/Reason for Visit Interaction 0.59 1.88 0.17-2.03 0.40 
Male 1.38 1.40 0.71-2.67 0.35 
Age (years) 1.02 1.05 0.92-1.13 0.65 
Moderate-to-Severe Asthma 2.27* 1.42 1.14-4.51 0.02 
Number of Asthma Medications 0.80 1.14 0.62-1.03 0.08 
Number of Co-morbid Conditions 0.90 1.10 0.75-1.08 0.25 
Length of Visit (minutes) 1.01 1.02 0.97-1.05 0.66 
Caregiver Education (years) 1.11 1.08 0.96-1.27 0.17 
Tape Cut-Off 0.79 1.67 0.29-2.15 0.65 
Private Insurance Coverage 0.84 1.37 0.46-1.56 0.59 
Number of Past Visits with Physician 1.003 1.01 0.98-1.03 0.78 
Number of Yrs Since Physician Completed 
Medical School 0.99 1.02 0.96-1.02 0.55 
Male Physician 1.43 1.57 0.59-3.47 0.43 
Patient Experiencing Symptoms 1.45 1.33 0.83-2.53 0.19 
Patient Has Poor Pulmonary Function 
Scores 1.73 1.55 0.74-4.06 0.21 
Patient Reports QoL Problems 1.32 1.46 0.63-2.77 0.46 
Clinic 2 2.41 2.10 0.57-10.30 0.23 
Clinic 3 1.04 1.95 0.28-3.84 0.96 
Clinic 4 0.79 1.73 0.27-2.31 0.67 
Clinic 5 1.22 1.79 0.39-3.82 0.74 
p<0.05     
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not associated with a decreased likelihood of discussing control medication adherence (OR 
0.59. 95% CI 0.17-2.03). The mean ratio of deviance to DF for this model was 1.34, 
indicating adequate model fit. 
 
Education on Importance of Control Medication Adherence 
 Table 28 shows the results from the model with Education on Adherence Provided as 
the dependent variable. As with Aim 1, the cases where the tape cut off were excluded from 
analysis. The interaction of patient race and reason for the visit was not associated with a 
decreased likelihood of education on adherence being provided (OR 1.19, 95% CI 0.29-
4.94). The mean ratio of deviance to DF for this model was 1.08, indicating adequate model 
fit. 
 
Additional Analyses 
 After the primary analyses were completed, several sensitivity analyses were run to 
compare different models. The results of these analyses are presented below. 
 
Complete Case Analyses 
 Models for Aims 1 and 2 were re-run using complete case analysis (dropping 
observations) to address missing values in the dataset.  The number of patients included in 
the models was reduced from 296 to 254 in the three models for discussion of symptoms, 
pulmonary function, and QoL, and from 251 to 218 in the models for control medication 
adherence. In the regression on discussion of QoL, patient race changed from a non-
significant predictor to a significant predictor. In Aim 1, minority patients were less likely to  
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Table 28  - Regression of the Education on Adherence Discussion on Patient, Caregiver, and 
Physician Characteristics, and Clinic Identifiers with a Patient Race/Reason for Visit 
Interaction  (n=212) 
     
  Odds Ratio Robust SE 95% CI p value 
Minority 1.07 1.76 0.35-3.24 0.91 
Asthma-Related Visit  2.42 1.86 0.72-8.16 0.15 
Race/Reason for Visit Interaction 1.42 2.16 0.31-6.43 0.65 
Male 1.24 1.47 0.59-2.63 0.57 
Age (years) 0.96 1.07 0.84-1.10 0.56 
Moderate-to-Severe Asthma 0.92 1.39 0.49-1.75 0.80 
Number of Asthma Medications 1.05 1.25 0.68-1.62 0.82 
Number of Co-morbid Conditions 0.98 1.11 0.80-1.21 0.87 
Length of Visit (minutes) 1.02 1.32 0.96-1.08 0.52 
Caregiver Education (years) 1.06 1.07 0.93-1.21 0.37 
Private Insurance Coverage 0.86 1.52 0.38-1.96 0.72 
Number of Past Visits with Physician 1.01 1.02 0.98-1.04 0.58 
Number of Yrs Since Physician  
Completed Medical School 1.02 1.02 0.98-1.06 0.40 
Male Physician 1.38 1.96 0.37-5.18 0.63 
Patient Reports Non-Adherence 8.35* 1.59 3.37-20.70 <0.0001 
Clinic 2 4.32 3.12 0.46-40.21 0.20 
Clinic 3 1.66 2.14 0.37-7.38 0.51 
Clinic 4 0.89 1.55 0.38-2.10 0.79 
Clinic 5 1.54 1.91 0.43-5.49 0.50 
p<0.05 
    
 
discuss quality of life than white patients (OR 0.39, 95% CI 0.19-0.79).  In Aim 2, the 
significance of the interaction term did not change.  
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Patient Race  
 Models were re-run in which the variable Patient Race was modified so that only 
patients who selected African-American/Black as their race (either alone or in conjunction 
with another race) were included as a minority patient. The number of patients included as a 
minority was reduced from 131 to 89. The other 42 patients were not included in these 
models. This modification did not change the significance of any of the primary independent 
variables. 
 
Reason for Visit  
 Models for Aim 1 were re-run, stratified by the reason for the visit. This modification 
did not change the significance of the patient race variable. 
 All models for Aim 1 and 2 were re-run, in which 16 patients who were visiting the 
doctor for an asthma-related reason, but were classified as ‘Other’, were transferred to the 
‘Asthma’ group. This increased the number of patients with an asthma-related reason from 
165 to 181. In Aim 1, in the regression on the quality of life discussion, the reason for the 
visit became a significant predictor. A patient visiting the doctor for asthma was more likely 
to discuss quality of life issues than a patient visiting the doctor for another reason (OR 1.9, 
95% CI 1.11-3.54). This modification did not change the significance of the interaction term 
in any of the models for Aim 2. 
 
Clinic Identifiers 
 All models for Aim 1 and 2 were re-run, without including the clinic identifiers. In 
Aim 1, reason for visit became a significant predictor for providing education on adherence. 
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A physician was more likely to provide education on the importance of adherence if the 
reason for the visit was asthma compared to something else (OR 2.11, 95%CI ). This 
modification did not change the significance of the interaction term in any of the models for 
Aim 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER SIX - DISCUSSION 
 
Pediatric asthma is one of the most common chronic pediatric conditions in the U.S., 
and minority children with asthma have been shown to suffer worse asthma-related health 
outcomes than white children with asthma (Targonski, Persky et al. 1994; Akinbami 2006; 
Erickson, Iribarren et al. 2007). This research examined the relationship between a patient’s 
race and patient-provider communication with pediatric asthma patients. It focused on 
communication concerning the following topics of asthma management: symptoms, 
pulmonary function, asthma-related quality of life, and adherence to control medications. 
These topics are among those highlighted in the NEAPP guidelines for asthma management. 
Previous research suggests that effective communication about these aspects of asthma 
management may lead to better asthma control and health outcomes for asthma patients 
(NHLBI 1997; Wissow 1998). Patient race was hypothesized to be associated with 
differences in patient-provider communication for these topics of asthma management. This 
association would support patient-provider communication as a contributor to disparities in a 
pediatric asthma population, and suggest one mechanism through which communication may 
be contributing to disparities. This section summarizes and discusses the major findings of 
this study, as well as the limitations, strengths, and directions for future research. 
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Summary of Findings 
The bivariate analyses did not support an association between patient race and 
communication about asthma symptoms, pulmonary function or asthma-related quality of 
life. These topics were no less likely to be discussed with minority patients than with white 
patients. However, the bivariate analyses did support an association between the reason for 
the visit and communication about asthma symptoms, pulmonary function, and control 
medication adherence. The reason for the visit remained significant in the multivariate 
analyses for these outcomes. This finding can be interpreted two different ways. On one 
hand, it is encouraging that patients visiting the physician for asthma are discussing these 
important topics of asthma management, in accordance with recommended guidelines. 
However, on the other hand, it also suggests that these topics are less likely to be discussed if 
the patient is visiting the physician for a non-asthma related reason. Due to the fact that 
asthma is a chronic disease, asthma management needs to be regularly monitored by the 
physician.  
This study only considered two levels (asthma or non-asthma) for the reason for the 
visit, as well as sensitivity analyses for which some reasons associated with asthma (e.g., flu, 
pneumonia) were switched from non-asthma to asthma. The switching did not significantly 
alter the results in the multivariate analyses. Future studies may consider other levels for the 
reason for the visit. For example, many patients were visiting the doctor for an annual well-
child check up or physical. In this present study, these patients were included in the same 
category as patients visiting for other acute reasons, such as stomach cramps (both were in 
non-asthma group).  A future study may consider whether asthma management is as likely to 
be discussed during a yearly physical as for an asthma visit, as compared to visit for other 
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reasons. A study of this nature, examining several levels for the reason for the visit, may 
provide additional information as to how the reason is associated with whether asthma 
management is discussed.  
Although previous studies have shown that minority children are more likely to 
experience symptoms, the results from this present study did not show that minority children 
were any more likely to report experiencing symptoms than white patients. Minority and 
white children were also very similar in the likelihood of any asthma symptoms being 
discussed, as well as the inclusion of specific aspects of asthma symptoms: nighttime 
symptoms, exercise-induced symptoms, daytime symptoms and symptom frequency. For all 
patients, asthma symptoms were discussed in more than 90% of the visits, and there was no 
difference between minority and white patients in the comprehensiveness of the symptom 
discussion scores, suggesting that physicians tend to be compliant with that particular 
recommendation from the NAEPP guidelines, without regard to patient race.   
Patient race was also not shown to be associated with whether pulmonary function 
(either spirometry or peak flow) was discussed. There was communication about pulmonary 
function in slightly more than half of the visits. Even though it is less than the frequency of 
communication about symptoms, this is not necessarily out of line with the recommendation 
of the NAEPP guidelines because: 1) a spirometry test is not recommended to be 
administered at every visit, and 2) peak flow meter checks are not recommended to be 
discussed at every visit, and have been de-emphasized in the most recent guidelines (2007) 
which were issued while data collection was in progress.  
Quality of life was discussed the least of any of the four topics. For the entire sample, 
and for minority and white patients, quality of life was discussed in slightly less than one-
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third of the visits. One possible explanation for this finding is that physicians may feel these 
more subjective areas are not as important indicators of asthma control as more clinical 
measures, such as symptom report and pulmonary function. QoL, while not normally 
assessed via standardized, validated instruments during routine medical visits, is still an 
important component of an asthma management discussion. In particular, QoL, especially the 
domain of activity limitations, may be the easiest way to convey to the child the importance 
of obtaining optimal control through control medication adherence. For example, a young 
child who doesn’t comprehend the need to regularly take medicine for clinical reasons, such 
as improving FVC scores, may be able to more easily understand the relationship between 
not taking medicine and not being able to play outside after school.  
Finally, bivariate analyses revealed that patient race was associated with the 
discussion of control medication adherence and the provision of education about the 
importance of the adherence to control medications. However, the direction of these 
associations was contrary to the hypothesized direction, with discussions more likely to occur 
for minority patients than white patients. This was a surprising finding, and contradictory to 
what previous research would suggest. Previous research has found that minority patients are 
more likely to under-utilize control medications, and be less adherent to these medications 
than white patients.  
One possible explanation for the finding in this study is that physicians are aware of 
the research literature suggesting that minority patients are less adherent than white patients, 
and therefore, physicians are more cognizant of the need to discuss this issue and to reinforce 
to minority patients the importance of adherence. The difference was not likely due to 
observed non-adherence, because minority and white patients were almost identical in self-
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reported non-adherence. This finding was also somewhat surprising, given that previous 
research suggests that adherence tends to be worse in minority patients, compared with white 
patients.  
In multivariate analyses, the association between patient race and communication 
about control medication adherence disappeared. It is likely that this association was 
confounded by the reason for the visit variable, which remained significant (OR 2.04, 
p=0.02). Minority patients were more likely than white patients to be visiting the physician 
for asthma than a non-asthma reason, thus confounding the relationship between patient race 
and discussion of control medication adherence.  
The multivariate model predicting whether control medication adherence was 
discussed also had the additional explanatory variables of whether or not the patient reported 
experiencing symptoms, whether the patient had poor pulmonary function scores (either from 
spirometry or peak flow) or whether the patient reported experiencing quality of life 
problems. It was surprising that none of these factors predicted whether adherence to control 
medication was discussed.  One explanation for this finding is the possibility that some 
physicians are more apt to discuss medication adherence than others, regardless of any 
asthma-related problems that may arise during the course of the visit. Other physicians may 
be less apt to discuss adherence under the same circumstances. Finally, it is possible that the 
magnitude of the difference in communication about adherence education was too small to be 
observed with multivariate analysis in this study.  
In the final model predicting whether the physician provided education about the 
importance of medication adherence, the report of patient non-adherence remained a highly 
significant predictor (OR 8.30, p<0.001) of the physician providing education about the 
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importance of adherence. There were no significant differences in the report of non-
adherence between minority and white patients, again somewhat surprising since previous 
research suggests that non-adherence is more prevalent for minority patients than white 
patients. However, it is interesting to note that non-adherence was reported most often by the 
parent, and not the patient. One possible explanation for this finding is that patients, 
especially the younger patients, are not likely to admit, or even comprehend, that they have 
not been taking their medication according to physician instructions. Also, especially for the 
younger patients, their parents may be assuming most of the responsibility for the child’s 
medication-taking behavior patterns, and in a better position to know if the child is adherent 
or not. One implication of parents assuming most of the responsibility for their child’s 
medication-taking behaviors is that interventions and programs designed to improve 
adherence may need to involve the parent as well as the patient.  
Another point to consider is whether parents’ beliefs about medication-taking and the 
importance of adherence may be driving their child’s non-adherence. Parents of children with 
asthma may believe that control medications only need to be used when symptoms appear, 
that the medication will cause too many side effects, or that their child may become too 
dependent on the medication (Farber, Capra et al. 2003; Bender and Bender 2005). Parents 
also report that they may simply forget to give their child their medication (Burgess, Sly et al. 
2008). An implication of this is that many adverse outcomes experienced by pediatric asthma 
patients may be due to their parent’s beliefs or medication-taking patterns. A future study 
may even consider whether parents and children with chronic diseases, each requiring daily 
medications, exhibit the same degree of adherence (or non-adherence), and how closely the 
adherence of the child aligns with the parent’s beliefs about medication-taking.  
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For almost all areas, the physician initiated discussions of asthma management. This 
may indicate that the physician is dominating and driving the conversation. This can be 
interpreted in two ways. It is probably safe to assume that patients and their caregivers are 
not familiar with the guidelines for asthma management, and therefore unaware of several 
methods of assessing asthma control. For example, patients and caregivers may not be aware 
that nighttime symptoms are particularly indicative of asthma control, and therefore need to 
be discussed separately, in addition to regular daytime symptoms. In this study, a discussion 
of nighttime symptoms was initiated by the physician during 83% of the visits (where it was 
discussed). Pulmonary function, in particular assessment by spirometry, is another area 
where discussion was initiated almost exclusively by the physician (97%). There were no 
instances where the patient initiated discussion about pulmonary function (spirometry or 
peak flow), and only a few instances where the caregiver initiated the discussion. I think it is 
an indication of effective disease management that physicians are initiating discussions about 
important topics that are unlikely to be discussed otherwise. It is interesting to note that 
quality of life is an area where the patient or caregiver was most likely to initiate a 
discussion, particularly negative emotions. This again may suggest that this area is not 
considered as important by the physician. 
The clinic findings are also worthy of comment. There were several regressions 
where there were significant differences in the clinic identifiers (Clinic 1 was the reference 
clinic in all models). While data collection was in-progress, additional descriptive 
information was collected from each clinic, including information about patient make-up, 
clinic staff, and specialized asthma practices. All clinics were exclusively pediatric clinics, 
with the exception of Clinic 6, which was excluded from analyses. All clinics reported that 
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they routinely screen patients for asthma, and administer a spirometry test as part of a routine 
asthma visit. However, the clinics differed slightly in their approach towards asthma 
management and education. For example, Clinics 2, 3 and 4 reported that they offered 
asthma education to children and their caregivers, while Clinics 1 and 5 reported that they did 
not. Also, only Clinic 3 reported that it offered a specialized asthma clinic, which it held 
every other month. Clinic 2 was the only to report that it had an asthma educator or specialist 
on staff.  
Differences in the resources offered by clinics to patients with asthma may provide 
insight into reasons by some of the significant clinic findings in the multivariate analysis. 
The comprehensiveness of the symptom discussion score was predicted to be 1.3 points 
higher for patients at Clinic 2 than for patients at Clinic 1, indicating a more comprehensive 
discussion of asthma symptoms during visits. As reported above, Clinic 2 was the only clinic 
that reported having an asthma educator or specialist on staff. Although all clinics reported 
routinely administering a spirometry test as part of a routine asthma visit, a discussion of 
pulmonary function was more likely to be discussed at Clinic 2 (OR: 3.14, p=0.04) and 
Clinic 4 (OR: 2.70, p=0.04) than at Clinic 1, indicating that this is not necessarily true. 
Therefore, clinic resources and practices may be influencing the level of care a patient 
receives more than other factors, such as patient race.  
Previous research in the area of patient-provider communication and race has 
produced conflicting results. Some studies report a clear association of patient race and 
communication. In a cross-sectional study of adults with asthma within 15 managed care 
organizations, African-Americans were more likely than white patients to rate the quality of 
their asthma care and communication with their physician less favorably (Okelo, Wu et al. 
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2007).  Other previous studies, comparing white and African-American adult patients with 
conditions including HIV and depression, have shown that, compared to visits with white 
patients, visits with African-American patients are more likely to be characterized as less 
participatory, with lower levels of affect, lower levels of rapport-building, less involvement 
in medical decision making, and higher levels of distrust (Cooper-Patrick, Gallo et al. 1999; 
Doescher, Saver et al. 2000; Johnson, Roter et al. 2004; Ghods, Roter et al. 2008; Cené, 
Roter et al. 2009).  
A study by Beach and colleagues, which examined communication between providers 
and adults with HIV, also yielded somewhat mixed results (Beach, Saha et al. 2010). The 
authors used the Roter Interaction Analysis System (RIAS) to analyze communication in 354 
patient encounters. The RIAS assigns each complete thought to 1 of 37 mutually exclusive 
and exhaustive categories of communication. The categories can reflect groups of exchange 
representing data gathering, patient education and counseling, relationship-building, and 
partnership building (Cooper, Roter et al. 2003). In the Beach study, the authors found no 
association between patient race and several communication characteristics, including 
patient-centeredness and socio-emotional talk. However, they report that physicians were 
significantly more verbally dominant with black patients, and that black patients provided 
less information, compared to white patients.  
Another study examining the association between patient race and patient-provider 
communication with patients with HIV reported that, in unadjusted analysis,  African-
American patients were significantly more likely than white patients to report positive 
communication experiences with their physician, such as the physician always listens 
carefully, always explains things in way that can be understood, always respects what the 
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patient has to say, and always spends adequate time with the patient (Korthuis, Saha et al. 
2008). However, once socio-demographic characteristics and site-of-care level indicators 
were included in the analysis, the only outcome that remained significant was ‘the physician 
always explains things in a way that can be understood.’ This study is similar to the present 
study, in that an initial observed relationship between patient race and communication 
disappeared in multivariable analyses, suggesting that initial findings of more favorable 
associations with communication for minority patients may be confounded by other factors.    
In light of these previous studies, results from the present study, showing no 
association between patient race and patient-provider communication, seem contradictory to 
what would be expected. Most previous studies have found an association between patient 
race and patient-provider communication, although not all aspects of communication have 
always been statistically significant. The  present study is somewhat different from these 
previous studies in that it focused on very disease-specific aspects of communication, rather 
than these more general and broad characteristics of communication. Therefore, the results 
from this present study, suggesting that patient race is not associated with communication 
about asthma management when other variables are considered, may be more reflective of 
the narrow focus of the study.  
In summary, the findings from this research do not support that patient race is 
associated with patient-provider communication regarding the aforementioned topics of 
asthma management. The interaction between patient race and reason for the visit was not 
associated with discussion of any topics of asthma management. An implication of these 
findings, for minority patients in particular, would seem to be that physician behavior, 
particularly communicating about asthma-specific topics in accordance with recommended 
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guidelines, is not a significant contributor to disparities in this population. However, as 
discussed above, these findings contradict several other studies, and no conclusions should be 
drawn on this study alone. Also, as discussed in the following sections, there were several 
limitations in this study, including a narrow focus on disease-specific communication, and 
additional research is needed to better understand additional aspects of communication in this 
population.  
  
Limitations 
There are several limitations that will need to be considered when interpreting the 
results from these analyses. First, the sample was pediatric patients attending pediatric clinics 
within one state. Therefore, the results may not be generalizable to other disease states or 
adult patients with asthma. Also, this analysis was cross-sectional in nature. It did not include 
any communication from previous physician’s visits, which may affect communication 
during the visit observed. In addition, there was no variable to indicate how closely the 
analyzed visit followed a previous visit. In some instances, it was clear that the patient had a 
very recent visit with the doctor. In others, it was clear that a longer time period had passed 
since the patient had seen the doctor. It is possible that this affected communication during 
the observed visit.  
In addition, this research did not consider verbal communication throughout the entire 
visit. Although the length of the overall visit was considered, only certain pre-determined, 
asthma-specific topics were included in the analysis, instead of looking at all aspects of the 
communication. Many previous studies of patient-provider communication utilize a more 
comprehensive method of analysis and coding, such as the RIAS described above. Also, non-
    142
age
 
verbal communication occurred during these visits; this information was not captured in the 
audio-tapes. Non-verbal communication was beyond the scope of this study, yet may provide 
an important direction for future research.  
Another limitation to consider is that this study may have been underpowered to 
detect smaller differences in communication between the two groups. Therefore, some of the 
differences observed in the bivariate analyses disappeared when the multivariate analyses 
were performed. This was most apparent in the models regarding communication about 
medication adherence. In bivariate analyses, physicians were more likely to discuss these 
topics with minority patients than white patients. This suggests another possible direction for 
future research. The inclusion of more patients may allow for these differences to remain in 
multivariate analyses, provided that the relationship is not confounded by other variables. 
  Another aspect not considered in this analysis was a measure of comprehension on 
the part of the patient or caregiver. Even though a topic was discussed, this does not translate 
to the patient and caregiver having a thorough understanding of the implications of the 
discussion, nor does it translate to behavior that the patient and/or caregiver will employ once 
they return home from the physician’s office.  
 The presence of the audio tape recorder in the exam room may also have had an 
impact on communication between the physician, parent and patient. The physician may have 
been more inclined to be more comprehensive than normal, knowing that the conversation 
was being recorded. Therefore, the frequency of discussions regarding the topics of asthma 
management may have been higher than would normally be expected. In addition, both the 
parent and the patient may have also have been impacted by the presence of the recorder. 
Either may have been more reluctant to speak openly about concerns that they had, regarding 
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asthma, or on other topics as well. In particular, this may have led to lower frequencies of 
initiating topics of asthma management.  
Finally, it is also important to consider that the patients who were excluded from the 
analysis due to problems with the audio were significantly different from the patients who 
were included in the analysis. One of the differences was in the reason for the visit, in that 
the patients who were excluded were significantly more likely to be visiting the doctor for 
asthma compared to the patients who were not. However, they did not differ by patient race. 
Since reason for the visit was found to be significant and patient race was not, it is unlikely 
that the inclusion of these patients in the analyses would have significantly altered the 
primary conclusions. 
 
Strengths 
There are several strengths of this research. This is the one of the first studies to 
examine the direct effect of patient race on patient-provider communication about specific 
topics of asthma management in a pediatric population. One strength is that it used actual 
audio recordings of the communication, instead of depending on patient, caregiver, or 
physician recall, eliminating any form of recall bias for communication. This gives a more 
accurate and complete description of the communication rather than relying on 
questionnaires alone. 
 Another strength of this study is that it utilized a coding instrument that was 
developed specifically to answer the questions that were integral to the study. The coding 
instrument allowed for easy quantification of the communication variables that were pre-
selected for inclusion in the analysis. 
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 A final advantage of the study is the fact that the participants were blinded to the 
hypotheses in this secondary research. Given the sensitive nature of race, it was beneficial 
that neither physicians nor patients/parents knew of the hypotheses of this particular study. 
Therefore, even if physicians altered their behavior and communication due to the presence 
of the audiotape recorder in the exam room, it is unlikely that they did so on the basis of the 
patient’s race.  
 
Practice Implications 
 The study results showing that communication about some topics of asthma 
management differed significantly by clinic could imply that the quality of asthma care 
received is dependent on the site of care. The five pediatric clinics reported offering 
additional resources and routine practices for asthmatic patients, to varying degrees, 
including specialized asthma clinics, an asthma educator or specialist on staff, routine 
spirometry testing, and offering asthma education to patients and their caregivers. In clinics 
where specific topics of asthma communication were not discussed as frequently as in others, 
clinic administrators may consider implementing more asthma-specific programs to improve 
the quality of asthma care at their site. This would be especially prudent if additional research 
were to show significant differences in other quality of care indicators or asthma-related 
health outcomes by different clinics.    
 In addition, the finding that the reason for the visit was highly significant in many of 
the models suggests that patients with asthma are not necessarily having their asthma control 
monitored when visiting the physician for non-asthma related reasons. While it is 
encouraging that patients visiting the physician for asthma are discussing asthma 
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management, the results of this study suggest that there is room for improvement for more 
frequent monitoring. More interventions could be directed towards physicians to routinely 
engage in dialogue regarding asthma control, regardless of the purpose of the visit. 
 
Future Research 
There are several questions that have been raised by the results of this research, which 
could direct future research. Communication is very complex, and this research took a fairly 
narrow view of the issue. Instead of using the coding instrument that was developed 
specifically for this project, the entire discussion could be reviewed using a more 
sophisticated coding system, such as the RIAS. Using this system would allow for a more in-
depth analysis of the communication, including additional characteristics considered in 
several previous studies of a similar nature, such as verbal dominance, patient-centeredness, 
information-seeking, and socio-emotional talk. Looking at these different dimensions of the 
entire discussion, rather than just whether certain topics are covered, may provide more 
information about any differences in communication. 
Future studies may also include greater variation in physician/provider type, or 
patient base. The majority of the providers included in this study were pediatricians who did 
not necessarily specialize in asthma. Future studies could include more pulmonologists who 
specialize in asthma, or more general practitioners, in addition to pediatricians. Studies of 
this nature would allow for the type of the physician to be included as a variable in the 
analysis, in order to observe any differences in communication patterns or styles. In addition, 
patients from different geographic areas could be compared to each other to observe whether 
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there are differences in communication by location (for example, north vs. south). The 
inclusion of more patients would also increase the power of future studies. 
As mentioned above, non-verbal communication is also an important aspect to 
consider. There are non-verbal cues that could have affected communication, especially for 
the patient. A future research study could video-record the communication between the 
patients and their doctors, and examine differences as a function of patient race. Non-verbal 
clues may include observation of body language (e.g., leaning, touching), facial expressions, 
and maintaining eye contact.  
 
Conclusion 
In conclusion, patient race was not found to be significantly associated with patient-
provider communication about asthma symptoms, pulmonary function, asthma-related 
quality of life, or control medication adherence, all important asthma management topics. 
Despite these findings, asthma disparities still persist in this population. More 
research is needed to determine whether other aspects of communication are associated with 
the race of the patient or his/her caregiver in a pediatric asthma population. In the event that 
patient-provider communication is not found to be associated with patient race, other factors 
that have been proposed to contribute to racial disparities warrant further research as well.  
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APPENDIX 1. Guidelines for Classifying Asthma Severity in Children 5-11 Years of Age 
(Modified from the 2007 NAEPP Guidelines) 
 
 
        
Classified as Intermittent: 
     
Symptoms no more than 2 days a week     
Nighttime awakenings no more than 2 days a week    
Rescue medication use no more than 2 days a week   
No interference with normal activity     
Pulmonary Function: Normal FEV1 between exacerbations, FEV1 > 80% predicted, 
 FEV1/FVC>85%      
       
 
 
Classified as Mild Persistent: 
    
Symptoms more than 2 days a week but not daily    
Nighttime awakening 3-4 times a month     
Rescue medication use more than 2 days a week but not daily   
Minor activity limitation      
Pulmonary Function: FEV1 at least 80% predicted, FEV1/FVC >80%  
        
        
Classified as Moderate Persistent: 
    
Symptoms daily       
Nighttime awakenings more than once a week but not nightly   
Rescue medication use daily      
Some activity limitation      
Pulmonary Function: FEV1 between 60-80% predicted, FEV1/FVC = 75-80% 
       
 
 
Classified as Severe Persistent: 
    
Symptoms throughout the day     
Nighttime awakenings often/nightly     
Rescue medication use several times a day    
Extremely limited in activities      
Pulmonary Function: FEV1 < 60% predicted, FEV1/FVC <75%   
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APPENDIX 2. Eligibility Screener 
 
 
ELIGIBILITY SCREENER 
 
Child/Patient Inclusion Criteria 
 
1. Is your child between 8 and 15 years of age? 
 
1         Yes - CONTINUE WITH Q #2 
 0 No – STOP, EXPLAIN, THANK 
 
2. Does your child read and speak English? 
 
1         Yes - CONTINUE WITH Q #3 
 0 No – STOP, EXPLAIN, THANK 
 
3. Has your child visited/been seen by a doctor at this clinic at least once before? 
 
1         Yes - CONTINUE WITH Q #4 
 0 No – STOP, EXPLAIN, THANK 
 
Caregiver Inclusion Criteria 
 
4. What is your relationship with the child? 
 
1         Parent or Legal guardian - CONTINUE WITH Q #5 
 0 No – STOP, EXPLAIN, THANK 
 
5. Are you at least 18 years of age? 
 
1         Yes - CONTINUE WITH Q #6 
 0 No – STOP, EXPLAIN, THANK 
 
6. Do you read and speak English? 
 
1         Yes - CONTINUE WITH Q #7 
 0 No – STOP, EXPLAIN, THANK 
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Child Asthma Severity Level 
 
7. What type of medication does your child take for his/her asthma? 
Interviewer: show list and pictures, check all appropriate boxes below and CONTINUE WITH Q #8. 
(Circle the dose if known where indicated; it does not affect classification but is important for Stephanie and 
Dennis) 
 
Rescuer/Reliever medication 
Bronchodilators 
(via inhaler or nebulizer) 
Controller medication 
Anti-inflammatory 
Short-acting beta-agonists 
a Albuterol (Proventil®, Ventolin®) 
b Bitolerol (Tomalate®) 
c Pirbuterol (Maxair®) 
d Terbutaline (Brethine®) 
e Levalbuterol (Xopenex®) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
z Other_______________ 
 
 
Inhaled Corticosteroids 
f Beclomethasone (Qvar®)     (Circle)   40 mcg,    80 
mcg) 
g Triamcinolone (Azmacort®) 
h Flunisolide (Aerobid®) 
i Fluticasone (Flovent®)   
                                (Circle)    44 mcg,    110mcg,    220 mcg  
j Budesonide (Pulmicort®) 
k    Mometasone (Asmanex) 
 
Systemic Corticosteroids 
l Prednisone (Deltasone®) list strength ________ 
m Prednisolone (Prelone®) list strength _________ 
n Methylprednisolone (Solu-Medrol®)list 
strength________ 
 
Anti-inflammatory: Mast-cell stabilizer 
o Cromolyn (Intal®) 
p Nedocromil (Tilade®) 
 
Long-acting beta agonist 
q Salmeterol (Serevent®) 
r Formoterol (Foradil®) 
 
Inhaled corticosteroid and long-acting beta agonist 
s Salmeterol and fluticasone (Advair® diskus) 
                          (Circle)  100 mcg,    250 mcg ,   500 mcg 
 
Methylxanthines 
t Theophylline (Slo-bid®, Theo-Dur®, Uniphyl®) 
           List Strength  _________ 
 
Leukotriene Modifiers 
u Zileuton (Zyflo®) 
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v Zarfirlukast (Accolate®) 
w Montelukast (Singulair®)     (Circle) 4 mg, 5 mg, 10 
mcg 
 
x Other________________________ 
y Does not know name 
 
 
8. In the past 12 months (the past year), how often has your child… 
 
 Never 1-2 times 
per year 
3-12 times 
per year 
More than 
2 times 
per month 
More than 
2 times 
per week 
Everyday 
a. Had wheezing 
(whistling sounds from 
the chest) with a cold? 
0 1 2 3 4 5 
b. Had wheezing 
(whistling sounds from 
the chest) without a 
cold? 
0 1 2 3 4 5 
c. Had an attack of 
wheezing that made it 
hard to breathe or catch 
his or her breath that 
persisted (or lasted) for 
a day or more? 
0 1 2 3 4 5 
d. Had a cough that 
would not go away? 0 1 2 3 4 5 
e. Complained that his or 
her chest felt tight or 
heavy? 
0 1 2 3 4 5 
f. Used his/her rescue 
inhaler for symptoms? 0 1 2 3 4 5 
g. Wheezed with exercise 
or running or playing 
hard? 
0 1 2 3 4 5 
h. Coughed with exercise 
or running or playing 
hard? 
0 1 2 3 4 5 
 
9. In the past 12 months,  (the past year) how often has your child’s sleep been disturbed because of 
wheezing, coughing, chest tightness, or shortness of breath? 
 
Never 1-2 times per 
year 
3-12 times per 
year 
1 time per 
month 
2-4 times per 
month 
5 or more 
times per 
month 
0 1 2 3 4 5 
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CHILD MEETS ASTHMA SEVERITY CRITERIA FOR THE STUDY IF: 
 
Moderate to Severe Persistent Asthma 
 
− Circled “5” on any question 8a through 8h or 9, OR 
− On 2 controller medications (checked at least 2 of f through w on Question #7or Advair since it 
has 2 medications in it) 
 
Mild Persistent Asthma 
 
− Circled “4” on at least one of  questions 8a through 8h  or 9 OR 
 
− On a controller medication (checked at least 1 of f through w on Question #7) 
        (if they are on Advair they are classified as moderate/severe) 
 
 
10. Child classified by research assistant as: 
 
0  Ineligible due to one of reasons above, including severity level 
1 Mild Persistent 
2 Moderate to Severe Persistent 
 
IF ELIGIBLE, CONTINUE with consent and assent process. 
 
 
IF NOT ELIGIBLE, STOP, explain, and thank them for their time. 
 
 
 
 
11. Child classified by Dennis or Stephanie as: 
 
1 Mild Persistent 
2 Moderate to Severe Persistent 
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APPENNDIX 3. Supplemental Coding Instrument 
 
 
Patient ID:  _________     Coder ID: _____________ 
Date of Visit:  _________     Date of Coding: ___________ 
 
 
Communication Variables 
Symptoms 
 i) Is asthma mentioned before any symptom discussion?   Y1 N0 
 ii) Does doctor ask about asthma-specific symptoms/problems?  Y1 N0 
 iii) Does doctor ask about general symptoms/problems?   Y1 N0 
 iv) Are asthma symptoms mentioned?     Y1 N0 
1a) Are asthma symptoms (any kind) discussed?     Y1 N0 
1b) Who initiates discussion about asthma symptoms?   D1    C2    P3   n/a9 
1c) Does patient or caregiver state that patient is experiencing  Y1  N0     n/a9 
 symptoms (any kind)? 
 1d) If yes, is it caregiver or patient?     C1 P0 n/a9 
 1e) Are nighttime symptoms discussed?     Y1 N0 
1f) Who initiates discussion about nighttime symptoms?   D1    C2    P3   n/a9 
 1g) Are exercise-induced symptoms discussed?    Y1 N0 
1h) Who initiates discussion about exercise-induced symptoms?  D1    C2    P3   n/a9 
1i) Are daytime symptoms discussed?     Y1 N0 
1j) Who initiates discussion of daytime symptoms?   D1    C2    P3   n/a9 
1k) Is symptom frequency discussed?     Y1 N0 
 1l) Who initiates discussion about symptom frequency?   D1    C2    P3   n/a9 
 1m) Does the doctor make any recommendation to alleviate  Y1 N0           n/a9 
        asthma symptoms? 
 
Pulmonary Function (Spirometry)  
 2a) Is spirometry discussed?      Y1 N0  
 2b) Who initiates discussion of spirometry?    D1    C2    P3    n/a9 
 2c) Are the results of day’s spirometry test discussed?   Y1 N0        n/a9 
2d) How does the doctor interpret the day’s spirometry test    G2    A1    P0  n/a9
       results? 
 2e)  Does the doctor make any recommendation to improve   Y1  N0     n/a9 
                    spirometry test results? 
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Pulmonary Function (Peak Flow) 
 3a) Who initiates discussion of peak flow?    D1    C2    P3    n/a9 
3b) Are current peak flow meter readings discussed?   Y1 N0 
3c) How does doctor interpret current peak flow meter readings?  G2    A1     P0  n/a9               
 3d)  Does the doctor make any recommendation to improve peak  Y1  N0     n/a9 
                    peak flow meter readings? 
 
Quality of Life 
 4a) Is activity limitation due to asthma discussed?   Y1 N0 
 4b) Who initiates activity limitation discussion?    D1    C2    P3    n/a9 
 4c) Does patient or caregiver report activity limitation?   Y1 N0 n/a9 
 4d) If yes, is it caregiver or patient?     C1 P0               n/a9 
 4e) Are negative emotions due to asthma discussed?   Y1 N0 
 4f) Who initiates negative emotion discussion?    D1    C2    P3      n/a9 
 4g) Does patient or caregiver report negative emotions?   Y1 N0   n/a9 
 4h) If yes, is it patient or caregiver?     C1 P0               n/a9 
 4i) Are missed school days due to asthma discussed?   Y1 N0 
  4j) Who initiates missed school days discussion?        D1    C2    P3      n/a9 
 4k)  Does the doctor make any recommendation to improve   Y1  N0      n/a9 
            patient’s quality of life? 
 4l)  Is the family’s asthma-related QoL discussed?   Y1 N0 
 4m) Who initiates discussion of family QoL?    D1    C2    P3   n/a9 
 
 
Control Medication Adherence 
 5a) Who initiates discussion about control medication adherence? D1    C2     P3    n/a9 
5b) Does patient or caregiver report non-adherence?   Y1 N0       n/a9 
5c) If yes, is it caregiver or patient?     C1 P0 n/a9 
5d)  Is reason for non-adherence given?     Y1 N0 n/a9 
 If yes, what is it? _____________ 
 
 
(Notes from Primary Coding Instrument) 
 
Is spirometry performed?         Y1 N0 
Is control medication adherence discussed?      Y1 N0 
Is education on control med adherence discussed?     Y1 N0 
Is peak flow discussed?         Y1 N0
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APPENDIX 4. Coding Rules for Supplemental Coding Instrument 
 
Coder Information 
First, record the patient ID/transcript number, coder initials, the date of the visit and the date 
of the coding on the top of the coding sheet. 
 
 
 
Information from Primary Coding Instrument 
 
Information on whether spirometry was performed as part of the medical visit is included in 
the Primary Instrument (Question 5x).  
 
Information on whether peak flow use was discussed during the medical visit is included in 
the Primary Instrument. Questions 28a-e will be merged into the final dataset. (It is likely 
that one variable, titled ‘Peak Flow Discussed’ will be created, and that any affirmative 
answer to Questions 28a-e will be considered an affirmative answer to this variable.) 
 
Information on whether control medication adherence was discussed is included on the 
Primary Instrument (Question 22a). Information on whether education on the importance of 
control medication adherence was provided is also included (Question 5b and 23a).  
 
Record all above information obtained from the Primary Coding Instrument at the bottom of 
the page. 
 
 
Symptoms 
Questions i,ii, iii and iv are used to determine the first three symptom variables. Based on 
research, the most common asthma symptoms that will be discussed are coughing, wheezing, 
chest tightness, or shortness of breath.  
 
Answer question i as ‘yes’ if there has been any mention of asthma prior to any discussion of 
symptoms.  
 
Answer question ii as ‘yes’ if the doctor asks about asthma specifically. This may include an 
asthma-specific symptom question, such as “Have you been wheezing at all?” It may also be 
a question that includes asthma but does not mention any specific symptom, such as “How 
has his asthma been?” 
 
Answer question iii as ‘yes’ if the doctor asks about any problems or symptoms. This could 
be a general question, or question related to some other condition.  
 
Answer question iv as ‘yes’ if the parent or patient mentions any symptoms, currently being 
experienced, that they attribute to asthma. This may include ongoing symptoms that the 
patient/parent is concerned about. It may include symptoms experienced only during certain 
activities (i.e running). It will not include symptoms that have been experienced in the past, 
but are no longer a problem.  
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The answers to these four questions will guide the coding of questions 1a-1d, according to 
the table below. As a follow-up question to 1c, note whether it is the patient or caregiver who 
initially makes the initial statement, if applicable, for question 1d. 
 
 
Coding Rules for Symptom Communication Variables 
SITUATION CODED VARIABLES 
Asthma has 
been 
mentioned 
Physician 
asks about 
asthma 
specific-
ally 
Physician 
asks about 
problems 
(not asthma 
specific) 
Patient or 
Parent 
Mentions 
Asthma 
Symptoms 
Discuss 
Asthma 
Symptoms
* (1a) 
Initiator
* (1b) 
Symptoms 
Experienced
* 
(1c and 1d) 
No No No No No N/A N/A 
No Yes No No Yes Physician No 
No No No Yes Yes Patient or 
Parent 
Yes/No 
No Yes No Yes Yes Physician Yes/No 
No No Yes  No No N/A N/A 
No Yes Yes No Yes Physician No 
No No Yes Yes Yes Patient or 
Parent 
Yes/No 
No Yes Yes Yes Yes Physician Yes/No 
Yes Yes No No Yes Physician No 
Yes No No No No N/A N/A 
Yes Yes No Yes Yes Physician Yes/No 
Yes No No Yes Yes Patient or 
Parent 
Yes/No 
Yes Yes Yes  No Yes Physician No 
Yes No Yes No Yes Physician No 
Yes Yes Yes Yes Yes Physician Yes/No 
Yes No Yes Yes Yes Physician Yes/No 
 * Coded Variable 
Symptoms (continued) 
Question 1e. – Code this question as ‘yes’ if there is any discussion about asthma symptoms 
experienced at night. This may include trouble falling asleep, or waking up anytime in the 
night, due to asthma symptoms. 
 
Example:  Are you coughing at night? 
     Is she wheezing during the night? 
 
 
Question 1f - If applicable, note whether the physician, parent, or patient first mentions 
nighttime symptoms. 
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Question 1g – Code this question as ‘yes’ if there is any discussion about asthma symptoms 
experienced during exercise, or other similar activities, such as playing at recess, PE class, or 
team sports. 
 
Example:   Do you have trouble breathing when you run? 
 
 
Question 1h - If applicable, note whether the physician, parent, or patient first mentions 
exercise-induced symptoms. 
 
 
Question 1i. – Code this question as ‘yes’ if the doctor specifically asks about asthma 
symptoms experienced during the day. This will include discussion of symptoms experienced 
during the day, that are separate from those experienced during physical activity (which 
would be exercised-induced). 
 
Example:  Do you have any symptoms during the day? 
  I hear her coughing when she’s brushing her teeth in the morning? 
 
 
Question 1j - If applicable, note whether the physician, parent, or patient first mentions 
daytime symptoms. 
 
 
Question 1k – Code this question as ‘yes’ if there is any discussion about symptom 
frequency, as related to any of the above events (nighttime, exercise, daytime, other). This 
discussion may be in relation to any period of time (a night, a week, month, etc.). Also, 
include discussions about the frequency of inhaler use IF it is clear that the doctor is asking 
about it in relation to the patient experiencing acute symptoms.  
 
Example:  How many times do you wake up during the night? 
     How often is your cough bothering you? 
  How many times did you have to use your inhaler last week (b/c you were 
wheezing)? 
 
Do not code as ‘yes’ if the discussion is primarily on duration of symptoms, instead of 
frequency. 
 
Example: How long have you had the cough?  (Do not consider this frequency) 
 
 
Question 1l - If applicable, note whether the physician, parent, or patient first mentions 
symptom frequency. 
 
 
    157
age
 
Question 1m – Code this question as yes if the doctor makes any recommendations (to either 
parent or patient) about helping the patient to alleviate or better control their symptoms. This 
may include changes in medication regimen, suggestions about how to avoid triggers, 
suggestion to limit play time, etc. This discussion must follow a discussion about asthma 
symptoms to be coded as ‘yes.’  
 
Example:  What I am hoping is that as we increase the steroid dose…he will have less of 
this wheezing… 
 Make sure you’re taking Advair. It’s going to help. 
 
 
Pulmonary Function (Spirometry) 
Question 2a – Code this question as ‘yes’ if the physician, patient, or parent clearly mentions 
a spirometry test or spirometry results. This will include if a parent or patient asks about a 
test, even if one is not performed. Spirometry is also often referred to as a ‘breathing test’ or 
‘lung test.’ 
 
Example:  Are we doing spirometry today? 
 
Question 2b – If applicable, note whether the physician, parent, or patient first mentions a 
spirometry test. 
 
Question 2c –If applicable, note whether the results of a spirometry test, performed on that 
day, are discussed. 
 
Question 2d – If applicable, note whether the physician says whether the results of the 
spirometry test are good or bad. If it is difficult to tell, or the physician is not emphatic about 
the results either way, code as ambiguous.  
 
Example: Your lungs sound great.…That’s real good, you’re over 100% across the 
board…(GOOD) 
   
…Um, they look ok, they could be better. (AMBIGUOUS) 
 
  These are pretty low, we need to get these up.. (BAD) 
 
 
Question 2e – Code this question as yes if the doctor makes any recommendations (to either 
parent or patient) about helping the patient to improve the results of a spirometry test. This 
may include changes in medication regimen, suggestions about how to avoid triggers, 
suggestion to limit play time, etc. This discussion must follow a discussion about spirometry 
to be coded as ‘yes.’  
 
Pulmonary Function (Peak Flow) 
If the information from the Primary Instrument indicates that peak flow was not discussed, 
questions 3a, 3b and 3c will not be applicable 
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Question 3a – If applicable, note whether the physician, parent, or patient first mentions a 
peak flow.  
 
Question 3b – Note whether current peak flow readings are discussed. This may include 
readings that the patient has been taking at home, or a peak flow test administered that day in 
the doctor’s office. 
 
Question 3c – Note whether the physician, parent or patient clearly states that the peak flow 
readings are not very good or are cause for any concern. For example, the patient or parent 
may report that the numbers have been ‘not good’ or ‘low’ lately. Or, the patient/parent may 
say the number to the physician, and the physician’s response indicates that the number is 
cause for concern. 
 
Example:  Let’s see if we can get those numbers up a bit for next time (says physician) 
     Ok, that’s not too bad but I think we can do better (says physician) 
 
Question 3c - Code this question as yes if the doctor makes any recommendations (to either 
parent or patient) about helping the patient to improve peak flow meter readings. This may 
include changes in medication regimen, suggestions about how to avoid triggers, suggestion 
to limit play time, etc. This discussion must follow a discussion about peak flow to be coded 
as ‘yes.’  
 
 
Asthma-Related Quality of Life 
Rules for this variable were adopted from the Pediatric Asthma Quality of Life 
Questionnaire. These variables will be coded as ‘yes’ if the patient or parent mentions any of 
the activity limitations or emotions specified in the Pediatric Asthma Quality of Life 
Questionnaire, or if the physician poses any quality of life-related question (from any of the 
two domains below). The Symptom domain is not included here, due to probable overlap 
with questions above.  
 
 
Questions in the Activities Domain 
 
Question 4a - Code this question as ‘yes’ if there is any discussion of whether the patient 
was bothered or affected by asthma in completing physical activities or felt unable to keep up 
with others. This may include a question posed by the physician that is answered in the 
negative. This is different from exercise-induced symptoms (question 1g), in that the 
discussion must include some type of inability to participate in these activities as normal (if 
the patient was not experiencing asthma symptoms). 
 
Example:  It’s not keeping him back from playing? 
Your asthma is definitely worse….going to make is harder for you to do 
stuff…. 
  Can you run….as much as the other boys? 
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Question 4b – If applicable, note whether the physician, parent or patient first mentions 
activity limitations. 
 
Question 4c – If applicable, record whether the patient or caregiver reports any type of 
limitations or alteration of physical activities due to asthma, or feelings of not being able to 
keep up with others.  
 
Example:  Sometimes he gets out of breath he will have to sit down 
 
Question 4d – If applicable, note if it is the caregiver or patient who mentions that the 
patient is experiencing activity limitations.  
 
 
Questions in the Emotions Domain  
 
Question 4e -Code this question as ‘yes’ if there is any discussion of specific (negative) 
feelings related to asthma. The trigger words (from the PAQoLQ) include: Frustrated, 
Worried, Concerned, Troubled, Angry, Irritable, Different, Left Out, Frustrated (because 
couldn’t keep up with others), Uncomfortable, and Frightened by an attack. Others will 
include Sad, Angry Embarrassed or Upset. This may include a question posed by the 
physician that is answered in the negative. 
 
Question 4f – If applicable, note whether the physician, parent or patient first mentions 
negative emotions associated with asthma. 
 
Example: I feel sad sometimes because I have asthma. 
 
Question 4g – If applicable, record whether the patient or caregiver reports any negative 
feelings (listed above) due to asthma.  
 
Question 4h – If applicable, note if it is the caregiver or patient who mentions that the 
patient is experiencing negative emotions.  
 
Question 4i -  Code this variable as ‘yes’ if there is any discussion of asthma-related missed 
school days for the patient.   
 
Example: Does he have to miss school because of his asthma? 
 
Question 4j – If applicable, note whether the physician, patient or caregiver first mentions 
asthma-related missed school days. 
 
Question 4k - Code this question as yes if the doctor makes any recommendations (to either 
parent or patient) about helping the patient to improve patient’s quality of life. This 
discussion must follow a discussion about quality of life to be coded as ‘yes.’  
 
Question 4l – Code this question as yes if there is any discussion of how the patient’s asthma 
is affecting other members of the immediate family/household. This may include discussion 
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of a parent missing work, or not being able to devote as much time as desired to another 
child. It may also include negative emotions that the parent is experiencing specifically due 
to the child’s asthma. 
 
Example: We weren’t able to go to the beach because of her asthma. 
  I get worried watching her play sometimes.  
 
Question 4m – If applicable, note whether the physician, the parent, or patient first mentions 
any affect of the patient’s asthma on the family’s quality of life. 
 
 
Control Medication Adherence 
If the information from the Primary Instrument indicates that control medication adherence 
was not discussed, questions 5a-5c will not be applicable. Also, these questions assume the 
child was already on a control medication. This information will be obtained from the 
Eligibility Screener and Parent After Visit Survey.  
 
Question 5a - If adherence was discussed, indicate whether the physician, parent or patient 
initiated the conversation. If the doctor asks about whether the patient is taking the 
medication every day or as directed, the physician will be coded as the initiator. If the parent 
or patient volunteers the information without being asked, code the parent or patient as the 
initiator.  If the doctor gives information/instructions on taking the medicine everyday, this 
will count as an adherence discussion. 
 
Example: This is the Advair, you have to take it everyday… 
  Is she pretty good about taking it most of the time..? 
 
Question 5b – Code this question as ‘yes’ if the patient or caregiver reports that the patient 
has not been completely adherent. This may include reports of skipping doses, forgetting 
doses, or not getting refills in a timely manner. 
 
Example: I forget to take it at night sometimes 
  When he stays with his father he doesn’t always take his medicine. 
 
Question 5c – If applicable, note whether the patient or the caregiver reports non-adherence. 
 
Question 5d – If applicable, note whether the reason that the patient is non-adherent is given. 
If so, note what the reason is. (This information will be categorized once coding is complete.) 
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